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Abstract
The central idea in Fragment Based Ligand Discovery (FBLD) is to identify
small, low molecular weight compounds (MW < 250) that bind to a particular
protein active site. Hits can be used to efficiently design larger compounds with
the desired affinity and selectivity.
Three approaches to FBLD are described in this thesis.
The first topic is the development and assessment of different chemoinformatics
procedures to select those fragments that maximally represent the chemical fea-
tures of a larger compound library. Such a fragment library could be of great
value in the so-called “SAR by Catalogue” approach, where the initial stage of
fragment growth is by selecting existing compounds that contain sub-structures
of the hit fragments. Five schemes implemented in the Pipeline Pilot software
are described.
The second project was to develop improved approaches to processing Thermal
Shift Analysis (TSA) data. The shift in melting temperature can indicate that a
ligand binds and thus stabilises a protein. A program, MTSA, has been written
which allows more straightforward processing of the experimental data than ex-
isting available software. However, detailed analysis of fragment screening data
highlighted difficulties in defining the melting temperature and suggest that TSA
is not sufficiently reliable for routine screening use.
Finally, a number of proteins were assessed experimentally for suitability for
FBLD: N-myristoyl transferase (NMT), the bacterial homologue of a GlcNAcase
enzyme (BtGH84) and the model system hen egg white lysozyme (HEWL). It
was not possible to produce suitable NMT material due to the inherent instability
of the protein produced in York. The screening results of HEWL with a new
Surface Plasmon Resonance (SPR) assay, a cell based activity assay and TSA
were inconsistent and difficult to interpret. However, BtGH84 was suitable for
screening by both TSA and SPR. The resulting fragment hits are suitable starting
points for further evolution.
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Chapter 1
Introduction
This thesis describes the development and application of methods in Fragment
Based Ligand Discovery (FBLD), which has emerged over the past ten years as
an innovative approach to the early stages of drug discovery. This first chapter
provides a brief historical introduction to drug discovery and describes the origins
of, and context for, the fragment based approach. This introduction includes
a more comprehensive review of the concepts and approaches to the design of
fragment libraries for screening, which is of particular relevance to the work
described later in the thesis. The chapter concludes with an overview of the
organisation of the thesis and the aims of the research.
1.1 Drug Discovery
1.1.1 A Historical Perspective
A medicine is a drug that is used for the treatment or prevention of a disease
or condition. Since ancient times people have used plant extracts for medicinal
purposes – discovered accidentally or empirically by testing. Examples of the
earliest drugs include salicylic acid (found by chewing willow bark, today used as
salicylic acid acetate in Figure 1.1), opium alkaloids, cannabis and ephedrine. All
the major civilisations of the ancient world developed the practice of medicine
with associated pharmacies which combined extracts from herbs and plants (and
occasionally minerals) to produce treatments for various ailments and conditions.
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For example around 1300 B.C., the Minoans exported opium to Egypt, where it
was used to calm crying children.
Figure 1.1: Acetylsalicylic acid. Marketed under a large number of brand
names, famous example: Aspirin (Bayer)
It was not until the 18th century that chemical science developed sufficiently
to isolate individual components with scientists such as Scheele and Lavoisier
using crystallisation to purify the active ingredients. In addition, metals (such as
mercury and antimony) and salts (such as silver nitrate) could now be purified
for use as drugs.
However, it was the late 19th century before chemical methods advanced suf-
ficiently to enable the determination of chemical structure and the ability to
synthesize individual compounds, giving birth to the modern pharmaceutical in-
dustry. Some of the first apothecary companies moving into large-scale drug
production were Merck, Schering and Boehringer, followed by chemical compa-
nies such as Bayer and Hoechst.
(a) Paracetamol (b) Ibuprofen
Figure 1.2: Paracetamol and ibuprofen. Paracetamol, also acetaminophen:
analgesic and antipyretic effects, Ibuprofen: analgesic and antipyretic effects
Until the middle of the 20th century, drugs were discovered by making compounds,
and testing for an effect on appropriate animal or cellular models and looking for
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(a) Tamoxifen (b) Captopril
Figure 1.3: Tamoxifen and Captopril. Tamoxifen: selective estrogen receptor
modulator, Captopril: first orally-active angiotensin-converting enzyme (ACE)
inhibitor.
the desired effect or phenotype. The ideas for synthesis came from analysis of
known drugs and their metabolites. This is how drugs such as paracetamol and
ibuprofen were discovered (Figure 1.2). Alongside such “make and test” strate-
gies, the 1950s to 1970s saw an increased understanding of metabolic pathways,
the biochemistry of viruses and bacteria and the identification of some of the
key receptors (such as the first steroid receptors). This gradually introduced the
idea that modulating the activity of a specific target was an effective strategy for
drug discovery for some diseases and conditions. Examples include the develop-
ment of steroid hormone modulators (e.g. tamoxifen, a pioneering breast cancer
treatment, Figure 1.3 a, recently reviewed by Jordan, 2006) and angiotensin-
converting enzyme (ACE) inhibitors. Captopril was the first orally-active ACE
inhibitor and is used to treat hypertension (Figure 1.3 b, Ondetti et al., 1977;
Rubin et al., 1978).
The design of compounds was usually guided by an understanding of the molec-
ular enzymology and making compounds that looked like the substrates or which
mimicked the transition state (for enzymes). One such example was an initial
attempt at an inhibitor, Neu5Ac2en (Figure 1.4 b), a neuraminidase-transition
stage analogue for sialic acid (Figure 1.4 a), for influenza (Meindl and Tuppy,
1969).
However for complex conditions – such as many psychiatric disorders – phenotypic
screening continued to be the main way for discovery until very recently. The
primary reasons are that therapeutic benefit comes from affecting a whole system
of targets and cellular processes. For this reason, although projects are influenced
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(a) Sialic Acid (b) Neu5Ac2en
Figure 1.4: Sialic Acid and Neu5Ac2en. Sialic acid: also known as N-acetyl
neuramic acid (Neu5Ac), Neu5Ac2en: transition state analogue.
by the knowledge of targets, the primary driver for compound optimization is in
vivo testing.
During the late 1980s, molecular biology revolutionised target discovery and there
have been rapid and continuing improvements of our understanding of the molec-
ular basis of diseases. An example is a research programme starting in the 1980s
with the intention to finding drugs for the treatment of hypertension and car-
diovascular diseases. The scientists at Pfizer tried to find inhibitors of phospho-
diesterase (PDE5). The starting point was a weak phosphodiesterase inhibitor
found in the literature which was originally an anti-allergy compound. It showed
an effect in vitro and in an animal model. Computational modelling and ra-
tional chemistry increased the affinity and selectivity of the initial compound.
Structure-affinity relationships and pharmacokinetics properties were optimised
and led to Sildenafil (Figure 1.5). The drug proved not be very effective in the
treatment of cardiovascular conditions, but having a positive effect of erectile
dysfunction and is now marketed as Viagra (Campbell, 2000). Sildenafil is a
selective inhibitor for PDE5. Nevertheless, weak interactions with other isoforms
of the protein can lead to side effects. For example transient visual disturbances
may have resulted from the interaction with PDE6 (Wallis et al., 1999).
Perhaps the first example of structure based drug design is the discovery of in-
fluenza drugs targeting neuraminidase. Analysis of the crystal structure of the
enzyme neuraminidase in complex with the transition state mimic Neu5Ac2en
(Figure 1.4 b) showed there was an additional pocket at the base of the active site.
Computational analysis using some of the earliest fragment ideas (the program
GRID; Goodford, 1985; see also Section 1.1.7) identified that a positive amino or
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Figure 1.5: Sildenafil. PDE5 inhibitor marketed as Viagra.
guanidinium group would have enhanced affinity. Synthesis of such compounds
resulted in Relenza (marketed by Glaxo; Figure 1.6 a) with another mimic, Tam-
iflu (from Gilead Sciences, Figure 1.6 b), closely following (Von Itzstein et al.,
1993; Colman, 2006; Lew et al., 2000). The target-oriented approach to drug dis-
covery has dominated for the past 20 years; this has led to most projects following
a standardised drug discovery process: the “drug pipeline”. Before discussing the
pipeline in more detail, it is important first to consider the properties that are
required in a drug molecule.
(a) Zanamivir (b) Oseltamivir
Figure 1.6: Zanamivir and oseltamivir. Zanamivir is marketed as Relenza,
Oseltamivir as Tamiflu respectively.
1.1.2 Drug-like Molecules
During the 1990s, many drug discovery projects failed in later clinical trials be-
cause the drug candidate molecules did not have the right balance of properties
for efficacy when given to man. In the late 1990s, Lipinski et al. (2001, first in
1996) analysed the physicochemical properties of known orally available drugs.
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The Lipinski Rule of Five states that oral absorption and permeation of a com-
pound are better if it has:
 ≤ 5 hydrogen bond donors (expressed as the sum of OHs and NHs)
 ≤ 10 hydrogen bond acceptors (expressed as the sum of Ns and Os)
 ≤ 500 Da molecular weight
 ≤ 5 CLogP
(More explanation on molecular descriptors follows in Section 2.4 on page 57.)
The so-called Rule of Five was a landmark definition, as although it has oc-
casionally been over-used as a concept (good drugs are coming through which
do not obey the rules; some people forget it is just an empirical guide for oral
bioavailability), it has increased the attention paid to such properties for drug-like
molecules.
A drug molecule has to achieve a sufficient concentration at the site of action in
the body to bind to and modulate the target for a long enough period. A large
number of parameters are monitored and optimised during the drug discovery
process (see Section 1.1.3 below), the most important of which are:
Affinity
The affinity between a ligand and a protein can be determined with a various
number of affinity constants such as KD, IC50 etc. The stronger a drug is binding
to a protein (i.e. the smaller the affinity constant), the less amount of drug is
needed for the desired effect. This also reduces unwanted side effects. The type of
affinity constant obtained depends on the used assay. The dissociation constant
KD is in particular important because it is an universal constant and does not
depend on the assay conditions. It corresponds to the concentration of ligand at
which the binding site of a protein is half occupied. The IC50 is the half maximal
inhibitory concentration. It measures the effect of a compound in inhibiting a
biological or biochemical function in an assay (for example a dose-response assay),
and hence varies between experiments.
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Selectivity
A highly selective drug can reduce undesired side effects. However, drugs target-
ing a certain protein class, e.g. kinases, will all target the same substrate pocket
across the species, and selectivity is difficult to achieve. Relenza (zanamivir) se-
lectively inhibits influenza-specific neuraminidase (Figure 1.6 a, Barnett et al.,
2000). Sometimes, selectivity is not desired, for example for broad spectrum
antibiotics (e.g. amoxicillin in Figure 1.7 a). Binding to different isoforms of a
protein can also increase the effect and decrease toxicity, e.g. non-selective COX
(cyclooxygenase) inhibitors such as paracetamol (reviewed in Botting, 2006; 1.2
a). In contrast, selective COX-2 inhibitors (e.g. celecoxib) are controversial these
days because they might exhibit thrombotic cardiovascular problems (Figure 1.7
b, Mukherjee, 2002).
(a) Amoxicillin (b) Celecoxib
Figure 1.7: Amoxicillin and celecoxib.
Efficacy
The measurement of efficacy is therapeutic and often target dependent. During
the early stages of discovery, cell assays are used to monitor whether the drug
gets into cells. Usually they monitor whether any effect on cell biology can be
observed, often seen as an increase or decrease in the presence or modification
of some protein in the cell. These so-called pharmacodynamic (PD) markers
indicate what effect the compound is having on the body. Often, such markers
are also followed during pre-clinical development and clinical trials, to show that
the compound is reaching its site of action.
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ADME/PK
Pharmacokinetics is the measurement of the effect of the body on the drug. To
be effective, drugs need to be absorbed (A), be transported to or diffuse to the
site of action (distribution, D), appropriately evade or interact with the body’s
defence mechanisms for destroying foreign small molecules (metabolism, M) and
be excreted (E) at a suitable rate for therapy.
Toxicity
Toxicity is more appropriately known as tolerability. All molecules are toxic at
some dose; what is important is that the drug has minimal unwanted side effects
at therapeutic doses. This can be characterised in vitro by monitoring binding
to a selection of receptors, ion channels, transporters and enzymes (the panel
provided by Cerep is the most widely used) or by checking mutagenic potential
in an Ames test (McCann et al., 1975). The important check is in vivo, checking
whether the compound can be tolerated by the animal at an escalating dose.
1.1.3 The Drug Pipeline
The drug discovery pipeline can be represented as a linear process, summarised in
Figure 1.8. It consists of three major stages: discovery, pre-clinical development
and clinical trials. The discovery stage identifies a compound with the appropriate
drug-like properties to be taken forward as a clinical candidate. The pre-clinical
phase prepares the compound for introduction into man. The clinical trials check
first that the compound is safe and then that it is effective and how best to
provide it to which patients.
The terminology used to define and the metrics used to delineate the different
parts of the discovery stage vary between organisations and also depend on the
therapeutic area (for example, many CNS drug discovery pipelines introduce in
vivo activity requirements quite early in the process; some oncology indications
may not show therapeutic effect until in man). However, most have similar
characteristics:
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Figure 1.8: Drug Discovery Pipeline. The typical drug discovery approach
starts with the identification of a target. After hit identification and hit to lead
optimisation, the compound enters pre-clinical development and then enters three
phases of clinical trials. (Figure adapted from Hubbard, 2006)
The first step is to identify the molecular target (Lindsay, 2003; Egner et al.,
2005). This can be a protein, a nucleic acid or a multi-component complex.
In many ways, a target is not truly validated until a drug that binds only to
that target at therapeutic doses has been successfully used as a medicine for a
number of years. For most new targets, the most that can be hoped for is a strong
biological rationale, based on an understanding of the disease biology and relevant
pathways, usually reinforced by cell or animal experiments where the target is
disrupted (siRNA or knock-out), or for some conditions, from identification of
particular mutations in patients.
The next step is to find hits that bind to the target and affect its activity. These
can be relatively weak (low µM affinity, see Section 1.1.2). A process of ex-
ploratory chemistry (known as hits to leads) makes small changes to the hits to
establish them as suitable for optimisation. The dominant criteria is establishing
some understanding of which parts of the molecule are important for activity and
how they can be modified (so-called SAR, structure-activity relationships) and
that the compounds are amenable to further synthesis. At this stage, the other
“drug-like” properties (see Section 1.1.2) are considered, but mainly to identify
what needs to be changed during optimisation.
The most intensive step in discovery is lead optimisation. Here, the structure of
the compound is altered to improve its properties, as measured by a range of in
vitro, cellular and in vivo assays. The aim is to generate a clinical candidate with
the desired mix of affinity, efficacy, ADME and physicochemical properties. At
this point, the compound that could become a drug is fixed.
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Pre-clinical development assesses the safety and feasibility of launching clinical
trials in man. Synthetic routes are explored for making the large quantities of
pure compound needed for clinical trials. The safety of the compound is assessed
through an escalating series of dosing of various species as well as checking for
activity in a panel of standard safety assays (Ames/Cerep panel etc.). Depending
on the therapeutic area, there are continuing in vivo trials in animals to iden-
tify particular conditions or combination treatments. In addition, there can be
considerable work on formulations – that is finding how best to deliver the drug
during clinical trials.
Clinical trials are divided into phases I, II and III. In phase I, the safety of the
drug is tested on a small number of healthy volunteers. Phase II assesses the
actual efficacy of the drug while several hundreds of patients with the relevant
disease/condition are given the drug or a placebo. Additional information about
safety are also collected. In phase III, the trials are up-scaled to thousands of
patients to obtain more information about side effects and the drugs effectiveness.
If the drug passes all phases it can finally be launched on the market (Hubbard,
2006). Nevertheless, only one in nine drugs entering clinical development will
make it to the market (Paul et al., 2010).
1.1.4 Lead-like Molecules
The late 1990s and 2000s saw an increased focus on compound properties in the
drug discovery process. The Lipinski Rule of Five informed the criteria for a
molecule to be considered drug-like; further analysis attempted to define what
properties are desirable in a lead compound to give the maximum chance of
retaining drug-like properties in the optimized compound. Such analyses led to
the idea of lead-like molecules, with properties as:
 ≈ 450 Da MW
 -3.5 < CLogP < 4.5
 ≤ 4 rings
 ≤ 10 non-terminal single bonds
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 < 5 hydrogen bond donors
 < 8 hydrogen bond acceptors
Leads have simpler chemical features to make them suitable for further chemical
optimisation, an established structure activity relationship (SAR) series where
similar compounds exhibit similar activity and have favourable ADME properties.
In addition, patents issues of a scaffold should be avoided (Oprea et al., 2001).
1.1.5 A Matter of Chemical Space
In the 1990s, high throughput screening (HTS) was set in place by most pharma-
ceutical companies. With HTS, large compound libraries are screened in biochem-
ical assays by robotic systems. The libraries often derive from earlier projects
and combinatorial chemistry resulting in most HTS compounds already being
drug-like according to Lipinski’s Rule of Five, which leaves little room for lead
optimisation. That also means the HTS libraries cover only a small part of the
chemical space. For drug-like compounds in the size of 30 main atoms (C, N,
O and S), the chemical space is estimated to comprise 1060 molecules (Bohacek,
1996). Even with a library of 1 million compounds, only a very small part of the
chemical space can be covered. Another major drawback is the need for a suitable
and robust assay. A bigger part of the chemical space can be assessed with virtual
screening where compounds are docked into a 3-dimensional model of the protein
target. The approach is most successful when the high resolution structure of the
protein is known. Nevertheless, restraints are the scoring functions which predict
the rank of the most likely binding compound.
Hann et al. (2001) state that the probability if a compound is a hit depends on
the complexity of the compounds, rationalising the low success rate of HTS. If it
is too small, hits will not be detected in a screen while if they are too complex,
the likelihood of finding a hit in a random number of molecules is low. Hann and
colleagues suggested screening smaller sized compounds. Today, the suggested
smaller compounds are referred to as “fragments”. If a fragment is considered
to have only 11 main atoms, the fragment space contains 107 molecules (Fink,
2005). Comparison of the chemical space of molecules with 11 and 13 main
atoms respectively shows that the addition of two heavy atoms increases the
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chemical universe already from 26.4 million to 977 million compounds, i.e. 37-fold
(Reymond et al., 2011). Compared to the 1060 molecules in the drug-like space,
the number of fragments which have to be tested experimentally is significantly
minimized.
Useful starting points for lead identification for most targets can be identified
from a relatively small (typically 1000-member) library of low molecular weight
compounds in the 120–300 Da range.
1.1.6 Guiding Lead Selection and Optimisation
Since most screening campaigns result in more than one hit, sensitive choices
need to be made. A useful metric for lead selection was introduced by Hopkins
and colleagues to assess the quality of a binder and guide lead optimisation: The
ligand efficiency index (LE) is defined as affinity per size (Hopkins et al., 2004)
after an initially suggested concept by Kuntz et al. (1999) (also summarised in
Perola, 2010):
LE =
∆Gbinding
NNon−hydrogenAtoms
(1.1)
where NNon−hydrogenAtoms is the number of non-hydrogen atoms, and the free
binding energy ∆Gbinding (Gibbs energy) is defined by:
∆Gbinding = −RTlnKD (1.2)
with R the gas constant, T the absolute temperature and KD the dissociation
constant.
A more practical description for LE uses affinity parameters directly measured
by most experiments:
LE =
pKi/pKD/pIC50
NNon−hydrogenAtoms
(1.3)
An alternative description for the LE, but not as frequently used, is referred to
as binding efficiency index BEI (Abad-Zapatero and Metz, 2005):
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BEI =
pKi/pKD/pIC50
MW (kDa)
(1.4)
The LE was extended with consideration of the energy of binding per functional
group (Hajduk and Sauer, 2008; Verdonk and Rees, 2008) and including a con-
sideration of the lipophilicity. Lipophilic compounds obtain their binding energy
by desolvation which is not specific. Thus too lipophilic compounds can be more
promiscuous. The lipophilic ligand efficiency LLE was introduced by Leeson and
Springthorpe. in 2007:
LLE = pKi/pIC50 − ClogP/ClogD (1.5)
where LogP is the octanol-water partition coefficient and LogD the octanol-water
distribution coefficient. The higher the value, the higher the lipophilicity. Frag-
ments tend to be more polar than other compounds which is another advantage
of using fragments (Congreve et al., 2008). The ligand efficiency based on pIC50
(Equation 1.3) is typically between 0.3 for initial hits and 1.5 for matured drugs
(Siegal et al., 2007). Thus a useful fragment hit should have at least a LE of 0.3
to become a drug obeying the Rule of Five (Congreve et al., 2008). A study by
Hajduk (2006a) reveals that every added mass unit increases the affinity equally.
1.1.7 Earlier Studies Supporting the Fragment
Idea
The first ideas of deriving information for rational drug design from energy in-
formation of functional groups binding to a protein target appeared already in
the 1980s and early 1990s. In the beginning, the idea of the additivity of in-
trinsic binding energies was derived (Jencks, 1981; Andrews et al., 1984). The
computer program MCSS (Multiple Copy Simultaneous Search; Miranker and
Karplus, 1991) places functional groups in the active site of a protein. There are
also some modelling approaches of linked-fragments, e.g. LUDI (Bo¨hm, 1992)
and CAVEAT (Lauri and Bartlett, 1994). Furthermore, GRID finds binding
sites and estimates the binding energy using an interaction grid of various inter-
actions at the surface (Goodford, 1985). SPROUT designs new molecules while
31
adding functionalities to a primary structure which fits to a binding site (Gillet
et al., 1993). HOOK builds up on information from MCSS to derive information
about functional group sites and links them (Eisen et al., 1994). Complementary
to MCSS, the experimental approach MSCS (Multiple-solvent Crystal Structure)
was achieved by soaking organic solvents into crystals to map the protein surface
(first by Allen et al., 1996; discussed in detail by Mattos and Ringe, 1996; En-
glish et al., 1999). These studies reveal that already in the 1980s, the binding of
a compound was considered to result from a contribution of all its components.
The first practical approach to screening fragments dates back to the mid 1990s.
Abbott Laboratories detected many weak binding compounds for FKBP (im-
munosuppressant FK506 binding protein) via NMR (Shuker et al., 1996). Two
low micromolar fragments binding to adjacent pockets were optimised and linked
to a potent inhibitor. This article is nowadays known as the beginning of Frag-
ment Based Ligand Discovery (FBLD) (Figure 1.9).
Figure 1.9: HTS versus FBLD. (A) A typical HTS library contains millions
of complex scaffolds which are screened for fitting in the active site of a target
protein. (B) Fragments are less complex and thus more likely to fit into sub-
pockets of the active site. (C) After initial binding of fragments, the hits can be
evolved into larger lead compounds
1.2 Fragment Based Ligand Discovery
Over the last fifteen years FBLD has come of age, with a series of compounds
now entering the clinic. The main constraints are the need for a method that
can reliably detect weak binding and strategies for evolving the fragments into
larger lead compounds. Fragments detected binding to the active site can be
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evolved to larger compounds, either by linking or merging fragments together
or by growing the fragments to pick additional interactions (Figure 1.9). In
nearly all cases reported to date, this fragments evolution has relied on access to
experimentally determined structures of fragments bound to the target either by
X-ray crystallography or by high field NMR techniques (Jhoti, 2007a; Pellecchia
et al., 2008).
1.2.1 Detecting Fragment Binding
Typically, fragments bind to a target with an affinity (KD) in the 100 µM to
100 mM range. Detecting such weak binding is a challenge for most binding
assays and routine fragment screening has relied on the development of a range
of biophysical methods. The first published description of FBLD by the Abbott
group was detected by the perturbation of the HSQC (Heteronuclear Single Quan-
tum Correlation) spectrum of isotopically labelled protein (Shuker et al., 1996).
Later, commonly used methods to detect binding were also ligand-observed NMR
methods such as STD (Saturation Transfer Difference), crystallography, high con-
centration screening and mass spectrometry (Figure 1.10).
Two new methods have gained importance in recent years. The first is not yet
widely published, but is increasingly used. The thermal shift method is based on
monitoring the change in the temperature at which a protein unfolds during a
binding event, by monitoring the increase in fluorescence from a dye that interacts
into the protein as it is heated and unfolds (Kranz and Schalk-Hihi, 2011).
A more widely reported development is the increased use of surface plasmon
resonance (SPR) where either the target or a ligand is attached to a surface
whose optical properties change with molecular weight (Figure 1.10). Although
this technique has been available for some time, the recent increase in use has
come not only with improved sensitivity instruments, but also with increased
experience of strategies for robust attachment of the target to the surface and a
growing experience base for recognising artefacts (developments in Ha¨ma¨la¨inen
et al., 2008 and in Proll et al., 2009).
In addition, considerations of the kinetics of binding are gaining increased atten-
tion in the selection of compounds in drug discovery (Tummino and Copeland,
2008). It remains to be seen whether this kinetic characteristic is retained from a
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Figure 1.10: Typical flow from the fragment to the drug. The three es-
sential elements of a fragment-based discovery platform are a library of suitable
fragments, a method for identifying which fragments bind and a strategy for
evolving the fragments to larger hits for optimisation to lead compounds.
core scaffold to the final drug candidate – this could then be an additional metric
for the selection of fragments to progress.
Most practitioners are now converging on a common approach where a rela-
tively high-throughput technique (ligand-monitoring NMR or SPR) is used to
identify fragments that bind. These hits are often (particularly for challenging
protein-protein interaction targets) cross-validated by another biophysical tech-
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nique before being taken forwards for X-ray structure determination. Most are
finding a hit rate between 2 and 10%) even with small libraries of only 1,000 or
so fragments. This experience contrasts with HTS where 106 or more compounds
often fail to provide suitable lead compounds.
Despite this success, there are continued efforts to develop improved methods for
detecting and characterising fragment binding. A particularly striking method
is the TINS approach where the target is immobilised on a resin and ligand-
monitoring NMR signals measured (Siegal et al., 2007). The advantage is that
low amounts of protein are required and that it may be suitable for membrane
proteins. Calorimetric methods (Recht et al., 2008) may eventually gain the
sensitivity and throughput for the screening of fragments and consideration of
enthalpy/entropy characteristics may become an important mechanism for se-
lecting which fragments to progress (Freire, 2008).
1.2.2 Evolving Fragments
The past few years have seen a rapid increase in the number of papers which
describe advanced lead or clinical candidate compounds that have evolved from
fragments. All, to date, have relied on structural information to guide optimisa-
tion. The three main strategies which can be identified for progressing fragments
are linking, merging and growing (Figure 1.10). If more than one fragment is
discovered and those bind to different parts of the active site these fragment can
either be linked directly or via a suitable linker. The issue is to find the appropri-
ate linking strategy which does not change any distances or angles of the firstly
discovered fragments in order to achieve higher potency. This constraint makes
that strategy rather challenging. Merging also requires more than one bound
fragment. A catalogue of compounds is searched to find compounds which com-
bine functionalities of all compounds in their original position. Growing works by
substitution at one or more functional groups of the discovered fragment in order
to add groups with additional binding capacity. The directions of substitution
are called growth vectors. This method is usually successful and so is the most
popular strategy. (Hubbard, 2008; Congreve et al., 2008)
The following paragraphs describe some recent examples.
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The original SAR by NMR approach of Abbott (Hajduk, 2006b) relied upon find-
ing suitable chemistry to link two separately identified fragments. There are two
recent examples of this approach the Hsp90 programme from Abbott (Huth et
al., 2007) and one of the approaches adopted in the discovery of PKB inhibitors at
Astex (Saxty et al., 2007). The experience echoes that found by most practition-
ers, that it is difficult to find effective chemistry to link fragments together that
retains the orientation and position of binding of the individual fragments and
delivers the expected gain in potency. It remains to be seen whether the further
development of computational tools such as CONFIRM (Connecting Fragments
Found in Receptor Molecules) will help. A library is searched to find appropriate
bridges for fragments binding to a target. The hits are automatically linked and
docked to the target protein (Thompson et al., 2008).
A more successful method uses the structure of the fragment in the binding site
to guide growth of the fragment. Here, two main ideas are evident. The first is
where the structure of the fragment bound to the target is used as a substructure
to direct an in silico search of available compounds directories. This method is
known as SAR by catalogue (Figure 1.11). The powerful approach is in partic-
ular interesting for academic groups who have no access to a team of medicinal
chemists but is also realised in Big Pharma where FBLD is integrated in paral-
lel to conventional HTS. In some cases (as in the Hsp90 example form Vernalis;
Brough et al., 2008) the compounds identified are further filtered by focussed
docking to the target. This idea of using fragments as an initial screen or window
into larger collection of compounds is becoming a feature of the continued inte-
gration of fragment screening alongside HTS in large pharmaceutical operations.
An example is the virtual fragment linking approach at Novartis (Crisman et al.,
2008) and there are yet unpublished reports of similar strategies being adopted
at other companies.
The second growth method that has been widely reported as successful is where
the detail of the structure of the fragment-target complex is used to identify how
and where to grow or modify the fragments to increase potency or selectivity.
Two very recent examples have been published. In a particularly elegant example,
Astex synthesised a small number of compounds to progress rapidly from a weak
fragment to a potent inhibitor of Aurora kinase (Howard et al., 2009). A similar
approach at SGX, led to the rapid identification of a 78 nM JAK-2 kinase inhibitor
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Figure 1.11: SAR by catalogue. (1) Screen a Fragment Set (2) Find a hit (3)
Find nearest neighbours in a Non-Fragment Library (4) Find a stronger binding
hit
(Antonysamy et al., 2009).
The final method of fragment evolution is that of merging structural information
about fragments and known ligands. A recent example is the development of
PDPK1 (formerly known as PDK1) inhibitors by Vernalis, where the structures of
the fragments and initial hits from SAR by catalogue, were combined to generate
potent inhibitors which showed activity on cells (Hubbard, 2008).
Many of the examples of FBLD from smaller structure-based companies have
targeted kinases. There are historical and commercial reasons for this. The
companies had been founded as kinases were identified from cancer genomics and
there was seen to be a relatively low barrier to phase I trials in oncology. In
addition, this class of proteins has a well-defined and druggable active site and
are, in general, structurally tractable. However, there is also an increasing number
of reports of fragments being successful on other target classes for application in
the range of therapeutic areas. One reason is that fragment-based methods have
been used in large organisations as a backup strategy for drug targets that had
failed in HTS. The successes (particularly for protein-protein interactions such
as the Bcl-2 family; Oltersdorf et al., 2005) have highlighted a major advantage
of the fragment approach. Small compounds are more likely to bind into the
target binding site than the large, decorated compounds found in most HTS
collections. Although there can be challenges in determining crystal structures,
many are now finding fragments as an attractive approach for generating initial
hits against challenging targets. Recent examples from the literature are for β-
secretase (Albert et al., 2007; Congreve et al., 2007), prostaglandin D synthase
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(Hohwy et al., 2008) and hepatitis C virus NS5b RNA polymerase (Antonysamy
et al., 2008). In addition, the approach can be used on nucleic acid targets,
such as tRNALys3 to inhibit the HIV-1 reverse transcriptase initiation complex
(Chung et al., 2007).
For well-behaved targets, it is relatively straightforward to identify many dozens
of fragments that bind and in appropriate cases, generate crystal structures for
many of the fragments bound to the target. One challenge is the selection of
fragment(s) to progress. Fragment-based hit identification strategies are now
being integrated alongside HTS in many large pharmaceutical organisations.
Nevertheless, the base of every success of fragment hit identification is the se-
lection of an appropriate fragment library. This library must have a reasonable
size of compounds – preferably less than 1,000 compounds. At the same time it
should represent the chemical space as best as possible and also be as diverse as
possible.
1.3 Fragment Library Design
The success of FBLD greatly depends on the fragment library. As in any screening
process, the quality of the library dictates the quality of the hits found. Quality
in this case means compounds covering a wide range of chemical space with no
toxic or reactive groups and having the ability to be developed into drug-like
compounds. For fragment screening, there are additional constraints placed by
the screen at high concentrations and the need for appropriate synthetic routes
to evolve the fragment into lead compounds. The available literature on fragment
library design has been sparse during more than one decade of FBLD. However,
this is changing with a recent upsurge in publications.
In 2003, Astex introduced the Rule of Three for Fragments (Ro3) (Congreve et
al., 2003) which is based on Lipinski’s Rule of Five (Ro5) for drug-like compounds
(Lipinski et al., 2001, first in 1996). The Ro3 states that a fragment has:
 < 300 Da MW
 ≤ 3 hydrogen bond donors
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 ≤ 3 hydrogen bond acceptors
 ≤ 3 ClogP
 ≤ 3 number of rotatable bonds
 ≤ 60 A˚2 polar surface area
Many groups followed these guidelines to design their fragment library. Never-
theless, summaries by Brewer et al. (2008) and Law et al. (2009) reveal that
this is mostly considered a rough guide. Often, hydrogen bond acceptors and
number of rotatable bonds are higher (up to 8 hydrogen bond acceptors and up
to 6 rotatable bonds). However, a fragment should possess a molecular weight
of at least 150 Da (Babaoglu and Stoichet, 2006) to minimize reorientation of
the bound fragment during its evolution. Very small fragments are also often
found to bind in different orientations (Siegal et al., 2007); in addition, below
about 120 Da, the fragments bind only at quite high concentrations and at many
different sites, as seen in the Multiple Solvent Crystallographic Screen method,
pioneered by Mattos and Ringe (1996) and English et al. (1999).
Most libraries are constructed from chemoinformatics pipelines that take available
compounds and identify a representative subset that exclude reactive or toxic
molecules (Verheij, 2006) and assess solubility and chemical diversity. One of the
final steps is the rather subjective selection by medicinal chemists of compounds
and identification of a representative subset. Although risk of bias it does ensure
eventual hits will be progressed. Finally, rigorous quality control is required for
validation and continued curation of the library. The variants to this library
generation process include selection of privileged fragments from the analysis of
known drug compounds, or generating target-focussed libraries by including a
pharmacophore screen.
The following paragraphs give a historical perspective of fragment library design
before moving on to give an overall overview of the aim and the chapters in this
thesis. The different library design approaches are summarised under the key
design strategies:
 Intense filtering, diversity and visual selection criteria
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 Selection based on shapes and scaffold
 Libraries for special approaches
 Fragments based on known drugs
 Focussed fragment sets
1.3.1 Selection Based on Intense Filtering, Diversity and
Visual Inspection
Most published procedures of fragment library generation are based on selection
on physiochemical properties, the Ro3, intensive filtering of an input set to reduce
size, diversity criteria and visual inspection. A similar approach seems to be
applied by most Big Pharma. Several examples are listed below.
However, it is difficult to characterise and compare the quality of the different
fragment libraries from different organisations as comparative screening data is
not available. The only metric available is the reported hit rate; however that
depends on the sensitivity and cut-off of the assay used. However, in general, it
can be seen that the hit rate decreases as the average molecular weight of the
libraries increases beyond 200 Da, which is as expected from the arguments of
complexity of Hann et al. (2001).
Vernalis Library
A detailed description of fragment library generation is published by Vernalis
(Baurin et al., 2004). For Vernalis, the requirements of a library are a 2 mM
aqueous solubility and 200 mM solubility in DMSO for stocks. The compounds
must be stable in stocks and experiments. Furthermore, the fragment library
has to balance costs and practical issues with chemical diversity. The overall
library comprises 1,300 compounds. The first steps were achieved by automated
filtering. Unwanted groups such as anhydrides, aziridines or epoxides were re-
moved. Then, the compounds were filtered by wanted functionalities, e.g. at
least one ring of five or more members or one of specified functionalities such as
a carboxylic group. Compounds were selected to be diverse and to contain ap-
propriate physicochemical properties for the screening method, ligand-observed
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NMR. Compounds should also be easily tractable for chemical evolution. How-
ever, the final compounds were selected by medicinal chemists based on visual
inspection which introduced a subjective choice.
Astex Library
The screening process from Astex called Pyramid primarily uses X-ray crystal-
lography (Hartshorn et al., 2005) to screen two complementary sets of fragments.
Both sets contain relatively simple molecules of mostly between 100 and 250 Da.
The first of the two sets is a drug fragment set. From known drugs, low molecu-
lar weight ring systems and simple carboxylic and heterocyclic ring systems were
selected. The latter two were used for combination with side chains frequently
occurring in drugs, lipophilic chains and a set of N-substituents to generate a
virtual library. The library with 4,513 compounds was translated into SMILES
(introduced in Section 2.2 on page 52) and searched for commercially available
compounds. After manual inspection in order to remove toxic groups, a final set
of 327 compounds was purchased. The second set comprised of fragments tar-
geted against particular proteins and protein classes. The sets were constructed
by a virtual screen. A database with 3.6 million compounds of chemical suppliers
was filtered for desired physicochemical properties such as the Ro3. The obtained
compounds were docked into several protein conformations to obtain a protein
targeted set. The protein targeted sets were constructed using information of
literature and patents. After further evaluation such as enumeration with known
drugs, available compounds were purchased.
SGX Pharmaceuticals Library
SGX Pharmaceuticals (Blaney et al., 2006) selected their library based on the
minimisation of molecular weight, CLogP (Chapter 2) and complexity. Further-
more, the fragments must be accessible by rapid synthetic optimisation. There-
fore the compounds contain two to three chemical handles. A high proportion
of their compounds contain bromide whose anomalous dispersion signal helps
for structure validation when screening with X-ray crystallography. Compounds
containing non drug-like properties (Hann, 1999) were excluded if there were no
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specific chemical handles. To maximise the diversity of their library the com-
pounds were selected based on diverse ring system and 4-point pharmacophore
analysis (Mason, 1999). They also included ring systems of known drugs which
are contained in the MDDR (Elsevier MDL, 2004). Additionally, the compounds
must be soluble in high concentrations to facilitate screening by X-ray crystallog-
raphy. Finally, about 1,000 compounds were selected for the screening library.
Roche and GSK Libraries
Roche and GlaxoSmithKline are also using fragment screening in their lead dis-
covery projects. However, not much is known about the design of their libraries.
Roche selected their 2,000 strong fragment library based on the Ro3 and is screen-
ing with SPR (Hubbard et al., 2007). GSK has a set of compounds of reduced
complexity of in-house and purchased compounds. The compounds are slightly
bigger with a heavy atom count up to 21 atoms. The compounds were filtered
for non lead-like properties and their diversity was determined based on 3D phar-
macophore keys (Leach, 2006).
Evotec Library
Evotec has two separate fragment libraries which were constructed on different
principles (Brewer et al., 2008). The first was built for high concentration screen-
ing (HCS) with biochemical assays, the second for NMR screening. Both libraries
comprise about 20,000 compounds. The build-up of the HCS set started from
a database of in-house and commercially available compounds. Toxic and reac-
tive compounds were removed. Compounds were further filtered for a predicted
aqueous solubility higher than 1 mM, followed by a filter for physicochemical
properties such as number of hydrogen acceptors and molecular weight. The frag-
ments were selected based on UNITY fingerprints (introduced in Section 2.3.1 on
page 54) to obtain high diversity. All compounds were finally visually inspected
by medicinal chemists. The selection for the NMR set originated from a col-
lection of commercially available drug- and lead-like compounds. The collection
was filtered based on equal representation of substructures. Toxic and reactive
compounds were removed. The compounds were further filtered for molecular
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weight, CLogP and solubility and for physicochemical properties such as num-
ber of rotatable bonds (more in Section 2.4 on page 57). The fragments were
then validated for bioactivity and the availability of analogue compounds and
synthetic tractability was guaranteed. No unnecessary chemical restraints were
introduced such as bromine containing compounds for X-ray screening. The size
and diversity of the screened subset depends on the costs of the assayed pro-
tein. For costly proteins, a diverse subset of 5,000 compounds is selected using a
chemical dissimilarity algorithm.
AstraZeneca Library
One year later, AstraZeneca published their approach (Blomberg et al., 2009)
to design a 20 k generic library and a 1.2 k generic NMR screening library.
Both libraries were assembled from the AZ in-house library and from vendor
catalogues. The selection of compounds from these libraries followed the Core
and Layer method (CaL). That procedure selects from pools of structures and
uses decreasingly strict selection criteria. The first selection of compounds is
based on substructural requirements as the number of heavy atoms. The next
step applies practical properties of the sample (availability of solid and availability
of analogues). If a structure has a high number of nearest neighbours it is likely
to represent a prototype and to be synthetically easily accessible.
Pfizer Library
Recently, Pfizer described their approach to fragment library design (Lau et al.,
2011) as three stages consisting of filtering corporate and commercial libraries for
physicochemical properties and unwanted groups, applying diversity criteria and
finally a visual inspection of the compounds.
BioFocus Library
The BioFocus fragment library was selected based on the Ro3 (Pollack et al.,
2011) whereof compounds with unwanted functionalities were removed. The li-
brary was assessed for coverage of the chemical space and for diversity. 190,000
compounds from a the ChEMBL database containing bioactive drug-like small
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molecules were extracted based on the binding constant to their target. Com-
pounds were condensed into 1,500 clusters and the coverage with the fragment
library was assessed based on FCFP 6 fingerprints. 52% of the BioFocus library
were represented as substructures in the ChEMBL set and in total 1,308 clusters
were covered.
1.3.2 Selection Based on Shapes and Scaffolds
Another big group of common library design strategies is based on a shape or
scaffold selection.
Vertex Library
One of the first descriptions of how to design such a library was Vertex SHAPES
method (Fejzo et al., 1999). Their collection was derived from shapes which
are most commonly present in known drugs. The aim of their library for NMR
screening was the assembling of small molecules that optimised many factors at
the same time such as solubility, cost, synthetic tractability diversity and sepa-
ration of NMR peaks. Known therapeutics were decomposed into substructures
consisting of side chains, linkers and rings. Linkers and rings together were han-
dled as frameworks. An analysis of the CMC database (Comprehensive Medicinal
Chemistry, MDL Informatics Systems) showed that only 41 of these frameworks
including atom type and bond order described about 24% of all known drugs.
They combined those 41 frameworks with the 30 most common drug side chains.
Those compounds were used as templates for a substructure search of the ACD
database (Available Chemicals Directory, MDL Informatics Systems). The re-
sults were further filtered for beforehand specified side chains, solubility and in-
herent synthetic complexity or for representation of frequently occurring classes
in the CMC but not being within the 41 frameworks. The resulting compounds
were commercially available, soluble, pure and not reactive.
Plexxikon Library
The scaffold-library by Plexxikon started with the selection of compounds in the
range of 120–350 Da from 17 different suppliers (Card et al., 2005). Compounds
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with reactive groups were removed. The remaining compounds were fragmented
into smaller substructures through cutting of rotatable bonds. These substruc-
tures were then classified by chemical similarity. All compounds with > 0.85
Tanimoto similarity (more about similarity coefficients in Section 2.5 on page 58)
to another compound were removed. The process resulted in a fragment library
of 20,360 compounds which represent about 80% of the scaffold space.
ZoBio and Pyxis Discovery Libraries
The compounds of the fragment library of ZoBio and Pyxis Discovery (Siegal
et al., 2007) obey the Ro3 and four other themes: diversity guaranteed by the
scaffold-based classification approach (SCA) and by shape, amino acid derivates
and scaffolds present in natural products. Out of a pool of 70,000 fragments, the
first 500 fragments were selected for maximal diversity with the SCA approach.
For this purpose, molecules were fragmented in their ring systems and side chains.
With four descriptors (maximum number of smallest set of smallest rings, number
of heavy atoms, sum of heavy atomic numbers, number of bonds) the complexity
of the scaffolds was represented. The ratio of ring atoms to side chains gave
a cyclicity score. For the amino acid theme, the motifs of the 20 amino acids
connected to small rings were used. Scaffolds present in orally available drugs
and commercially available natural products were used as templates to search
representative molecules in the 70,000 fragment library to represent the natural
products theme. The selected fragments were compared with the whole pool and
500 fragments were selected to optimise the overall shape of the library. The
resulting final fragment library contained about 2000 compounds.
Broad Institute Library
Another article in 2011 describes the application of diversity-oriented synthesis
to fragment library design in order to create more three-dimensional fragments
(Hung et al., 2011). A fragment set with more sp3-rich compounds covers a bigger
part of the chemical space. In addition, more three dimensional compounds have
more suitable growth vectors to grow into sites otherwise possibly inaccessible.
The synthesised compounds further possess chemical handles. They do not only
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facilitate chemical optimisation, but also improve solubility and binding potency
due to more hydrogen bond donors and acceptors.
1.3.3 Specifically Purposed Fragment Libraries
Some companies have developed distinctive strategies for fragment screening and
evolution that require specialised libraries.
Sunesis Pharmaceuticals Library
In 2000, Sunesis Pharmaceuticals Inc. published their “tethering” approach of
FBLD (Erlanson et al., 2000). Binders are discovered by the formation of a
disulphide bond between the ligand and a cysteine residue of the target. Thus,
the Sunesis’ fragment library comprises disulphide containing compounds and a
library of about 1,200 members was synthesised. The library are screened in
pools by mass spectrometry.
Graffinity Pharmaceuticals Library
Graffinity Pharmaceuticals published their approach by SPR imaging (Neumann
et al., 2007). The possibilities with SPR allowed the company to design a diverse
library of 20,000 fragments. The Graffinity approach is based on coupling frag-
ments onto gold chips. Therefore compounds were synthesised on long linkers
with a thiol group at the terminus which is for the covalent coupling.
Novartis Library
Novartis published the design of a fluorinated fragment library which they are
using for their NMR approach (Vulpetti et al., 2009).
1.3.4 Fragments Based on Known Drugs
A newer academic approach is based on known drugs. Gianti et al. used Pipeline
Pilot to implement protocols that identify substructures of known drugs and drug-
like virtual screening sets. The resulting virtual library was used as template
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to generate a privileged fragment library which was further filtered for desired
physicochemical properties and unwanted functional groups. The procedure led
to a final collection of 29,500 compounds (Gianti and Sartori, 2008).
1.3.5 Focussed Fragment Libraries
More recently, smaller fragment libraries for individual targets or classes or tar-
gets appeared by academic groups. A retrospective analysis of kinase inhibitors
helped to design new kinase focussed libraries (Akritopulou-Zanze and Hajduk,
2009). Analyses of this type will be used by others to design novel fragments to
increase intellectual property freedom or increase coverage of particular chemo-
types. One example is the synthesis of a focussed fragment library of nine com-
pounds used to discover an inhibitor of Mcl-1 and Bcl-XL (Prakesch et al., 2008).
Agrawal et al. (2010) designed a library of small molecule chelators for the screen-
ing of metalloproteins with promising success. Chelators demonstrate suitable
binding affinities and good platforms for optimisation.
1.3.6 Relevance of the Rule of Three
The Rule of Three is widely quoted as the criteria for designing a fragment library.
The phrase attracted much attention, as it echoes the Rule of Five from Lipinski
et al. that had a real impact on medicinal chemistry practices in the early 2000s.
However, the Rule of Three is not useful and has attracted some criticism. For
example Ko¨ster et al. (2011) from the Klebe group assembled a fragment library
that did not conform to the Ro3 and screened it against endothiapepsin. Only
four of their eleven hits obeyed the Rule of Three.
In general, the trend of recent years (following the chemical space analysis of
Reymond et al., 2011) is for the average molecular weight of libraries to fall -
many have an average molecular weight of around 200 Da. It is the physical
properties of the compounds and their potential for chemical evolution that is
more important.
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1.3.7 Conclusion and Thesis Outlook
Naturally there are many more fragment libraries in use but not published. The
section of the published fragment libraries summarised above reveals that al-
though characteristics are known and discussed, a simple and straightforward
guide to library design is often missing. There is significant bias in the selection
of compounds with the constraints of the assay conditions as a major considera-
tion. To date, there has been no description of a library which has been designed
to represent the available chemical space. If the members of a fragment library are
representative substructures of the chemical space (or respectively all available
compounds), a superstructure search can be a quick way of fragment evolution.
The first part of this thesis targets this problem and introduces a number of
protocols for fragment library generation (Chapter 3 on page 62).
1.4 Aims in The Thesis
The work presented in this thesis is in three parts.
The first project was to implement an automated procedure to design and to
validate a fragment library that maximally represents superstructures and phar-
macophores. The aim is to have a fragment library from which hit fragments can
be readily evolved by purchase from available chemical databases. Such methods
will be of use to academic groups embarking on fragment based approaches to
identify tools for chemical biology. In addition, such methods may be of value to
institutions or companies which maintain large physical libraries of compounds,
where the fragment library can be designed to maximally represent the com-
pounds available.
The second part of the work was to test the fragment library on a number of
protein targets. The main focus of screening methods was on Thermal Shift
Analysis which led to the implementation of a new analysis program MTSA,
developed to improve the quality and ease of analysis of results generated by
that technique. The program MTSA and further analysis of the thermal shift
technique represent the third theme of this thesis.
The protein targets were N-myristoyl transferase (NMT), Hen egg white lysozyme
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(HEWL) and the GlcNACase enzyme, BtGH84. NMT is an enzyme established
by Prof. D. Smith (Biology) as a potential drug target for a number of tropical
diseases (in collaboration with Prof. Tony Wilkinson and Dr. Jim Brannigan
at the University of York, various scientists at Imperial College, Dundee Uni-
versity and the National Institute for Medical Research NIMR and with some
input from the pharmaceutical company, Pfizer). However, it proved difficult
to generate stable NMT for fragment screening. In an attempt to work with a
more tractable target (the protein can be purchased and it crystallises readily),
some work was performed with HEWL, for which a lot of literature is avail-
able. However, screening experiments with the enzyme were not reproducible.
Another carbohydrate binding target, BtGH84, was under study by a visiting
post-doctoral fellow (Dr. Jens Landstro¨m) and following his initial work, fur-
ther screening and analysis was performed. Many compounds were screened, and
inhibitors, inhibitor enhancers and what appear to be activity enhancers were
obtained.
The organisation of the thesis is as follows:
Chapter 2 introduces relevant chemoinformatics methods.
Chapter 3 describes the developed fragment library protocols and their evalua-
tion.
Chapter 4 introduces the thermal shift analysis and explanation of the imple-
mented program MTSA.
Chapter 5 gives an overview about the protein target NMT which was subcloned
to attach a double His6 tag and which was further tested for fragment screening
suitability.
Chapter 6 deals with HEWL for which several screening techniques were set up,
but delivered inconsistent results.
Chapter 7 summarises the results of screening 500 compounds against BtGH84
with thermal shift analysis with cross validation by surface plasmon resonance
and initial crystallisation trials.
Chapter 8 discusses the melting point definition used for thermal shift analysis
and questions the suitability of the method to screen low affinity binders with
that method.
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Chapter 9 summarises and discusses the previous chapters and gives and outlook
for future work.
Chapter 10 lists materials and methods deployed in this work.
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Chapter 2
Introduction to
Chemoinformatics
The fragment library design part of this project (Chapter 3, page 62) relies on
a range of chemoinformatics methods. This chapter introduces computational
handling of chemical structures, description of physiochemical properties and
similarity methods are introduced.
2.1 Chemoinformatics
Although many of the methods and ideas had been in use for decades, the term
Chemoinformatics was first introduced by Dr. Frank Brown in 1998. He de-
scribed it as “the mixing of those information resources to transform data into
information and information into knowledge for the intended purpose of making
better decisions faster in the area of drug lead identification and organization.”
(Brown, 1998) The term is also known as cheminformatics, chemical informat-
ics or chemiinformatics. The phrase is used widely and the discipline needs to
be distinguished from computational chemistry. The main focus in computa-
tional chemistry is constructing a model of a molecular system (at the orbital,
atomic or molecular level) from which properties of the system can be calculated.
In contrast, chemoinformatics is the handling of all sorts of information about
molecules. This may be derived from computation but also covers everything
from experimental data to where the sample is stored. There are three main
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aspects to chemoinformatics: the different representations of chemical structure
and handling, the calculation and representation of molecular properties and the
informatics methods that are used to store, search and analyse the structures
and properties (Engel 2006, Chen 2006, Leach and Gillet, 2007). The following
sections provide an introduction and summary of these different aspects.
2.2 Representation of 2D Structures
There are many possible ways to computationally represent chemical structures.
One can imagine an image file (Figure 2.1 a) or the IUPAC name (Interna-
tional Union of Pure and Applied Chemistry) (Figure 2.1 c). However, to search
substructures and to perform calculations, these notations are not very helpful.
The most sensible way to approach that problem is by graph theory: A graph
contains nodes (corresponding to the atoms) connected by edges (bonds). The
nodes and edges can have additional properties. For a chemical structure that
could be a certain atom type or the type of bond (Figure 2.1 b). The problem
of whether two graphs are the same is known as “graph isomorphism”. The
information of a molecular graph needs to be communicated to and from the
computer. One way is via so called connection tables. These tables may include
atoms, bonds, coordinates and more. Connection tables can be included in SD
files (structure data files) which were developed by MDL Information Systems
(Dalby et al., 1992) and contain information about atoms, bonds, connectivity
and coordinates (Figure 2.2). Alternatively, linear notations can be used. One
of the earliest linear representations was the Wiswesser Line Notation (WLN)
(Wiswesser, 1954). However WLN was surpassed by the more recent SMILES
notation (Simplified Molecular Input Line Entry Specification) (Weininger, 1988).
In SMILES, the atoms of a molecule are represented as letters of their atomic
symbol. Upper and lower case letters express aliphatic and aromatics atoms re-
spectively. Several other symbols describe bonds and their character, branches
are indicated with brackets (Figure 2.1d). For example C stands for methane
and CC(= O)O stands for acetic acid. In most cases, many different ways of rep-
resentation exist for one and the same molecule, however for computational han-
dling a canonical (uniform) representation is necessary. In contrast to SMILES,
InChI (IUPAC International Chemical Identifier) produces a unique string for ev-
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ery structure that is based on an extremely formalized version of IUPAC names
(www.iupac.org/projects/2000/2000-025-1-800.html).
Figure 2.1: Caffeine in different representations. The molecule caffeine is
represented as (a) an image file, (b) as a graph, (c) with its IUPAC name, (d) in
SMILES and (e) in InChI.
2.3 Searching Structures
Databases are used to store, manipulate and search molecules and additional
information such as name, physicochemical properties, assay data etc. The sim-
plest task is to search a complete molecule in the database. The wanted molecule
is translated into a canonical representation and the database is either simply
searched from the beginning or with the help of a hash key which directs straight
to the physical location on the hard drive. A hash key is a short integer which is
generated of a longer string by a hash function. With hashing, data can be in-
dexed and retrieved faster because the hash key is shorter than the original value.
More difficult is the search for substructures. A complex query can be transmit-
ted in SMARTS (http://www.daylight.com/dayhtml/doc/theory/theory.smarts.
html) which is the query extension of SMILES. Substructure searching can be
performed with graph theoretical methods. For large databases, a two-step mech-
anism is mostly applied to make searches fast and efficient. First, the struc-
tures which cannot match the query are eliminated (ideally at least 99% of all
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Figure 2.2: Caffeine as an sd file. The structure data file of caffeine contains
a connection table. The individual features are highlighted and annotated.
molecules). Secondly and more computationally intense, a subgraph isomorphism
algorithm (the most known being the adjacency matrix based algorithm by Ull-
mann, 1976) is performed to identify if the substructures are the same.
2.3.1 Fingerprints
The first step of database screening is usually performed using a bit string rep-
resentation of the molecules where a “1” stands for the presence of a certain
feature, e.g. a structural motif or a certain element, and a “0” for its absence
(Figure 2.3). These bit strings are called fingerprints. These fingerprints are also
used for similarity and clustering methods. There are two most commonly used
types of bit strings: structural key fingerprints and hashed fingerprints.
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Figure 2.3: Example of a bit string screen. In this example phenol is the
query. A possible bit string representation is shown on the right. If caffeine and
serotonin are entries in the database, it is impossible for caffeine to match because
the bit set in the query bit string is not set in the caffeine bit string. However it
is set in serotonin which would thus pass the initial screening filter.
Structural Key Fingerprints
The position of the key in a structural key fingerprint corresponds to the presence
or the absence of a certain structural motif such as “oxygen” or “at least one
ring of size 6”. The quality of that method depends on the accuracy of the
structural motif library. Some structural key fingerprints use a predefined library
of structural motifs like for example the MDL (Molecular Design Limited) keys.
MDL offers a limited amount of public keys which are released to the public and
a bigger number of private keys which are proprietary. The 166 public keys are
referred to as MDL Public Keys. MDL structural keys are developed for rapid
substructure searching in smaller to medium-sized databases.
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Hashed Fingerprints
The second method is the use of so called hashed fingerprints which do not need
a predefined library. Thus they are universally applicable. Path based hashed
fingerprints generate all possible paths of connected atoms in the molecule up to
a defined length. For example the molecule OC=CN has the paths C, O and N of
length zero, OC, C=C and CN of length one, OC=C, C=CN of length two and
OC=CN of length three. All these paths are used to set bits in a bit string. They
are hashed which also means that every bit in the final fingerprint can set by more
than one feature. This collision can result in a higher number of false positives
when screening. These paths are hashed to set the final bit string. Hashed
fingerprints can result in a higher number of molecules to be searched with the
slow graph isomorphism algorithm since the hashing method allows the same bit
to be set by different features resulting in a collision. The major representative
hashed fingerprints are those from Daylight Chemical Information Systems Inc.
(Daylight).
Other common classes of hashed fingerprints are the Extended Connectivity
Fingerprints (ECFP) and its variant the Functional Class Fingerprints (FCFP)
(SciTegic) which use initial atom identifiers for atoms and their environment
(Rogers and Hahn, 2010). Both are very effective in similarity searches. ECFP is
based on atom types and FCFP on generalised types (where for example all halo-
gens appear as equivalent). ECFPs and FCFPS represent a much larger set of
features than substructure based MDL fingerprints. They also can be processed
quicker because they are fast to calculate. ECPFs and FCFPs are generated in
a similar way. The only difference lays in the initial assignment step for each
atom of the molecule. The initial assignment of an ECFP gives each atom of the
molecule an identifier which is based on information of the atom type, atomic
mass, functional group etc. For the FCFPs the functional class of the atom
serves for the initial identifier. The assignment generates an initial code which
is hashed into a single 32-bit integer value which corresponds to the initial atom
identifier. From there the extended connectivity code calculates the next gener-
ations and removes duplicates. The first iteration considers the next neighbours
for each atom and updates the code. For the second iteration the next sphere of
neighbours is considered and so on up to the maximum diameter.
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Sometimes a combination of structural keys and hashed fingerprints is employed,
for example in the UNITY system (Unity).
The following chapter uses clustering and similarity searches with the program
Pipeline Pilot (Accelrys), where the default fingerprint FCFP 4 (Functional class
extended-connectivity fingerprint of maximum diameter 4) was used.
2.4 Molecular Descriptors
To manipulate and analyse chemical structures, a diverse range of molecular
descriptors is used. The next two sections describe the most important descriptors
which were used for the subsequent fragment library generation in Chapter 3.
2.4.1 Property Count
The simple property count counts, for example, the occurrence of a certain ele-
ment or hydrogen bond acceptors and donors. In the following, hydrogen bond
acceptors are defined as oxygen, nitrogen, sulphur or phosphorus with one or
more ion pairs. However, some groups are excluded such as: positively charged
atoms, amides and pyrrole-type nitrogens as well as aromatic oxygen and sul-
phur in heterocyclic rings. The hydrogen donors in this thesis are defined as
oxygen, nitrogen, sulphur or phosphorus when they have at least one hydrogen
atom attached.
2.4.2 Physicochemical Properties
One of the most important physicochemical properties is the partition coefficient
between n-octanol and water: P . Usually, P will be expressed in its logarithmic
form LogP . The reason why LogP is so important when working with drugs is
that drugs need to be water soluble enough to be transported to the cells, but
also hydrophobic enough to pass through the cell membrane. Commonly used
algorithms to determine LogP are CLogP (a program developed by Leo and
Hansch, 1993) and ALogP by Ghose and Crippen (Ghose and Crippen, 1986;
Ghose and Crippen, 1987; Ghose et al., 1988; Viswanadhan et al., 1989). CLogP
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works on fragmentation of the molecule into parts of which the solubility is known
whereas ALogP is atom based.
The next important physicochemical parameter is the aqueous solubility S which
also influences the bioavailability of drugs in the body. In this thesis, it is cal-
culated with the help of a multiple linear regression model based on electrotopo-
logical state (E-state) indices (Hall et al., 1991; Huuskonen, 1999; Tetko et al.,
2001). The index includes information about the electronic state of the atoms
influenced by the other atoms of the molecule in the context of the molecular
skeleton (Hall and Kier, 1995). The molecular solubility is expressed as LogS
with S being in the units mol/l.
Also the surface area and volume of a molecule are used as descriptors for frag-
ments and non-fragments. Here, the total surface is calculated using a 2D ap-
proximation.
2.5 Similarity Coefficients
A search of a database against a defined query or similar compounds requires a
method for calculating similarity (SIM). The searches are usually based on 2D
fingerprints. Many different similarity and distance measures for binary finger-
prints are available. If a are the bits set to 1 in molecule A, b the bits set to 1
in molecule B and c the bits set common in A and B and n is the total number
of properties, then the formula for the binary variables of the commonly used
Tanimoto coefficient (Jaccard, 1901; Tanimoto, 1957) is:
Tanimoto (Jaccard) coefficient SIMAB =
c
a+b−c
The Tanimoto coefficient compares all features (bits) present in two molecules.
Because smaller compounds contain less features (and thus have less bits set
to 1), the Tanimoto coefficient automatically punishes smaller compounds when
compared to larger ones. A fragment which is fully included in another compound
(i.e. being the exact substructure of another molecule) would not appear as 100%
similar. This is known as an asymmetric problem. The solution which is applied
in this thesis is the use of an asymmetric similarity coefficient, the Tversky index
(Tversky, 1977; Bradshaw, 1997).
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2.5.1 Tversky Coefficient
The general definition of the Tversky coefficient is given in Equation 2.1.
SIMTversky =
c
c+ β ∗ (a− c) + γ ∗ (b− c) (2.1)
where β and γ are additional weighing factors. If γ is set to 0 and β is to 1,
features only present in the superstructure compound are not taken into account
and leads to the equation:
SIMTversky =
c
a
(2.2)
The Equation 2.2 now represents the formula of a superstructure search. This
means a fragment is 100% similar to another compound if the latter fully includes
the fragment how graphically represented in Figure 2.4.
Figure 2.4: The Tversky coefficient. The Tversky coefficient produces a 100%
similarity if the fragment is fully included in the bigger reference compound. It
results in a 50% similarity if only half of the fragment is included. Thus, it
corresponds to a superstructure search.
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However, setting both weighing factors to 1 (β = 1 and γ = 1) results in the
Tanimoto coefficient (Jaccard, 1901; Tanimoto, 1957) which is used to compare
molecules of similar size. Equation 2.3 represents a similarity between two struc-
tures.
SIMTanimoto =
c
a+ b− c (2.3)
2.6 Clustering
Clustering itself is widely used in many disciplines. There are many different ap-
proaches to clustering which can be grouped into hierarchical and non-hierarchical
clustering. Hierarchical methods divide a set into ever-smaller regions or merged
sets as they move up the hierarchy. To rapidly cluster large data sets, the pro-
gram used in the following chapter (Pipeline Pilot) uses a partitioning method
which is non-hierarchical. A set of compounds is divided into ever smaller sub-
sets based on a maximum dissimilarity method: A random molecule is chosen
and named the cluster centre. The most distant molecule to this one is the next
cluster centre. The next cluster centre is formed by the molecule the most dissim-
ilar to both chosen cluster centres and so forth until sufficient cluster centres are
selected. The remaining molecules are assembled around these cluster centres.
The Pipeline Pilot cluster component is based on the Tanimoto coefficient and
the default and employed fingerprint was FCFP 4.
2.7 The Program Pipeline Pilot
Pipeline Pilot is a scientific program which offers preimplemented computational
modules in order to create work flows for automated processes such as analysing
and reporting data. The program allows scientists to focus on innovation rather
than programming tedious but known tasks. There are many possibilities to cus-
tomise parameters of the components or to script in the program’s own language
Pipeline Pilot Script. All protocols presented in the following chapter are imple-
mented with the professional edition of the program Pipeline Pilot from Accelrys.
The major reason for using the professional edition was that it runs on a server
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- resulting in much faster calculations. Furthermore, the professional edition has
additional features such as the “diverse molecules” component. However, the aim
was to generate protocols which also work with the free academic edition. Thus,
there exists a simplified version of each protocol for the free academic version.
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Chapter 3
Fragment Library Design
This chapter describes an approach used to identify a set of fragments that max-
imally represent a number of available compounds and therefore is a Fragment
Set suitable for the SAR by catalogue approach. Input Libraries of compounds
from suppliers are filtered to remove unwanted functionality, duplicates and salts
and then split into Fragment and Non-Fragment Libraries. A number of differ-
ent chemoinformatics approaches are used to identify Fragment Sets that contain
compounds from the Fragment Library that maximally represent the chemical
space of the compounds in the Non-Fragment Library. The characteristics of the
compounds in the final Fragment Sets are compared to determine the best selec-
tion procedure. All protocols were implemented with the program Pipeline Pilot
(Section 2.7 on page 60). Both the professional edition and the student edition
of the program were used during implementation.
3.1 Input Libraries
Compounds were downloaded from the ZINC database (Irwin and Stoichet, 2005)
(http://zinc.docking.org/) for three different suppliers to guarantee that the de-
termination of the best performing Fragment Set selection is not biased in favour
of a certain supplier. Single representation for each molecule of 600,220 com-
pounds from Asinex (http://www.asinex.com), 79,228 from Maybridge (http://
www.maybridge.com) and 321,371 from Specs (http://www.specs.net) were used
as Input Libraries.
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All of the following protocols were implemented with Pipeline Pilot. Clustering
and similarity were performed using FCFP 4 fingerprints. (Refer to Chapter 2,
page 51 for an introduction.)
3.2 Separation into Fragments and
Non-Fragments
The Input Libraries downloaded from the websites named above were divided
into Fragments and Non-Fragments as an initial preparation for Fragment Set
selection. The Input Library corresponds to the chemical space and the Fragment
Library to the fragment space.
Figure 3.1 summarises the process of the separation into Fragments and Non-
Fragments. Duplicates were removed based on canonical SMILES (Section 2.2,
page 52), with every molecule following the first occurrence being discarded.
Further, all salts were removed. In addition, SMARTS strings (Section 2.3, page
53) listed in Table A.1 (on page 188) were used to identify compounds for removal
that contain unwanted chemical functionality. The SMARTS filter contained 68
queries based on the papers of Baurin et al. (2004) and Verheij (2006).
Figure 3.1: Separation into libraries of Fragments and Non-Fragments.
After removal of duplicates and salts (not shown as separate step), the Input Li-
brary is filtered for unwanted groups defined in a SMARTS file. The compounds
are further filtered for molecular weight; all compounds >250 Da (>300 Da if
containing Sulphur) are written to the Non-Fragment Library. The smaller com-
pounds are further filtered for other fragment-like properties and then written to
the Fragment Library.
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Several steps were applied to further select compounds of the Input Library after
removing duplicates, salts and molecules containing unwanted groups. The num-
ber of compounds resulting from each of those steps is summarised in Table 3.1
with a detailed overview in Table 3.2. All compounds with a molecular weight
MW > 250 Da (> 300 Da if sulphur is present) were assigned to a so-called
Non-Fragment Library. The correspondingly named Fragment Library contains
all compounds with an MW ≤ 250 Da (≤ 300 Da if sulphur containing) excluding
molecules which did not satisfy the criteria of an extended Rule of Three (Ro3)
filter (page 38 for a definition). In an earlier test with the Asinex compounds,
use of the original criteria of the Ro3 had removed a very high number of pre-
fragments: Only 10% pre-fragments were selected for the Fragment Library. This
is consistent with the criticism of the Ro3 mentioned by others (Ko¨ster et al.,
2011, Section 1.3.6, page 47).
The extended Ro3 used to select fragments (with differences to the original Ro3
criteria in brackets if different) was:
 Atom count > 0
 100 ≤ molecular weight ≤ 250 Da (300 Da if sulphur) (< 300 Da)
 N-count + O-count (hydrogen acceptors) ≤ 6 (≤ 3)
 Hydrogen donors ≤ 3
 ALogP ≤ 3 (CLogP ≤ 3)
 Number rotatable bonds ≤ 5 (≤ 3)
 Molecular polar surface area ≤ 80 A˚2 (≤ 60 A˚2)
 Molecular solubility (calculated as LogS) ≥ -3.3 (not used)
3.2.1 Determination of the Solubility Threshold
The addition of the Molecular Solubility to the criteria is a strong selection filter
which tends to remove many compounds (Section 2.4, page 57). The Molecular
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Table 3.1: Input and output size of Libraries The numbers and percentages
of compounds remaining during preparation of Fragment and Non-Fragment Li-
braries from the Input Libraries. *Percentage calculated relative to number pass-
ing the MW filter.
Input Library Asinex Maybridge Specs
Initially from Zinc database 600,220 79,228 321,371
– duplicates removed 5,330 (1%) 2,322 (3%) 3,965 (1%)
– salts removed 0 (0%) 0 (0%) 0 (0%)
– unwanted functionality removed 317,755 (53%) 38,812 (49%) 196,331 (62%)
MW <250 Da (<300 Da with S) 24,914 (4%) 9,512 (12%) 17,620 (5%)
– removed with properties filter 13,450 (54%)* 5,050 (53%)* 8,829 (50%)*
– removed with solubility filter 3,768 (15%)* 1,434 (4%)* 3,150 (17%)*
Fragment Library 7,696 (1%) 6,484 (8%) 5,641 (2%)
Non-Fragment Library 252,221 (42%) 28,582 (36%) 103,455 (32%)
Table 3.2: Failed compounds in numbers Number of compounds in the low
MW list that fail the properties filters to be included in the Fragment Library.
MW: Molecular weight, HA: Hydrogen bond acceptors, HD: Hydrogen bond
donors, ALogP, RB: Number of Rotatable Bonds, PSA: Polar surface area.
MW<100 HA>6 HD>3 ALogP>3 RB>5 PSA>80
Specs (8,829) 38 (0.4%) 424 (5%) 57 (0.6%) 5,016 (57%) 640 (7%) 3,977 (45%)
Maybridge (5,050) 0 (0%) 213 (4%) 84 (2%) 2,482 (49%) 263 (5%) 2,954 (58%)
Asinex (13,450) 11 (0.1%) 1,183 (9%) 108 (0.8%) 4,870 (36%) 1,148 (8%) 9,004 (67%)
Solubility component implemented in Pipeline Pilot estimates the aqueous sol-
ubility of the compounds. In the section above, a solubility threshold of LogS
≥ -3.3 was chosen and here the reason for this choice will be explained. The
aim was to find a balance between the likelihood of solubility and the number of
remaining compounds. This was achieved with an empirical approach.
First, the aqueous solubility calculator of Pipeline Pilot was compared to that one
of the program MOE (Molecular Operating Environment, Chemical Computing
Group; done by Dr. Ijen Chen of Vernalis). Vernalis had good experience with the
solubility prediction of MOE. In a comparison of estimated solubility calculated
with both programs, Pipeline Pilot estimates stricter i.e. a lower solubility, than
MOE. As a result, the Pipeline Pilot solubility estimation can be trusted in the
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same manner as MOE’s.
The number of compounds removed on the basis of the threshold of aqueous
solubility was determined for compounds of Asinex and Specs during initial tests.
The percentage of compounds passing the individual solubility thresholds were
comparable (Tables 3.3 and 3.4).
Table 3.3: Number of Asinex compounds removed when adjusting sol-
ubility filter
All compounds Asinex: 600,220
After strict Ro3: 8,750 100%
Solubility LogS Passed Passed Failed
100 µM -4.0 8,027 92% 723
200 µM -3.7 7,318 84% 1,432
300 µM -3.5 6,656 76% 2,094
400 µM -3.4 6,299 72% 2,451
500 µM -3.3 5,940 68% 2,810
1 mM -3.0 5,940 68% 2,810
2 mM -2.7 3,696 42% 5,054
Table 3.4: Number of Specs compounds removed when adjusting solu-
bility filter
All compounds Specs: 321,371
After strict Ro3: 7,212 100%
Solubility LogS Passed Passed Failed
100 µM -4.0 6,546 91% 666
200 µM -3.7 5,860 81% 1,352
300 µM -3.5 5,306 74% 1,906
400 µM -3.4 5,013 70% 2,199
500 µM -3.3 4,665 65% 2,547
1 mM -3.0 3,693 51% 3,519
2 mM -2.7 2,813 39% 4,399
In the earlier PhD project of Dr. Kerrin Bright (Bright, 2009), the aqueous sol-
ubility threshold was set to 100 µM. 180 fragments were purchased from Specs.
Thereof, 8 compounds were impure and a further 68 insoluble at 200 mM in
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DMSO or at 100 µM in aqueous buffer. As 37% of the above compounds were
insoluble under the given conditions, this indicates the necessity of a more con-
strained threshold. Tables 3.3 and 3.4 highlight that a 100 µM filter let 90% of
the fragments pass the threshold. Conversely, this means if 37% less had passed
the filter, it is more likely that all were soluble. 90% (the number of passed com-
pounds) reduced by 37% corresponds to 66.7%. With regards to the Tables 3.3
and 3.4, this corresponds to approximately 500 µM aqueous solubility at which
LogS is equal to -3.3, hence this was taken as the new threshold.
3.3 Selecting a Fragment Set
There are many different possibilities for how one can approach the generation
of a subset of fragments which represents chemical space to the largest extent.
This section describes five different fragment library design procedures. All the
presented protocols start with the initial separation of the chemical space into
Fragment Library and Non-Fragment Library (Figure 3.1). Subsequent steps
vary depending on the individual protocol. They include clustering to guarantee
diversity and are compared to superstructures to guarantee high coverage of the
full chemical space. The final selection of fragments is written to a file called the
Final Fragment Set.
The following protocols are shown as implemented in the Pipeline Pilot Profes-
sional Edition (version 8.0.1.500). In this project, the program was installed to
run on a server for faster calculations. There is always an additional version
implemented in the freely available Student Edition (version 6.1.5.0).
3.3.1 Cluster All
In the Cluster All protocol (Figure 3.2), the initial separation into two libraries
is performed as described above (Figure 3.1). All compounds of the Fragment
Library are compared to all compounds of the Non-Fragment Library. Each
fragment is therefore augmented by a property of average similarity to all of
the Non-Fragments. The similarity is calculated with the asymmetric similarity
coefficient by Tversky (page 59) (Figure 3.2 2). Step 3 clusters both libraries into
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a pre-defined number of clusters (Section 2.6, page 60). Each cluster is written
to a separate file (Figure 3.2 3). Finally step 4 reads every cluster sequentially
and finds the fragments in each of them. The fragment with the highest average
similarity per cluster, as calculated in step 2, is selected and written to the file
Final Fragment Set (Figure 3.2 4). The computation time of this protocol is just
a couple of minutes when Pipeline Pilot Professional is run on the server.
Figure 3.2: Cluster All Selection of Final Fragment Set based of clustered
libraries.
3.3.2 Cluster Fragments
The second protocol, Cluster Fragments (Figure 3.3), works in a similar way to
the Cluster All protocol: All input compounds are split into two libraries (Figure
3.1). Secondly, each fragment is given a new property: average similarity to all the
Non-Fragments (Figure 3.3 2). The difference is in the final step which clusters
the Fragment Library only (not both Libraries as in Cluster All). Subsequently,
that fragment with the highest average similarity in each cluster is selected and
written to the Final Fragment Set file (Figure 3.3 3). The computation time of
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this protocol is just a couple of minutes on the server.
Figure 3.3: Cluster Fragments Selection of Final Fragment Set based of clus-
tered Fragments.
3.3.3 SIM within Cluster
This protocol, SIM within Cluster, (Figure 3.4) works like the previous ones using
the Cluster component. The difference here is that the two Libraries are clustered
first. Then the similarity between Fragments and Non-Fragments is calculated for
each cluster separately (Figure 3.4 2). The fragment with the highest similarity
to the Non-Fragments in its cluster is selected and written to the Final Fragment
Set (Figure 3.4 3). The protocol runs within a couple of minutes with the Pipeline
Pilot Professional version on the server.
3.3.4 Substructures
The following approach to fragment selection differs from the previous ones (Fig-
ure 3.5) and is not based on clustering. In the protocol Substructures, all frag-
ments from the Fragment list are further “fragmented” into substructures. The
presence of those substructures in the Non-Fragment list is rated. Those frag-
ments whose substructures are most present in the Non-Fragments are selected
(Figure 3.5 2).
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Figure 3.4: SIM within Cluster Selection of Final Fragments Set based on the
similarity within clustered Libraries.
Two rather similar modules used to count the presence of those substructures
are available in Pipeline Pilot (Substructure Count and Substructure Map). Be-
cause they produce different results, they are treated separately. However, the
logical procedure remains the same. In Substructure Count all occurrences of the
substructures in all Non-Fragments are counted. Whereas if a query is mapped
with the Substructure Map component, the count will increase by one indepen-
dent of the number of mapped queries. Depending on the library size, these two
protocols may take days to run on the server with the Pipeline Pilot Professional
edition.
Figure 3.5: Substructures Selection of Final Fragment Set based on a substruc-
ture search.
3.3.5 Iterative Removal
The final and most complex method is called Iterative Removal and has been
implemented with some help from Eddy Vande Water from Accelrys. Figure
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3.6 (steps 2–4) shows the logic of this protocol. In step 2, the number of Non-
Fragments which have a Tversky similarity > 60% to each fragment is counted.
The 100 fragments with the highest number of such “nearest neighbours” (find
more details below in Section 3.4.2) are then compared and the most diverse
compound selected for the Fragment Set and removed from the Fragment Li-
brary. In step 3, the compounds with a Tversky similarity > 70% (Section
2.5.1, page 59) to this selected Fragment are removed from the Non-Fragment
Library. The calculation is then repeated (back to step 2) with the reduced Frag-
ment and Non-Fragment Libraries to identify the next most diverse Fragment
with a high number of nearest neighbours and so on to eventually generate the
Fragment Set of desired number of compounds (step 4). The similarity cut-offs
were chosen to maximise the number of Non-Fragments for subsequent selections.
Preliminary calculations showed that 50% Tversky similarity removes too many
Non-Fragments and 80% too few (more in Section 3.4.2).
On the server with the Pipeline Pilot professional edition, the protocol will be
finished a few hours after initiation. A slightly modified version without the
Diverse Molecules component can run on the Pipeline Pilot student edition.
3.4 Additional Information to the Selection
Protocols
3.4.1 Computation Time
The execution of the Pipeline Pilot protocols depends on the size of the input
library, on which machine the calculation takes place and also on the number
of fragments which must be selected for the Final Fragment Set. However as a
rough guide, protocols based on clustering, Iterative Removal and the Substruc-
ture protocols take minutes, hours and days respectively for execution.
3.4.2 Nearest Neighbour Definition
The protocol Iterative Removal and some of the following analysis protocols
require a definition of the term “nearest neighbour”. “Neighbours” are com-
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Figure 3.6: Iterative Removal Selection of Final Fragment Set based on itera-
tive removal of top fragment and nearest neighbours.
pounds whose similarity to the fragment can be calculated with the Tanimoto or
Tversky coefficient (Section 2.5, page 58). “Nearest neighbours” are compounds
which have a similarity coefficient above a certain threshold between 0 and 1
(i.e. between 0 and 100%). Because here the compounds are fragments and the
neighbours are larger compounds, the Tversky coefficient was used. Figure 3.7
illustrates, for the example of the Specs compounds, the nearest neighbour distri-
bution. It is illustrated how many compounds have how many nearest neighbours
for the thresholds 50–80%. The distribution is shown as histograms with a bin
size of 1,000 compounds. One may note by the shape of the histograms that have
a 50% similarity (Figure 3.7 a) as nearest neighbour definition includes far too
many compounds whereas an 80% similarity (Figure 3.7 d) excludes too many
compounds. Thus a nearest neighbour needs to be defined between 60 (Figure
3.7 b) and 70% Tversky similarity (Figure 3.7 c).
The Iterative Removal protocol was run using the 60% definition and the 70%
definition, as well as with the combination of both. The run using 60% has
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(a) 50% SIM (b) 60% SIM
(c) 70% SIM (d) 80% SIM
Figure 3.7: Nearest neighbour distribution. A screenshot from the Pipeline
Pilot output shows the distribution of nearest neighbours depending on threshold
set for definition of nearest neighbour. The similarity is calculated between the
Fragments and the Non-Fragments of Specs.
been found to remove too many compounds, whereas using 70% removed too
few. Nevertheless a combination of both values was found to perform best: The
fragment with the highest number of nearest neighbours is selected based on
60% similarity. However, only those reference compounds being more than 70%
similar to that selected fragment are removed from the Non-Fragments. Thus,
the Iterative Removal is carried out based on two different definitions of “nearest
neighbour”.
3.4.3 Determination of Fragment Set Size
For a suitable analysis of the protocols, the size of Final Fragment Sets needed to
be decided. Table 3.1 on page 65 gives an overview on the size of the Fragment
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Set during each step towards the final fragment selection. For example, the
supplier Specs offers 321,371 input compounds. Those compounds were broken
down into two Libraries consisting of 5,641 fragments and 103,455 non-fragments.
For the analysis in this thesis 200 fragments were selected for the Final Sets. A
bigger number was thought not to give a diverse and representative subset which
can also be seen in Figure 3.8: The number of nearest neighbours decreases
rapidly with the Iterative Removal procedure. A Fragment Set bigger than 200
would represent too high percentage of the Fragment Library, making 200 the
optimal Fragment Set size. However, the SIM within Cluster and the Cluster
All procedure generate a slightly smaller number. Due to the implementation of
those procedures, there are possible clusters which do not contain any fragments.
(a) Asinex (b) Maybridge
(c) Specs
Figure 3.8: Decrease of nearest neighbours for the Iterative Removal
Procedure. A screenshot of the Pipeline Pilot output shows the available num-
ber of nearest neighbours decreases rapidly with this procedure. Pictured are the
number of nearest neighbours removed by the procedure Iterative Removal for
the selected fragments (in selection order) for all three test libraries – Asinex,
Maybridge and Specs.
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3.5 Profiling the Fragment Set
The aim of the selection protocols is to generate a Fragment Set which represents
the maximum number of Nearest Neighbours in the Non-Fragment library.
The following analysis shown is applied to the Specs compounds as an exam-
ple. Good experience with this supplier was made in previous buys (e.g. clean
compounds, reasonable prices and quick delivery). However, complete analysis
was done with compounds from Asinex and Maybridge to avoid any bias towards
a particular supplier and delivered comparable results (Appendix B). Fragment
Sets were profiled with their physicochemical and quality criteria such as diversity
and drug-like properties. This section gives the results of the profiling process.
Table 3.5: Physicochemical profile of the Fragment Sets of Specs - Part 1
Properties of the Fragment Sets generated by the different protocols for Specs
and an overview of the original Fragment Libraries of all three supplier lists. An
overview for the individual Fragment Sets of all suppliers can be found in the
Appendix in Tables B.1 - B.3. MW: Molecular weight, AC: Number of heavy
atoms (non hydrogen), FC: Formal charge, ALogP, HA: Number of hydrogen
bond acceptors.
Library MW AC FC ALogP HA
Asinex 216.5±33.35 15.3±2.30 -0.23±0.47 1.11±1.03 3.1 ±0.99
Maybridge 203.4±30.71 14.3±2.17 -0.18±0.42 1.36±0.89 2.9±1.03
Specs 205.4±37.69 14.5±2.63 -0.11±0.42 1.35±0.94 2.8±1.03
Cluster All 180.1±37.56 12.7±2.87 0.01±0.40 1.32±0.91 2.5±1.18
Cluster Fragments 179.5±36.87 12.7±2.80 0.01±0.38 1.33±0.86 2.5±1.12
SIM within Cluster 201.9±38.42 14.3±2.79 -0.04±0.43 1.48±0.92 2.8±1.18
Substructure Count 220.7±28.24 16.3±1.74 0.00±0.40 1.95±0.62 2.7±1.07
Substructure Map 237.7±26.34 17.3±1.46 -0.01±0.22 2.10±0.65 2.6±0.93
Iterative Removal 174.9±31.58 12.2±2.23 -0.11±0.32 1.38±0.96 2.1±0.85
3.5.1 Profiling for Physicochemical Properties
The fragment sets were profiled for physicochemical properties using the methods
implemented in Pipeline Pilot. Tables 3.5–3.7 give an overview about the physic-
ochemical properties of the generated Fragments sets. They are also graphically
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represented in Figure 3.9. A detailed overview can be found in the appendix in
Tables B.1–B.3 .
Table 3.6: Physicochemical profile of the Fragment Sets of Specs - Part 2
HD: Number of hydrogen bond donors, RB: Number of rotatable bonds, PSA: Po-
lar surface area, LogS: Solubility, ArB: Number of aromatic bonds.
Library HD RB PSA LogS ArB
Asinex 0.8±0.76 2.42±1.30 57.9±14.35 -2.30±0.76 7.09±3.57
Maybridge 0.7±0.75 1.94±1.27 56.6±14.78 -2.34±0.69 7.10±3.50
Specs 0.8±0.71 2.18±1.45 54.1±15.35 -2.33±0.74 6.90±3.31
Cluster All 0.7±0.69 1.44±1.30 49.8±17.84 -2.12±0.86 6.77±4.13
Cluster Fragments 0.7±0.71 1.59±1.35 48.9±17.60 -2.11±0.84 6.54±3.92
SIM within Cluster 0.7±0.67 1.90±1.43 52.3±16.13 -2.30±0.88 7.51±3.98
Substructure Count 0.8±0.78 2.21±1.11 49.3±16.67 -3.01±0.26 12.73±2.03
Substructure Map 0.7±0.81 1.77±0.93 47.2±17.05 -2.79±0.44 8.76±3.92
Iterative Removal 0.4±0.62 1.54±1.26 42.7±16.13 -2.17±0.77 6.02±2.98
Table 3.7: Physicochemical profile of the Fragment Sets of Specs - Part 3
R: Number of rings, ArR: Number of aromatic rings, RA: Number of ring assem-
blies.
Library R ArR RA
Asinex 1.9±0.63 1.3±0.69 1.5±0.52
Maybridge 1.8±0.73 1.3±0.67 1.4±0.55
Specs 1.8±0.71 1.2±0.63 1.4±0.52
Cluster All 1.7±0.78 1.2±0.77 1.3±0.51
Cluster Fragments 1.6±0.74 1.2±0.72 1.3±0.51
SIM within Cluster 1.9±0.73 1.4±0.75 1.4±0.55
Substructure Count 2.4±0.52 2.2±0.43 2.0±0.33
Substructure Map 2.9±0.68 1.5±0.71 2.1±0.44
Iterative Removal 1.5±0.70 1.0±0.54 1.2±0.45
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Figure 3.9: Properties of Fragment Libraries and Specs Fragment Sets.
The first rows show the physicochemical property distribution of the three Frag-
ment Libraries by supplier. The following rows show how these properties are
distributed for the Fragment Sets generated with each of the different protocols on
the example of Specs. MW: Molecular weight, ALogP, RB: Number of rotatable
bonds, PSA: Polar surface area, AC: Number of heavy atoms (non hydrogen),
FC: Formal charge, LogS: Solubility, HA: Number of hydrogen bond acceptors,
HD: Number of hydrogen bond donors, R: Number of rings, ArR: Number of
aromatic rings, ArB: Number of aromatic bonds, RA: Number of ring assemblies.
3.5.2 Quality Selection Criteria
In addition to the physicochemical properties the Fragment Sets were profiled as:
(a) The number of Nearest Neighbours with greater than 70% Tversky similarity
(SIMILARITY)
(b) The average number of Non-Fragments that have less than 70% Tversky
similarity for each fragment (NON-SIMILAR)
(c) The average similarity for each Fragment with drug-like molecules, calculated
as (1) the average similarity with compounds from the Non-Fragments library
that satisfy Lipinski’s Rule of Five (DRUG-LIKE 1) and (2) the average
similarity with compounds from the World Drug Bank (www.drugbank.ca)
(DRUG-LIKE 2)
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Table 3.8: Quality criteria and analysis The six quality criteria and their
outcome for the different procedures. SIMILARITY is the number of nearest
neighbours with > 70% Tversky similarity, NON-SIMILAR is the average num-
ber of Non-Fragments that have less than 70% Tversky similarity for each frag-
ment, DRUG-LIKE 1 is the similarity to Non-Fragments filtered with the Lipin-
ski filter, DRUG-LIKE 2 is the similarity with molecules from the World Drug
Bank, DIVERSITY 1 is the average Tanimoto similarity within the Fragment
Set and DIVERSITY 2 is the standard deviation of an equal cluster distribu-
tion within the Fragment Set. The asterix marks the best performing procedure
where SIMILARITY is high, NON-SIMILARITY is low, DRUG-LIKE 1 is high
and DIVERSITY 1 and 2 are low.
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Cluster All
Asinex 217,156 246,820 0.421 0.307 0.201 6.34*
Maybridge 23,446 28,190 0.373 0.295 0.172 7.62
Specs 95,103 100,239 0.406 0.309 0.179 8.71
Cluster Fragments
Asinex 218,136 247,350 0.407 0.298 0.184 8.27
Maybridge 23,866 28,183 0.367 0.291 0.162 9.44
Specs 91,572 101,211 0.384 0.301 0.159 8.62
SIM within Cluster
Asinex 178,519 249,631 0.367 0.267 0.164* 8.40
Maybridge 18,848 28,385 0.331 0.264 0.145* 8.50
Specs 75,175 102,367 0.343 0.261 0.147* 10.28
Substructure Count
Asinex 108,589 249,439 0.390 0.267 0.256 10.03
Maybridge 11,072 28,446 0.337 0.250 0.200 9.54
Specs 45,757 102,508 0.367 0.265 0.235 11.42
Substructure Map
Asinex 121,667 250,317 0.367 0.276 0.201 11.42
Maybridge 11,865 28,462 0.349 0.281 0.191 6.79*
Specs 50,207 102,780 0.373 0.284 0.201 8.07*
Iterative Removal
Asinex 229,040* 245,541* 0.436* 0.319 0.198 10.07
Maybridge 25,198* 27,976* 0.407* 0.312 0.198 8.60
Specs 99,273* 98,749* 0.444* 0.335 0.193 8.18
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(d) The chemical diversity of the Fragment Set, calculated as
(1) DIVERSITY 1: the average Tanimoto similarity within the Fragment
Set and (2) DIVERSITY 2: how equally distributed the Fragment Set is
when clustered on fingerprint, calculated as the standard deviation of the
number of compounds in each cluster. In the results reported here, 20 clus-
ters were used as there were 200 fragments.
The protocols for this profiling analysis were implemented with Pipeline Pilot.
The execution time of the analysis protocols is a few minutes per library with
the Pipeline Professional edition on the server. Table 3.8 shows the result of the
analysis for all three suppliers.
3.5.3 Library Overlap
The five implemented protocols generate different Final Fragment Sets. Table 3.9
illustrates the overlap between the final libraries generated with the input from
Specs.
Table 3.9: Library overlap on Specs example Number of overlapping com-
pounds between the different Fragment Sets.
Procedure
Cluster
All
Cluster
Frag-
ments
SIM
within
Cluster
Sub-
structure
Count
Sub-
structure
Map
Iterative
Re-
moval
Cluster All x 80 13 11 8 36
Cluster Frag-
ments
80 x 15 12 8 35
SIM within
Cluster
13 15 x 17 10 8
Substructure
Count
11 12 17 x 69 10
Substructure
Map
8 8 10 69 x 6
Iterative Re-
moval
36 35 8 10 6 x
3.6 Discussion
Table 3.1 summarises the number of compounds from each supplier (Specs, May-
bridge and Asinex) that remained after each stage of processing. In addition,
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Table A.1 also shows the number of compounds removed in generating the Input
Library from each supplier for each of the unwanted chemical functionalities.
A large number of compounds are removed by the unwanted functionality filters.
The filters for nitro, methylene, tertiary or quaternary amines, acrylates and
atoms that are not C, N, F, Cl or S remove the most compounds. There is
a similar profile of exclusions across the three suppliers, except the Maybridge
Input Library has proportionately more acrylate and tertiary amine containing
compounds. In addition, the Maybridge Input Library contains a proportionately
larger number of compounds (12%) with low MW, compared to Specs (5%) and
Asinex (4%), but about the same percentage (50%) of these low MW compounds
from each supplier do not have the desired fragment properties. Table 3.2 lists
the number of low MW compounds that do not pass the various property filters
to be selected for the Fragment Library from the low MW list. The main failures
are based on polarity (ALogP and PSA), with similar percentages of compounds
failing for each of the suppliers.
The properties of the resulting Fragment Libraries are shown in Tables 3.5–3.7,
and shown as bar charts in Figure 3.9. The Fragment Library from Specs has
the expected distribution of properties given the criteria used for identifying
the Library, with the most striking feature being the hard cut-off for solubil-
ity. The property distribution is similar for the other Fragment Libraries from
Maybridge and Asinex (as would be expected given the strict criteria applied for
selection), although the Asinex derived fragments are overall slightly larger com-
pounds with more rotatable bonds, rings, H-bond acceptors and slightly more
negatively charged.
Fragment Sets were derived and profiled for each of the six protocols for each
Fragment Library from the three suppliers. In this section, the characteristics of
the process and the properties of the different Fragment Sets are discussed in de-
tail for one of the suppliers (Specs), with additional comments on any differences
seen for the other two suppliers.
The properties of the six different Fragment Sets derived from the Specs Fragment
Library are listed in Tables 3.5–3.7 and illustrated in Figure 3.9. Four main com-
ments can be made about the properties of the different Fragment Sets compared
to the parent Fragment Library. First, Cluster All, Cluster Fragments and Itera-
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tive Removal select smaller compounds, as reflected in the molecular weight and
heavy atom count. SIM within Cluster selects compounds with representative
properties, whereas the two Substructure protocols select larger compounds with
higher ALogP values. Secondly, Iterative Removal selects positively charged frag-
ments, whereas the other protocols select some negatively charged ones, giving a
small overall shift in the charged nature of the Fragment Sets. Also, compounds
in the Iterative Removal Fragment Set have fewer hydrogen bond donors and
acceptors. Thirdly, the Similarity within Cluster Fragments Set has the closest
property profile to the Fragment Library. Finally, there are surprising differences
in the properties of the compounds selected by the two Substructure protocols.
The Fragment Set produced by the Substructure Count method has more hydro-
gen bond donors and acceptors, more rotatable bonds and more aromatic bonds,
whereas the Fragment Set produced by the Substructure Map method has more
rings and ring assemblies, a higher ALogP and larger compounds. The Fragment
Sets derived by the six Protocols for the other suppliers show the same pattern
of differences in characteristics (summarised in Tables B.1–B.3).
Table 3.10: Final scoring of all procedures Each time when a procedure
performed best in one criterion (according to an asterix in Table 3.8), the relevant
protocol gets one score. DRUG-LIKE 2 was not taken into account because it
depends on the employed strategy (finding similar drugs or avoiding intellectual
property). With nine scores, the Iterative Removal performs outstandingly better
than the other protocols.
Protocol Score
Cluster All 1
Cluster Fragments
SIM within Cluster 3
Substructure Count
Substructure Map 2
Iterative Removal 9
Some of these differences in properties can be rationalised by the nature of the
protocols used. In SIM within Cluster, the compounds are clustered first and
then the most representative fragment is selected. Assuming that clustering on
FCFP 4 properties effectively clusters on the physicochemical properties, then
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it is not surprising this Fragment Set has the most similar properties to the
Fragment Library. On the other hand, the Substructure protocols will select for
larger fragments as more substructures will be present in such fragments and thus
a higher score obtained for the presence of substructures in the Non-Fragments.
The differences between Substructure Count and Substructure Map are due to the
way bonds and ring features are counted. For example, if a molecule has seven
more bonds and one more ring, then Count will give an increased score of eight,
whereas Map would give an increased score of just two. The differences seen in
the Iterative Removal set is probably because the smaller fragments will have a
higher Tversky similarity to more Non-Fragments and will thus be selected in the
first part of that Protocol. Such smaller fragments will also have a lower number
of hydrogen bond donors and acceptors as well. However, the small differences
seen in the average formal charge across the Fragment Sets is difficult to explain.
It may not be significant, given the small number of compounds with charges
that are present in the dataset.
Table 3.8 provides a profile of the overall characteristics of the Fragment Sets, con-
sidering the properties that are important for a screening collection. For these
properties, the best library would be one that has a high SIMILARITY (and
low NON-SIMILARITY) to the Non-Fragments, contains a diverse collection of
fragments (low DIVERSITY scores), and is DRUG-LIKE. On these criteria, the
Iterative Removal is overall the best performing protocol, with the exception of
DIVERSITY scores, where it is average (Tables 3.8 and 3.10). As high SIMI-
LARITY score is the primary aim of the library design, this has been analysed
in more detail. Figure 3.10 a plots the number of fragments (y-axis) from each
of the Fragment Sets that have more than a given number (x-axis) of compounds
in the Non-Fragment Library from Specs which are more than 50% similar by
Tversky. This metric reinforces the SIMILARITY calculation and shows that
the Iterative Removal protocol is the most effective at generating a library that
has the greatest coverage of the Non-Fragments. Figure 3.10 b shows how this
Fragment Set covers the Non-Fragments at range of Tversky similarity from 20%
to 90%.
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3.7 Concluding Remarks
Different protocols for selecting Fragment Sets that are representative of a com-
pound library were developed and investigated. The Iterative Removal protocol
generates the best Fragment Set, judged by the similarity to the Non-Fragments
and the overall characteristics of the Set. These protocols are relatively straight-
forward to implement and could be used to select fragments for screening with
an increased probability that nearest neighbour compounds will be available for
subsequent fragment evolution.
Two rounds of iteration led to the purchase of two new fragment sets in York
- called “Michele 1” and “Michele 2”. A preliminary version of the Iterative
Removal was used to create “Michele 1”. 201 fragments were purchased of Specs,
whereof 95% were soluble at 200 mM in DMSO-d6. The better solubility compares
well to older libraries generated in York (63%) justifying the more sensible filter
of 500 µM aqueous solubility (Section 3.2.1). “Michele 2” was created with the
final version of the protocol and built on “Michele 1”. Fragments were purchased
from Specs, Sigma Aldrich, Asinex and Maybridge, and solved at 200 mM in
DMSO-d6. Both libraries were stored on plates in the dark after quality control,
and then used to create a new database for York compounds. A full description
can be found in Appendix C on page 194. The fragment sets were used in
various screening campaigns in our institution and my results will be described
in Chapters 6 and 7.
The library design approach presented in this chapter could prove useful to oth-
ers for the design of fragment screening libraries that represent commercially
available libraries, the compounds available in a proprietary in-house collection
or a virtual library of compounds that could be rapidly synthesised given avail-
able resources. The protocols and a SMARTS file with unwanted functionalities
can be downloaded from http://www.ysbl.york.ac.uk/fragments/. The results of
this chapter were published as “Design of a Fragment Library that maximally
represent available chemical space” (Schulz et al., 2011).
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Figure 3.10: Nearest neighbour plots for Specs derived Fragment Set.
Number of nearest neighbour compounds at 50% Tversky similarity for different
Fragment Sets and number of nearest neighbours compounds for different Tversky
similarity values for the Iterative Removal Fragment Set. (a) Specs compounds
with 50% Tversky similarity. Number of compounds in the final fragment set
per number of neighbours to the Non-Fragments library; section shown larger
in (b). (c) Specs compounds at different Tversky similarities with the Iterative
Removal procedure. Number of compounds in the final fragment set per number
of neighbours to the Non-Fragments.
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Chapter 4
MTSA
Thermal shift analysis is becoming widely used as a method for screening buffers
and ligands to find stabilising conditions for proteins. For compound library
screening, a large amount of raw fluorescence data has to be analysed. The data
analysis software either provided by the equipment manufacturers or available in
the public domain is cumbersome to use. The aim of this chapter is to devise a
simple package that could be widely deployed for thermal shift assays. With this
in mind the program MTSA with a graphical user interface (GUI) was developed
within the statistical analysis package, Matlab (MathWorks) and its curve fitting
toolbox, which is available in most institutions. For each experiment, the program
outputs the melting temperature Tm, the deviation from a standard value ∆Tm
(the thermal shift), and the quality of the fit R2.
4.1 Introduction to Thermal Shift Analysis
Known for a long time (for example in Pace and McGrath, 1979), Thermal Shift
Analysis (TSA) has recently become widely established as an efficient and effec-
tive method to screen a protein for ligand binding or conditions that improve
stability. The method is based on heating a protein and recording the unfolding
curve. This recording can be achieved by different methods such as differential
scanning calorimetry or circular dichroism (Kranz and Schalk-Hihi, 2011), how-
ever fluorescence based experiments are usually carried out on plates in a qPCR
(Quantitative Real Time Polymerase Chain Reaction) machine. To record the
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melting curve, an environmentally dependent fluorescence dye is added to the
wells. When the protein starts unfolding (“melting”), the dye binds to the ex-
posed hydrophobic groups giving a change in fluorescence. Although the idea that
fluorescence increases when dyes bind to a protein’s hydrophobic regions was first
described nearly sixty years ago (Weber and Laurence, 1954), it has only recently
gained popularity as a method for screening protein-ligand interactions (Kranz
and Schalk-Hihi, 2011; Cummings et al., 2006; Sorrell et al., 2010), identifying
ligands that can aid crystallisation for structural studies, or screening for buffers
that can improve protein stability (Veddadi et al., 2006; Ericsson et al., 2006;
Niesen et al., 2007). The technique is also known as Differential Scanning Fluo-
rimetry (DSF), Temperature dependent Fluorescence (TdF) or “ThermoFluor”.
In some countries, ThermoFluor® is a registered trade name of a fully automated
instrumentation developed by 3-Dimensional Pharmaceuticals Inc., later merged
with Johnson and Johnson (Pantoliano et al., 2001; Matulis et al., 2004; Cum-
mings et al., 2006). The experiment can be carried out in 96-well or even 384-well
format, and the primary output is a plot of fluorescence against temperature for
each well or sample. For well-behaved systems, this curve is sigmoidal in shape
for temperatures around the melting temperature Tm.
4.2 Strategies of Data Analysis
A typical thermal shift experiment is pictured in Figure 4.1. The melting curves
of a protein used with a concentration series of ligand are recorded. If the lig-
and binds to the protein, it is assumed to stabilise the protein, and the melting
curves are shifted further to higher temperatures. In an ideal experiment, these
curves are of sigmoid shape and are fully symmetric. The melting temperature
Tm corresponds to the temperature where the protein is half folded and half de-
natured (Layton and Hellinga, 2010, Kranz and Schalk-Hihi, 2011). To analyse
the experiment mathematically a curve model is needed. For thermal shift exper-
iments derived by differential scanning fluorimetry (where the unfolding process
is followed using the fluorescence of a dye), there exists three common ways of
data analysis.
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Figure 4.1: Thermal shift experiment. In an ideal experiment, the protein
becomes stabilised by a ligand. This stabilisation leads to a shift of the thermal
melting curve towards a higher temperature.
4.2.1 The Thermodynamic Model
The developers of the ThermoFluor method use a thermodynamic model to fit
protein melting curves and to estimate the affinity of a protein-ligand interaction.
A similar derivation was also described by Zubriene et. al. (2009). Because the
ThermoFluor platform is widely used, this approach is discussed below. There is a
lot of confusion about thermodynamic models in the literature due to typographic
errors in various publications which have never been corrected. To address this
issue, the following paragraphs go more into mathematical detail of the model.
Two slightly different ThermoFluor approaches are available in the literature.
Both are based on an unfolding equilibrium model of protein in the native state
N , unfolded protein U , free ligand Lf and bound ligand Lb (Matulis et al., 2005):
U + Lf
KU−−−−−−⇀↽ −
unfolding
N + Lf
Kb−−−−⇀↽ −
binding
NLb (4.1)
The free energy is the total stability of the ligand-protein complex composed of
protein stability energy ∆GU(T ) plus binding energy ∆Gb(T ):
87
∆G(T ) = ∆GU(T ) + ∆Gb(T ) (4.2)
The equilibrium constant for protein unfolding KU is given by
KU =
[U ]
[N ]
= e−(∆GU (T )/RT ) (4.3)
and the ligand binding constant is given by
Kb =
[NLb]
[N ][Lf ]
= e−(∆Gb(T )/RT ) (4.4)
First Approach
The inventors of the ThermoFluor first described an approach to fit the melting
curves of a TSA assay (Pantoliano et al., 2001) specifies the fluorescence γ(T ) as:
γ(T ) = γu +
γf − γu
1 + e−∆Hu/R(1/T−1/Tm)+∆Cpu/R(ln(T/Tm)+Tm/T−1)
(4.5)
The five parameters are melting temperature at the midpoint of the transition
Tm, the unfolding enthalpy ∆Hu and heat capacity ∆Cpu, and the pre- and
post-transitional fluorescence levels γf and γu, estimated with the Levenberg-
Marquardt algorithm for minimizing the sum of the squares of the residuals.
In addition, the ligand binding affinity KL,Tm at Tm can be described with the
equation:
KL,Tm =
e−∆Hu,T0/R(1/Tm−1/T0)+∆Cpu,T0/R(ln(Tm/T0+T0/Tm−1)
[LTm ]
(4.6)
where KL,Tm is the ligand dissociation constant at Tm (midpoint of protein un-
folding in the presence of ligand), T0 is the midpoint of protein unfolding in
the absence of a ligand, ∆Hu,T0 the unfolding enthalpy in the absence of ligand,
∆Cpu,T0 , the unfolding heat capacity in the absence of a ligand, [LTm ], the free
ligand concentration at Tm ([LTm ] ' [L]local if [L]local  [Protein]total) and R the
universal gas constant (equation first described by Brandts and Lin, 1990).
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Second Approach
The second ThermoFluor approach and its derivation were described by Matulis
et al. (2005) and Kranz and Schalk-Hihi (2011). In contrast to the first approach
above, the fluorescence intensity γ(T ) does not depend on the unfolding heat
capacity ∆Cpu, but on two additional slope parameters m.
Matilus et al. (2005) and Kranz and Schalk-Hihi (2011) express the fluorescence
of the dye γ(T ) in the assay with the equation
γ(T ) = γF (T ) +
γU(T )− γF (T )
1 + e∆GU (Tm)/RT
= γU(T ) +
γF (T )− γU(T )
1 + e−∆GU (Tm)/RT
(4.7)
Unlike in Pantoliano et al. (2001), pre- and post-translational fluorescences are
described as linear functions depending on the temperature T . The baselines of
folded (F ) and unfolded protein (U) are expressed as
γF (T ) = γF,Tm +mF (T − Tm) (4.8)
γU(T ) = γU,Tm +mU(T − Tm) (4.9)
Two additional slope parameters m represent the slope of the temperature de-
pendent fluorescence. The term ∆GU(T ) in Equation 4.7 may be replaced with
the Gibbs-Helmholtz relationship (Equation 4.10). The parameters Gibbs free
energy of protein unfolding ∆GU(T ), unfolding enthalpy ∆HU(T ) and unfolding
entropy T∆SU(T ) depend on the temperature.
∆GU(T ) = ∆HU(T )− T∆SU(T ) (4.10)
The formula can be rewritten as a dependency from a reference temperature Tr,
corresponding to the Tm of the protein in the absence of a ligand, and the heat
capacity ∆Cp,U :
∆GU(T ) = ∆HU,Tr + ∆Cp,U(T − Tr)− T (∆SU,Tr + ∆Cp,U ln(T/Tr)) (4.11)
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According to Matulis et al. (2005), the Equations 4.7–4.11 can be summarised
by the final model:
γ(T ) = γF,Tm +mF (T −Tm) +
γU,Tm − γF,Tm + (mU −mF )(T − Tm)
1 + e(∆HU,Tr+∆Cp,U (T−Tr)−T (∆SU,Tr+∆Cp,U ln(T/Tr)))/RT
(4.12)
Equation 4.12 is fitted with a non-linear least squares algorithm to estimate the
six parameters γF,Tm , γU,Tm , mF , mU , ∆HU,Tr and Tm. The heat capacity ∆Cp,U
is considered to be temperature independent and kept constant. The value for
∆Cp,U is either measured with other methods or estimated based on protein
composition.
At this stage, there are some discrepancies in the literature between Matulis et
al. (2005) and Kranz and Schalk-Hihi (2011). After inspection, the derivation of
Equation 4.12 by Matulis et al. (2005) is correct, and the derivation by Kranz
and Schalk-Hihi (2011) contains some typographical errors. Their final equation
misses the term mF in the numerator of the fraction in Equation 4.12 and feature
a wrong bracket for RT in the exponential term of the denominator which results
in wrong units. These misleading typographical mistakes are really unfortunate
because the manuscript by Kranz and Schalk-Hihi (2011) is published in a special
issue of Methods in Enzymology about FBLD, which is likely to become a guiding
review article for scientists working on fragments (Kuo, 2011).
Furthermore, this second approach resulting in Equation 4.12 differs from the
derivation by Pantoliano et al. (2001) (Equation 4.5). More parameters (six
instead of five) are used for fitting. The heat capacity is not included in the fit
and kept fixed, whereas two new slope parameters mU and mF are introduced.
After deriving the fitting equation, Matilus et al. (2005) and Kranz and Schalk-
Hihi (2011) explain how the affinity of the ligand can be estimated using the
relationship in Equation 4.1. The total ligand concentration Lt is defined by
Lt = (1−KU)(Pt
2
+
1
KUKb
) (4.13)
where Pt the total protein concentration and KU and Kb and the two equilibrium
constants. The derivation of Lt is described in Cimmperman et al. (2008).
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Summarised, the ligand concentration needed to raise the protein Tm to a given
value can be expressed as:
Lt =(1− e−(∆HU,Tr+∆Cp,U (Tm−Tr)−Tm(∆SU,T−r+∆Cp,U ln(Tm/Tr))/RTm))
× (Pt
2
+ 1/e−(∆HU,Tr+∆Cp,U(Tm−Tr)−Tm(∆SU,Tr+∆Cp,U ln(Tm/Tr)))/RTm)
× (e(∆Hb(T0)+∆Gp,b(T−T0)−T (∆Sb(T0)+∆Cp,bln(T/T0))/RT )
(4.14)
After consultation of one of the authors, Dr. James Kranz (personal communi-
cation, 2012), he states that there is an additional typographical error with a ±
sign in Pantoliano et al. (2001) and Matulis at al. (2005) leading to wrong ligand
affinity KL,Tm and ligand concentration terms Lt. This error was also discovered
by Zhang and Monsma (2010) who explained the mistake originating in a con-
fusion of models: instead of the ligand binding to the native protein, the model
describes ligand binding to the unfolded protein. The model was corrected in
Zubriene et al. (2009), leading to the equations:
Lt = (KU,Tm − 1)(
Pt
2KU,Tm
+
1
Kb,Tm
) (4.15)
and
Lt =(e
−(∆HU,Tr+∆Cp,U (Tm−Tr)−Tm(∆SU,T−r+∆Cp,U ln(Tm/Tr))/RTm) − 1)
× (Pt
2
+ 1/e−(∆HU,Tr+∆Cp,U(Tm−Tr)−Tm(∆SU,Tr+∆Cp,U ln(Tm/Tr)))/RTm
+ 1/e−(∆Hb,T0+∆Cp,b(Tm−T0)−Tm(∆Sb,T0+∆Cp,bln(Tm/T0))/RTm)
(4.16)
To summarise, there are many calculation and typographical errors in the liter-
ature on TSA. A model for the ligand concentration is not used in this thesis.
4.2.2 The Boltzmann Model
Other groups, mainly those working on qPCR machines, use the Boltzmann equa-
tion (Equation 4.17) to fit the transition part of their data (Ericsson et al., 2006;
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Niesen et al., 2007; Sorrell et al. 2010). The equation describes the Boltzmann
distribution for the states of a system. Despite its name, the parameters here
do not strictly conform to the thermodynamic equation. General variables are
used instead of thermodynamic parameters. The parameter T ′ corresponds to
the point of inflection and midpoint between the asymptotes. The equation is a
four-parameter logistic model:
γ(T )Boltzmann = min+
max−min
1 + e
T ′−T
a
(4.17)
where γ(T ) is the fluorescence, min and max are the temperatures at the fluores-
cence intensity before the transition and at the end of the transition respectively.
In respect to the above named models, these variables correspond to γf and γu
in Equation 4.5. The melting temperature Tm is at T
′:
Tm,Boltzmann = T
′ (4.18)
and corresponds equally to the midpoint and to the point of inflection of the
transition curve.
4.2.3 Higher Order Polynomial Equations
There are also reports where researchers fit the fluorescence data with higher
order polynomial equations (Yeh et al., 2006; Niesen et al., 2007; Crowther et
al., 2009; Wang et al. 2011). In this case, the melting temperature Tm is defined
as the inflection point of the data. These models are not strictly based upon
thermodynamic equations.
4.3 The Program MTSA
While the ThermoFluor system provides analysis software with the device, the
current software for analysing melting curves produced on qPCR machines re-
quires rather tedious data preparation and manipulation. The fluorescence curves
need to be exported from the instrument, cut (which is often performed with an
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Excel tool from the Niesen group (Niesen et al., 2007)) and further exported to
separate fitting software to obtain the Tm. Some groups have developed software
in-house (Vedadi et al., 2006) for this analysis; others use a series of protocols
and scripts. In this chapter, a simple program was devised that could be widely
deployed. MTSA with a graphical user interface (GUI) was developed within the
statistical analysis package, Matlab (MathWorks) and its curve fitting toolbox,
which is available in most institutions.
The raw fluorescence data from qPCR machines is usually available in a ta-
ble where the rows signify the fluorescence at a particular temperature and the
columns the different wells or experiments when the data is exported as hori-
zontally grouped. It is good practise to include blanks (usually the protein in
a standard buffer with no ligand) at regular intervals to account for instrument
variability, such as plate edge effects, or for sample and pipetting errors.
The analysis begins with a “cut and paste” procedure of the table of fluorescence
data into the MTSA interface (Figure 4.2). The user enters the starting temper-
ature, temperature increment, and number of increments to define the columns
in the data table. In addition, the number of wells to be fitted and the position
of blank samples (e.g. ligand-free protein) are required.
The work in this thesis applied the thermal shift method to initial ligand screen-
ing, and thus does not require determination of thermodynamic parameters to
estimate the binding constant (Equations 4.6 and 4.14). Thus the more compli-
cated thermodynamic model (Equations 4.5 and 4.12), derived by the inventors
of ThermoFluor requiring knowledge of heat capacity, was discarded. First, the
heat capacity either has to be estimated based on protein sequence, or derived by
calorimetric characterisation, which is not convenient for straightforward assay
development. Second, the heat capacity is not temperature independent as the
authors state (Gomez et al., 1995). The Boltzmann equation has the same shape
as the thermodynamic model. Therefore, following the instructions in a Nature
protocol (Niesen et al., 2007), the Boltzmann equation was used for first fitting
experiments. However, its initial usage did not give satisfactory fits around the
asymptotes (Figure 4.3 a) so an additional parameter c was introduced. The
five-parameter logistic model is referred to as the Sigmoid-5 equation:
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Figure 4.2: GUI of MTSA. To use MTSA, the horizontally grouped data need
to be present in one block (the Stratagene machine for example exports in two
blocks, so data need to be pasted together first). Use the computer’s clipboard
to copy the block of fluorescence data. In MTSA, using the button ”Paste Data”
to paste from the clipboard. Enter the start temperature, increment and number
of cycles, as well as how many wells you want to have fitted. If you have blanks
on the plate, enter the well number of the first blank and the interval between
recurring blanks.
γ(T )Sigmoid−5 = min+
max−min
(1 + e
T ′−T
a )c
(4.19)
where a is the Hill slope (the steepness) and c is asymmetric factor introduced here
to account for the asymmetric shape of the curves in order to improve fitting. T ′
is a parameter approximately in the middle of the transition area. For c = 1 (i.e.
when the curve is fully symmetric), Sigmoid-5 becomes the Boltzmann equation
(Equation 4.17). Then Tm = T
′ and equal to the point of inflection and the
midpoint.
Because of the asymmetric factor c, this model is not strictly based upon ther-
modynamic equations. However, the non-thermodynamic models have been used
before to fit the melting curves (Sections 4.2.2 and 4.2.3).
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When c 6= 1, the Tm can be defined as either the midpoint (for further discussion
refer to Chapter 8 on page 151):
Tm,Midpoint = T
′ − a× ln(2 1c − 1) (4.20)
or as the point of inflection:
Tm,Inflection = T
′ − a× ln(1
c
) (4.21)
The program first identifies the temperatures Tmax and Tmin, where Tmax is the
temperature where the fluorescence is at its maximum, while Tmin represents
temperature of the minimum of the fluorescence data found on the left hand side
(lower temperature) of Tmax. The points for temperatures less than Tmin and
greater than Tmax are then discarded. The parameter T
′ is approximately the
melting temperature and set to 60 ± 50 . The remaining data points are fitted
with the Sigmoid-5 model.
It was found to be important to include boundary conditions for the fitting pa-
rameters: 0 < a < 10 and 0 < c < 10. The maximum and minimum fluorescence
must be within ±2% of the max and min values respectively. The fit is made
with a non-linear least squares method with a starting point of 5 for a, 1 for
c, maximum value at max and minimum value at min. These boundary condi-
tions were empirically determined to help the fit to be found. If min and max
are forced to be within ±2% of the experimental values, the fits become better
around the asymptotes
The default algorithm “Trust Region” was used which allows a less complex
function to reasonably reflect the function in the neighbourhood around a certain
point. Without these boundary conditions, the fitted data were exceeding the
max value resulting in lower quality fits. The start values are necessary to find
the actual fit.
Using the Sigmoid-5 equation, better fits were obtained compared to the more
widely used four-parameter Boltzmann equation (missing the asymmetric factor
c). This can be seen in Figure 4.3, which illustrates how the additional asym-
metric factor c of the five-parameter equation helps to fit the curves a bit more
smoothly, especially around the asymptotes.
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Figure 4.3: Comparison of four- and five-parameter fitting equation. The
data points of the same experiment were fitted with the standard four-parameter
Boltzmann equation (a) and with the five-parameter fit (b). The fit is better with
the five-parameter equation which is visible around the asymptotes (the blown
up section) and also in the coefficient of determination R2. The Tm differs in
almost 1 degree.
The program outputs a png file (an example is shown in Figure 4.3 (b)) for each
column of data (each experiment) showing how well the sigmoid curve fits the
original data. In addition, there is an output file (to be opened with a text editor)
which provides a log and summary of the calculation for all the experiments. It
contains a log of the fitting of each experiment, including the final equation of
fit, number of iterations, coefficients (including the range of their 95% confidence
interval) and the coefficient of determination, R2. Furthermore, the average Tm
(Tm) value is determined from the blanks (blank Tm) and the standard deviation
of Tm. The output file concludes with a summary of the experiment number,
Tm, ∆Tm and coefficient of determination R
2 (which expresses the correlation
between data points and fit).
The program has been designed to operate smoothly with simple cut and paste
input of data from different makes of qPCR machines (tested devices were AB
7300, AB 7500, Bio-Rad CFX96 and Agilent Stratagene MX3005), and to work
across different versions of different operating systems (please note that Java is
required; for Mac the correct version might have to be downloaded and the path
set). This means that there were not implemented some desirable features, such
as importing annotation of experimental detail (variation across manufacturers)
or outputting Excel spreadsheets (variation with different operating systems).
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However, the program does include some simple error checking to identify when
experiments have failed or did not produce optimal fits. If the standard deviation
of the blank Tm is greater than 0.2 or the coefficient of determination R
2 is less
than 0.999, then the program issues a warning. In our experience, a problem
with the blanks usually signifies a general problem with the experimental setup
(reagents or pipetting errors) and the plate should be repeated. Other problems
we have experienced include non-flat baselines, double-humped curves and wave-
like curves. The program will always try to fit input data if it can identify a
suitable max and min. However, odd-shaped curves will result in poor R2 values
and aberrations in the Tm values. These can be identified within the output file so
the user can then examine the raw fluorescence data by eye. In the final analysis,
the user needs to judge if the fit and the obtained Tm and ∆Tm is reliable or not.
To estimate ligand binding, a significant ∆Tm is often considered to be above
three times the standard deviation of the blank (Sorrell et al., 2010).
4.4 Concluding Remarks
In summary, a freely available tool was developed that significantly improves and
accelerates the analysis of thermal shift data, which is especially helpful for a high
throughput of plates. The program code and GUI (*.m and *.fig file) for the three
different approaches (1. Boltzmann fit, 2. Inflection point of Sigmoid-5 fit, 3.
Midpoint of Sigmoid-5 fit) can be downloaded from http://www.ysbl.york.ac.uk/
fragments/MTSA.
The program requires the curve fitting toolbox and a compatible version of Java.
Mac users might experience problems as on this operating system, Matlab uses the
Java version provided by the operating system. Refer to http://www.mathworks.
co.uk/help/matlab for further details.
A paper on the program MTSA was published in Analytical Biochemistry in 2012
(Schulz et al., 2012).
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Chapter 5
N-Myristoyl Transferase
This chapter describes attempts to produce the protein N-myristoyl transferase
(NMT) as a target for fragment screening. In summary, subcloning was performed
to obtain double His-tagged protein for immobilisation on a surface Plasmon
resonance (SPR) chip for fragment screening. The protein was assessed with
mass spectrometry and tested in initial SPR experiments. However, it proved
challenging to scale up expression and generate stable protein suitable for reliable
fragment screening. For these reasons the focus moved onto other proteins.
5.1 Background
This chapter deals with the NMT proteins from Leishmania donovani (ld), Leish-
mania major (lm) and Trypanosoma brucei (tb). Leishmania major and dono-
vani are parasites which are responsible for visceral and cutaneous Leishmania.
Trypanosoma brucei on the other hand is a parasite responsible for sleeping sick-
ness. N-myristoyl transferase catalyses the transfer of myristate from myristoyl-
coenzyme A (MCoA) to the N-terminal glycine of a substrate protein. This
process is important for the survival of the cells. While the binding site of MCoA
is conserved within the different organisms, the peptide binding site varies, thus
this site will be a good starting point to find selective inhibitors for drugs against
Leishmania (Bowyer et al., 2008).
The project was originally planned as a collaboration between Pfizer, University
of Dundee, University of York, NIMR and Imperial College. My part was the
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fragment screen in collaboration with Prof. Debbie Smith of the Centre for
Immunology and Infection at York.
5.2 Producing Double His Tagged ldNMT
5.2.1 Motivation
Surface Plasmon Resonance (SPR) is a powerful technique for identifying and
characterising the binding of small molecules and fragments to a protein (more
in Section 10.5). In a direct binding experiment, the protein is linked to the
SPR chip and the different small molecules flowed past. A number of different
attachment strategies are possible. An attractive approach is to attach the protein
through a His-tag to an NTA chip, exploiting the tag which is often present for
purification. This should ensure a consistent attachment through a defined point,
compared to methods such as biotinylation where any free NH2 group (such as
lysines) can be attachment points. However, often the protein does not stick very
well to the chip and bleeds off during the experiment. To prevent that, a second
His-tag can be added to the protein in order to make it stick more to the NTA
groups (Fischer et al., 2011). In the case of ldNMT, the double His6-tag building
was achieved via subcloning because a clone with a single His6-tag was already
available. In this thesis, “His-tag” refers to a hexa histidine tag, and “double
His-tag” to two hexa histidine tags separated by a spacer respectively.
5.2.2 Subcloning
The template used was a single N-terminal His-tagged ldNMT construct in pSKB2
aka pET28-PPX (from Dr. Jim Brannigan) containing a protease cleavage site.
It was ligated into a pET28a vector using NheI and SacI enzyme restriction sites
(according to the methods described in Section 10.2 on page 172). The primers
were designed to amplify the template sequence via PCR.
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5.2.3 Transformation
The ligation mixtures were transformed into XL10 Gold cells. The plasmids of the
five different cultures were extracted, digested with restriction endonucleases and
finally run on a 1% agarose gel (Figure 5.1). The concentration of the plasmids
is shown in Table 5.1.
Figure 5.1: Gel of Double Digest ldNMT in pET28a. The extracted and
digested plasmids of five selected colonies of the transformation procedure were
run on a 1% agarose gel.
Table 5.1: DNA concentration
1 2 3 4 5
53.3 ng/µl 69.6 ng/µl 45.7 ng/µl 54.6 ng/µl 55.4 ng/µl
5.2.4 Sequencing
Samples 2 and 5 contained the highest DNA concentration and were selected for
sequencing. Both plasmids showed a silent mutation on position 6 of the template
as shown in Table 5.2. It is known that this mutation was already present in the
initial template received from Dr. Jim Brannigan and was therefore not considered
to be disadvantageous. Plasmid 2 showed some errors in the added second His-tag
(data not shown). It was not obvious if that was due to an error in sequencing
or a mutation. Since plasmid 5 did not show any mutations and contained the
expected sequence, it was selected for further experiments and plasmid 2 was
discarded.
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Table 5.2: Silent Mutation
position 1 2 3 4 5 6
original gene A T G T C C
template A T G T C T
amino acid Met Ser
5.2.5 The New ldNMT Construct
Figure 5.2 illustrates the new ldNMT construct schematically. Table 5.3 shows
the sequence of the new ldNMT clone. The expressed protein has a mass of
53,128.5 Da and a theoretical pI of 6.68.
Figure 5.2: Double His6-tagged ldNMT construct. The construct consists
of two His6-tags on the 5’ end interrupted by two protease recognition sites.
5.2.6 Expression Tests
Plasmid stock 5 was used to transform into competent Escherichia coli Rosetta 2
(DE3) expression cells. Figure 5.3 illustrates that the protein is well expressed
during the first expression tests where the cells were lysed in Milli-Q. However,
the soluble fraction is not very big.
Several lysis buffers were tested (sugar, tris, tris glycerol, phosphate, details in
Section 10.2), but none of them improved the fraction of soluble protein. However,
these issues were known from experience with the single His-tagged protein (Dr.
Jim Brannigan, personal communication). Therefore, scale-up experiments were
performed straight away.
5.2.7 Scaling up Protein Production
To overcome the solubility issues, the protein was purified with a His trap crude
1 ml column (nickel-NTA) which contains larger pore sizes.
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Table 5.3: Sequence of double His6-tagged ldNMT
start of original sequence numbering: 1
10’ 20’ 30’ 40’ 50’
MGSSHHHHHH SSGLVPRGSH MASHHHHHHS SGLEVLFQGP HMSRNPSNSD
60’ 70’ 80’ 90’ 100’
AAHAFWSTQP VPQTEDETEK IVFAGPMDEP KTVADIPEEP YPIASTFEWW
110’ 120’ 130’ 140’ 150’
TPNMEAADDI HAIYELLRDN YVEDDDSMFR FNYSEEFLQW ALCPPSYIPD
160’ 170’ 180’ 190’ 200’
WHVAVRRKAD KKLLAFIAGV PVTLRMGTPK YMKVKAQEKG QEEEAAKYDA
210’ 220’ 230’ 240’ 250’
PRHICEINFL CVHKQLREKR LAPILIKEVT RRVNRTNVWQ AVYTAGVLLP
260’ 270’ 280’ 290’ 300’
TPYASGQYFH RSLNPEKLVE IRFSGIPAQY QKFQNPMAML KRNYQLPNAP
310’ 320’ 330’ 340’ 350’
KNSGLREMKP SDVPQVRRIL MNYLDNFDVG PVFSDAEISH YLLPRDGVVF
360’ 370’ 380’ 390’ 400’
TYVVENDKKV TDFFSFYRIP STVIGNSNYN ILNAAYVHYY AATSMPLHQL
410’ 420’ 430’ 440’ 450’
ILDLLIVAHS RGFDVCNMVE ILDNRSFVEQ LKFGAGDGHL RYYFYNWAYP
460’
KIKPSQVALV ML*
The crude lysate containing DNAse and protease inhibitor cocktail tablets was
applied to the column and eluted as fractions with a 20 mM to 1 M imidazole
gradient (Figure 5.4). The fractions were assayed by SDS-PAGE. Those found
to contain ldNMT were pooled and diluted in anion exchange buffer in prepa-
ration for the second purification step. The protein solution was loaded on a
HiTrap Q FF 5 ml column and eluted in fractions with a 20 mM to 500 mM salt
gradient. Fractions found to contain ldNMT protein were pooled together and
concentrated (for details see Section 10.3 on page 176). Several expression and
purification tests were performed. Although the protein expresses well, it is not
very soluble (Figure 5.3). The final yield from 500 ml of cell culture is about
0.7 mg. One major issue during these tests was protein appearing triple-banded
102
Figure 5.3: SDS gel of initial expression trial. ldNMT is expressed well as
one can see from lanes 1, 5 and 8 (expression at 16, 30 and 37 respectively)
containing the total lysate. However, most of the protein is insoluble which show
lanes 3 and 4, 6 and 7 and 9 and 10, where the first of each pair represents the
insoluble fraction and the second the soluble fraction (expression at 16, 30 and
37 respectively). (1) marker, (2)–(4) total lysate, insoluble fraction and solu-
ble fraction when expressed at 16, (5)–(7) total lysate, insoluble fraction and
soluble fraction when expressed at 30, (8)–(10) total lysate, insoluble fraction
and soluble fraction when expressed at 37. Cells were lysed in Milli-Q water.
on the gels (Figure 5.5, lanes 5–8) giving strong indication of degradation.
(a) Nickel-NTA (b) Anion Exchange
Figure 5.4: Chromatograms of ldNMT. Two chromatograms show the UV
absorbance (blue line), as ldNMT is eluted from the nickel-NTA column (a) and
eluted from the anion exchange column (b). The green line shows the gradient
of buffer B (imidazole and salt respectively).
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Figure 5.5: Gel of double His-tagged ldNMT showing triple bands. On
the gel, double His-tagged ldNMT is shown during the purification. One can see
that the protein still seems full length after the nickel chromatography (lane 2, no
degradation visible). However, the eluted fractions after the second purification
step, ion exchange chromatography, indicate triple bands on the gel (lanes 5–8)
assuming degradation of the protein. (1) marker (2) lysate (3) flow through after
nickel chromatography (4) flow through after anion exchange (5)–(10) selected
fraction after anion exchange chromatography
5.3 Mass Spectrometry
Mass spectrometry (MS) can be used to analyse proteins by measuring the mass
by charge ratio after ionising the sample. To confirm ldNMT degradation, a
sample was handed to Simon Grist who kindly performed the experiments on
the electrospray mass spectrometer (Section 10.4). It turned out that the double
His-tagged NMT is degrading from both ends.
The MS experiment shows three well-defined peaks at 53,209 Da, 51,712 Da,
50,834 Da (Figure 5.6) which could likely explain the triple band on the gel
(Figure 5.5, lanes 5–8). The calculated mass of the protein is 53,128.5 Da. The
masses of the three peaks can be explained with the sequence of double His-tagged
ldNMT when one assume one species corresponds to the phosphorylated full
length protein, one species misses the sequence MGSSHHHHHHSSG and another
species misses MGSSHHHHHHSSGLVPRGSH. Knowing the protein solution also
contains full length protein, some tests with SPR were performed (Section 5.5).
The aim was to capture the double His-tagged protein on the chip while washing
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off the degrading species containing only one His-tag.
Figure 5.6: Mass Spectrometry results of ldNMT. Three clear peaks ap-
peared at 50,834 Da, 51,712 Da and 53,209 Da which can be related to the triple
bands on the gels after ion exchange chromatography.
5.4 lmNMT and tbNMT
Expression cells containing lmNMT and purified tbNMT (both N-terminal His6-
tagged) were kindly provided by Dr. Jim Brannigan (Section 10.3). Together
with double His6-tagged ldNMT, all three NMT proteins were tested by SPR
experiments for their suitability for fragment screening.
5.5 SPR with NMT
Double His6-tagged ldNMT, single His6-tagged lmNMT and tbNMT were assayed
with SPR on a Biacore T100 machine. Attachment of the proteins via their His-
tags to the NTA of the chips was attempted. However, the proteins were bleeding
off the chip very quickly. To prevent this, the proteins were covalently immobilised
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by activating the carboxymethyl groups of the dextran coating with EDC/NHS,
assembling the protein via its His-tag and covalently binding it via its lysine
residues, followed by deactivation with ethanolamine. A typical immobilisation
sensorgram is shown in Figure 5.7 a. However several challenges appeared when
performing the experiments including inexplicable buffer effects, baseline drift
and detection of cofactor binding (Figure 5.7 b–f for a summary of representative
examples with tbNMT).
The following points summarise the experiments performed with NMT:
 Although knowing that ldNMT degraded, it was tested in HBS-P buffer
(0.01 M HEPES pH 7.4, 0.15 M NaCl, 50 µM EDTA, 0.05% Surfactant
P20) with the aim to catch the full length constructs on the NTA chip and
wash the degraded species away. However, the protein did not stick to the
chip and the double His6-tag did not show improved binding.
 LmNMT was tested in HBS-P buffer. It showed a high drop off rate and
also the response of MCoA was < 2 RU (response units).
 TbNMT was covalently bound to an NTA chip using HBS-P buffer. This
way, the proteins should all be oriented the same way without being washed
away during the experiment. After immobilisation, the buffer was changed
to Tris (200 mM NaCl, 50 mM tris-HCl, pH 7; following a protocol obtained
from collaborators in Dundee). Simple running buffer injections showed
unexpected buffer effects on the sensorgrams. The control MCoA did not
show any binding. When the protein was immobilised de novo, a response
of 36 RU could be observed for MCoA, however protein bleed-off was still
experienced. Since the bleed-off is rather linear, several inhibitors were
tested. However these tests proved to be challenging because the baseline
did not return to the original level and the ligands seemed to accumulate
on the chip.
5.6 Concluding Remarks
NMT proved to be a very challenging target. An SPR assay could not be estab-
lished with any of the three different NMT proteins. Whilst working with NMT,
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the test protein hen egg white lysozyme (HEWL) was used to establish parts
of the screen and test some of the fragments. Initial experiments with HEWL
looked very promising, thus the NMT project was postponed until a later stage.
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Figure 5.7: Examples of SPR experiments with tbNMT. (a) A typical
covalent immobilisation curve. tbNMT was immobilised to 8,000 RU. (b) MCoA
injected three times to a chip with covalently immobilised protein. Although the
baseline drifts severely a response of 40–50 RU can be observed. (c) Covalently
attached protein is bleeding of the chip. Overnight loss of about 3,000 RU.
(d) Unexpected buffer effects. (e) Test ligand with expected potency against
tbNMT of 2 µM builds up on the chip. Buffer injections (RB) with (+) and
without (-) MCoA and 5 mM sodiumhydroxide as regeneration to clean the chip
show unexpected responses. Running buffer injections exhibit binding curves.
(f) Running buffer injections show a binding effect. Binding compounds seems
to accumulate on the chip. A wash with 5 mM NaOH brings the curve below the
original baseline. 108
Chapter 6
Fragment Experiments with
HEWL
This chapter describes the experiments in fragment screening that were performed
for the protein Hen Egg White Lysozyme (HEWL). The work fell into four main
parts. A novel Biacore assay was developed where HEWL binds to the dextran
surface of a CM5 Biacore chip. After optimisation, the assay was used to screen
50 fragments from the “Michele 1” library, and potential hits were validated with
an established cell based activity assay. Subsequently, some fragments from the
“Michele 2” library were screened with thermal shift analysis. The issues with
processing the TSA data led to the development of the MTSA program described
in Chapter 4. Initial crystallisation trials have been performed when further work
was halted as a more promising target (BtGH84, Chapter 7) became available.
6.1 Background
Hen Egg White Lysozyme (HEWL) is a glycanhydrolase of 14 kDa. The protein
is often used as a model system because large quantities of stable, pure protein
are easily available and the protein readily crystallises. HEWL lyses cells by
cleaving the β− (1→ 4) glycosidic bonds of the murein cell wall (Mo¨rsky, 1983).
The enzyme was first discovered by Sir Alexander Fleming in 1922, when some
drops from his nose fell on an agar plate and killed the bacteria colonies on
it. It has become one of the most studied proteins in history and thus it is an
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excellent model system. There are a lot of known inhibitors, but most of them are
carbohydrate like. These properties make HEWL a suitable target for a fragment
screen to test the properties of the newly generated libraries described in Chapter
3.
For the following assays, the known inhibitors N,N’-diacetylchitobiose (chito-
biose) (Figure 6.1 b) and N,N’,N”-triacetylchitotriose (chitotriose) (Figure 6.1 c)
were used as control compounds. Chitotriose has an expected KD of 7–10 µM.
Chitobiose with a KD of 170 µM lies in the range of a good fragment hit. An-
other sugar which binds very weakly to HEWL is N-Acetylglucosamine (GlcNAc)
(Figure 6.1 a) that has a literature KD of 40–60 mM. All of the mentioned KDs
were obtained at pH 5.0 (Dahlquist et al., 1966). Glucose itself binds so weakly
to HEWL that it can be considered as a negative control and is used as such.
(a) GlcNAc (b) Chitobiose
(c) Chitotriose
Figure 6.1: GlcNAc, chitobiose and chitotriose. Structures of (a) Glc-
NAc (N-Acetylglucosamine), (b) chitobiose (N,N’-diacetylchitobiose) and (c) chi-
totriose (N,N’,N”-triacetylchitotriose) in Howarth representation.
6.2 The Alternative Biacore Screen with HEWL
CM5 chips are carboxymethylated dextran chips which are widely used for Bia-
core experiments (for an introduction to SPR see Section 10.5 on page 180). In a
conventional Biacore experiment, molecules are coupled to the surface via NH2,
-SH, -CHO, -OH or -COOH after special preparation. However, when HEWL is
injected onto an unprepared CM5 chip with the Biacore technology, the protein
binds to the dextran surface of the chip. This phenomenon was used to develop
this alternative Biacore screen, where the binding of a competitive ligand will be
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seen by reducing the quantity of HEWL that binds to the plain surface of the
chip. 1–2 mg/ml protein generates a signal of about 1000 response units (RU), so
a competitive ligand will give a much larger change in the signal compared to the
response of about 10 RU from binding of a fragment to HEWL conventionally
immobilized on the chip. The new screen described here is able to give responses
of about 200 RUs or more. Chitotriose with an expected KD of 7–10 µM reduces
the protein signal by about 250 RU. Since its KD of 170 µM lies in the range of a
good fragment hit, chitobiose was used as a positive control in the following ex-
periments. The stronger inhibitor chitotriose was used for initial tests. Relating
to the “conventional Biacore screen”, the new screen described here is referred to
as “alternative screen”. Details of the method are described in Section 10.5.3 on
page 182.
6.2.1 Screen Using the Alternative Biacore Assay
HEWL was screened with the Biacore T100 in PBS buffer with 5% DMSO in
96-well plates. The setup needs only one of four available flow cells compared
to the two flow cells required for the conventional screen. Therefore, the old
reference cell of an used CM5 chip can be recycled. The plate was set up with
alternating wells of fragment only and fragment plus protein. Figure 6.2 illus-
trates the sensorgrams of a typical experiment: A concentration series of ligand
with a fixed amount of protein is injected onto one flow cell of the sensor chip.
The peak height indicates how much protein is binding to the surface of the chip.
However, the curved shape of the response peak shows that the binding is not
saturating, which could be due to additional non-specific binding. However, NSB
(carboxymethyl dextran sodium salt in 0.15 M NaCl containing 0.02% NaN2)
was found not to reduce the non-specific binding or accumulation on the surface.
When the compound is competing for the active site of the protein, less protein
can bind to the chip and the response is alternated, i.e. reduced for inhibitors
and increased for activators.
Several HEWL concentrations were tested to estimate which concentration gives
a reliable response, but also does not overload the chip with protein. A HEWL
concentration of 1 mg/ml HEWL (68 µM) was found to be most suitable. When
the response peaks are plotted against the ligand concentration, dose-binding
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(a) Chitotriose and HEWL (b) Chitotriose only
(c) Chitotriose and HEWL
Figure 6.2: Sensorgrams of the alternative Biacore screen. HEWL con-
centration at 68 µM (a) Chitotriose and HEWL in buffer without DMSO. This
is a screenshot of one of the initial tests. (b) Another screenshot of the initial
test with chitotriose only in buffer without DMSO. These peaks are subtracted
from the curves with HEWL and chitotriose to eliminate the ligand response.
(c) HEWL with chitotriose in buffer without DMSO from an automated exper-
iment. Cycle 13 (red) and cycle 14 (green) show the concentration series of
chitotriose together with HEWL, cycle 15 (blue) and cycle 16 (pink) show the
concentration series of chitotriose only.
curves can be deduced. All points plotted and fitted in the following figures are
the average of two separate measurements. The positive controls chitobiose and
chitotriose tested in DMSO free buffer produce IC50 in the expected range (Figure
6.3). For chitotriose, data fitted with the method described in Section 10.6 (page
183) generate an IC50 of 33 µM in Figure 6.3 a, and in a later experiment an
IC50 of 69 µM in Figure 6.3 b. The averaged IC50 for chitotriose found in the
assay is thus at 51 µM and for GlcNAc at 10 mM. The literature KD is 7–10 µM
for chitotriose and 40–60 mM for GlcNAc. The corresponding sensorgrams for
these plots are shown in Figure 6.2. The point of the lowest concentration was
considered to be an outlier and had to be excluded from the fit.
Figure 6.4 shows some examples of the difficulties that can arise. It is possible
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(a) Chitotriose 1 (b) Chitotriose 2
(c) Chitotriose 1 and 2 overlaid (d) GlcNAc
Figure 6.3: Dose-response curves that can be fitted. The examples are of
chitotriose and chitobiose in DMSO free buffer. The data points derive from the
top of the peaks shown in the sensorgrams shown in Figure 6.2. Plotted are the
averages of duplicate measurements of which the response of the ligand only was
subtracted. (a) IC50 of 33 µM for chitotriose. (b) IC50 of 69 µM for chitotriose in
a second experiment. (c) Overlay of the two chitotriose dose-response data. (d)
GlcNAc with half concentration of HEWL (34 µM) and an IC50 of 10 mM. (n=2)
to fit the dose-response curves for chitotriose when in regular buffer (Figure 6.3
c), but if 5% DMSO were present, the data could not be fitted (Figure 6.4 a).
Nevertheless a reduction of the signal can be observed. Chitobiose which is
expected to bind in the affinity range of a fragment did not produce data that
could be fitted (Figure 6.4 d). At the highest concentration, data points of the
weakly binding GlcNAc and with medium affinity binding chitobiose show an
increase in signal (Figure 6.4 b and d). The same happens for the signal of
glucose at high concentration although this was tested in DMSO free buffer. For
none of these data sets could curves be fitted.
113
(a) Chitotriose in DMSO buffer (b) GlcNAc in DMSO buffer
(c) Glucose (d) Chitobiose in DMSO buffer
Figure 6.4: Non-fittable dose-response curves. (a) Chitotriose in 5% DMSO
buffer. (b) GlcNAc in 5% DMSO buffer (c) Negative control glucose. (d) Chi-
tobiose in 5% DMSO buffer; the 10 mM is only plotted as a single data point
because the duplicate was an outlier. (n=2)
The tests reveal that an IC50 determination with the alternative Biacore screen
can be challenging. However, binding of a ligand is clearly indicated when the
ligand is injected in a moderate concentration. An initial plate with 48 fragments
from the “Michele 1” fragment library was tested for further assessment of the
method (structures are shown in Appendix D). Figure 6.5 is an example of the
typical output from the assay, for the example of ysbl000266.
The following empirically derived classification was developed to analyse the bind-
ing of the individual compounds in a spreadsheet:
 Inhibiting R(P : Chito) < R(P : F ) − R(F ) < R(P ) − [R(P ) − R(P :
Chito)) ∗ 0.3]
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Figure 6.5: Fragment screen example sensorgram. For compound
ysbl000266 the sensorgram of a full cycle is shown. The injections follow in the
order: 1. fragment (1st peak green), 2. fragment and protein (2nd peak green), 3.
fragment (1st peak green), 4. fragment and protein (2nd peak green), 5. protein
(1st peak red), 6. chitotriose and protein (2nd peak red). If the fragment plus
protein (big green) peak minus the fragment only (small green) peak is signifi-
cantly shorter than the protein only (big red) peak, then the compound is likely
to bind. (n=2)
 Activating R(P ) + [R(P )−R(P : Chito]) < R(P : F )
 Otherwise interesting R(P : F )−R(F ) < R(P : Chito) ∗ 0.9
with R(P : F ):= response of protein with fragment, R(F ):= response of only
fragment, R(P : Chito):= response of protein with chitotriose , R(P ):= response
of protein only.
A number of compounds gave some response in this assay – both inhibiting and
increasing the binding of HEWL to the Biacore chip surface. The compound num-
bers are summarised in Table 6.1 (structures in Appendix D). These compounds
were investigated further.
6.2.2 Binding Affinity Assay with HEWL
To confirm the binding of the fragments detected with the alternative Biacore
binding screen, a follow-up assay was established to obtain the binding affinity
data for seven selected compounds (ysbl000266, ysbl000268, ysbl000273,
115
Table 6.1: Fragments hits with the alternative Biacore assay on HEWL
YSBL database entry
Inhibiting Activating Interesting
ysbl000266 ysbl000265 ysbl000267
ysbl000268 ysbl000279 ysbl000303
ysbl000273 ysbl000294 ysbl000304
ysbl000276 ysbl000297
ysbl000277 ysbl000298
ysbl000281
ysbl000291
ysbl000293
ysbl000295
ysbl000300
ysbl000276, ysbl000277 and ysbl000281). ysbl000261 was used as a negative
control because it did not show any binding in the initial screen. Chitobiose
served as positive control. Figure 6.6 pictures a bar chart of the responses of the
concentration dependent screen. The first two sets show the fragment response,
the second two sets the response of protein and fragments. From the left to the
right, the ligand concentration rises. The tops of the bars of the protein and
fragment set indicate a sigmoid shaped curve.
However, after correction (subtracting the fragment response as background from
the fragment plus protein response, some of the dose-response data are plotted in
Figure 6.7), the following results became obvious: For chitobiose (Figure 6.7 a)
and for the compounds ysbl000268 (Figure 6.7 c), ysbl000273 and ysbl000281
(Figure 6.7 d) the beginning of a downward pointing dose-response curve is
indicated. However, the responses do not saturate. For the negative control
ysbl000261 and also for ysbl000266 (Figure 6.7 b), the curves had an upward
trend at higher concentrations. For ysbl000276 and ysbl000277 the curves were
relatively flat and did not confirm any binding. Thus no dose-response curve
using equation 10.1 on page 183 could be fitted.
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Figure 6.6: Compound binding in the alternative HEWL screen The
bars represent the peak height (i.e. response unit in the sensorgrams) for each
injection. The lower bars are the responses for the fragment alone (used as a
blank subtraction); the higher bars are protein with fragment. In the event of
binding, the shape of the tops of the protein-ligand bars (minus the fragment bars)
should form a sigmoid curve. The values of the subtracted bars (height) can also
be plotted to obtain IC50 curves such as in the following Figure 6.7. Cycles 1–8
positive control chitobiose, 9–16 ysbl000266, 17–24 ysbl000268, 25–32 ysbl000273,
33–40 negative control ysbl000261, 41–48 ysbl000276, 49–56 ysbl000277 and 57–
64 ysbl000281.
6.2.3 Discussion of the Alternative Biacore Screen
The alternative Biacore screen is an interesting way of screening carbohydrate
binding proteins. The major advantages are the relatively high responses com-
pared to the conventional Biacore screen and the need of only one flow cell on a
Biacore CM5 chip. Old chips can be recycled and less consumables are needed.
Nevertheless the assay is challenging. Many side effects occur such as protein and
ligand building up on the surface as a consequence of the high concentrations.
Some of the data sets fit very nicely and give good dose-response curves (Figure
6.3), others are not fittable and show outliers (Figure 6.4). Most problems can be
explained by the high concentrations of protein and ligand used. The molecules
can be too sticky or precipitate resulting in odd signals. Figure 6.4 b and c il-
lustrate how the small molecules glucose and GlcNAc accumulate heavily on the
surface at higher concentrations. Also the fragments ysbl000266 and the negative
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(a) Chitobiose (b) ysbl000266
(c) ysbl000268 (d) ysbl000281
Figure 6.7: Binding affinity screen. (a) The responses demonstrate chito-
biose binding, but do not indicate saturation. Compounds ysbl000266 (b), and
ysbl000261 (negative control) accumulate on the surface and give a higher re-
sponse with higher concentration. ysbl000268 (c) and ysbl000281 (d) show the
beginning of an inhibition curve, but no saturation occurs like with chitobiose.
(n=2)
control ysbl000261 give a higher response with higher concentration (Figure 6.7
b). Figure 6.3 c displays how chitotriose gave respectable IC50 curves in regular
buffer, but produced curves with outliers when DMSO was present (Figure 6.4 a).
Although the fit for GlcNAc in regular buffer was possible and produced affinity
data in an expected range, the shape of the curve is not of desired quality (Fig-
ure 6.3) and the determined IC50 can only be taken as a guide. In the binding
affinity screen where the maximal concentration of chitobiose (KD of 170 µM)
was 10 mM the concentration should give a full IC50 curve for chitobiose (Figure
6.7 a). However the curve does not saturate. Considering these results, it is also
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important to recall that the IC50 is not the same as the KD. The IC50 is not an
absolute value and depends on the assay conditions. In the alternative Biacore
screen, the IC50 depends on the affinity and concentration of dextran on the chip
surface as well as on the protein concentration. In summary the higher the pro-
tein concentration, the higher the IC50. That fact can explain why the curves do
not reach saturation. In conclusion, the alternative Biacore screen is an interest-
ing new approach to screen carbohydrate binding proteins. However, the screen
requires more optimisation. At the present it is difficult to obtain reliable IC50
values (Figure 6.4). However, the alternative screen gave indication of fragments
binding to HEWL. The next section describes cross-validation of this fragment
binding using an enzyme activity assay using whole cells as substrate.
6.3 The Enzyme Activity Assay
HEWL is able to lyse some bacteria by cleaving β−(1→ 4) glycosidic bonds of N-
acetylmuramic acid and N-acetyl-D-glucosamine residues in mucopolysaccharide
cell walls. Micrococcus luteus – formerly known as Micrococcus lysodeikticus –
can be used as the substrate for a HEWL activity assay (first suggested by Shugar
1952). The turbidity of the solution with cells and enzyme can be recorded at
a 450 nm wavelength. As HEWL cleaves the cell walls the turbidity decreases.
When a ligand is present the HEWL activity should be either inhibited or acti-
vated and therefore the cleavage rate - measured in absorption units per second
(AU/s) - slows down or increases respectively.
The assay was set up in 96-well format on a plate reader with 2.3–4.6 µM HEWL
and 0.33–0.5 mg/ml Micrococcus luteus. The rate of cell lysis was used to generate
dose-response curves for the different ligands. The rate AU/s (alias the slope)
was determined with Excel. The points of the first 30 seconds were excluded to
allow the system to stabilise. In most cases the slope was determined for periods
of 30–230 seconds to ensure a linear slope. The stronger an inhibitor binds to
HEWL, the less negative the slope should be in theory. The slope was altered by
multiplication with the factor −10, 000 in order to give the dose-response curves
the classical sigmoidal shape (low concentration corresponds to high response and
vice versa, similar to the previous Biacore assays). If the lowest concentration
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was 0, then a value of 0.01 was used instead to plot on the logarithmic scale
(methods in Section 10.7 on page 183).
In Figure 6.8 some representative results of the enzyme activity assay are il-
lustrated. To demonstrate reproducibility, all data were recorded as duplicates.
Chitobiose shows a hint of inhibition (Figure 6.8 a) with the response falling for
about 10–20× -0.00001 absorption units at maximum ligand concentration. How-
ever, the curve does not reach saturation. Also compound ysbl000277 (Figure
6.8 b) indicates some inhibition with the response decreasing for about 7 × -
0.00001 absorption units. Like chitobiose the inhibition curve does not reach
saturation. However, the point at the highest concentration was found to be an
outlier and therefore the compound was not considered as a potential inhibitor.
Compounds ysbl000281 and ysbl000294 (Figure 6.8 c and d) show an oscillating
response within the range of about 5 × -0.00001 absorption units. For fragment
ysbl000281, the data points indicate a weak activation rather than an inhibition.
However, considering the change of response being much smaller than for chito-
biose, the compound unlikely shows activity. Fragment ysbl000294 does not show
activity.
The plots in Figure 6.9 illustrate the most interesting fragments of the screen: N-
acetylglycine (ysbl000265), o-toluic acid (ysbl000267) and benzothiazole (ysbl000
297) (Figure 6.10). All three show activating activity. The range of the response,
20 × -0.00001 absorption units, is in almost the same range as for chitobiose.
More solid of the compounds was purchased and they were tested in further
enzyme activity and thermal shift experiments (Sections 6.3.1 and 6.4.3).
Figure 6.11 shows the results of control experiments. Initially, the cells were
incubated with each of the three fragments (N-acetylglycine, o-toluic acid or
benzothiazole) in the absence of HEWL. No cell lysis was observed. Subsequent
addition of 4.6 µM HEWL to the same sample, the cells are lysed as previously.
The pH of the solution itself remains in the normal range after the lysis: pH 7.4
for N-acetylglycine, for o-toluic acid and benzothiazole, and pH 8.0 if chitobiose
is present. Micrococcus luteus cells without any additives in Milli-Q water have
a pH of 6.3.
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(a) Chitobiose (b) ysbl000277
(c) ysbl000281 (d) ysbl000294
Figure 6.8: Results of the enzyme activity assay. (a) Chitobiose shows
inhibition, but no saturation. (b) ysbl000277 also demonstrates inhibition, but
no saturation. The point as the highest concentration has to be considered as
an outlier. (c) The response of ysbl000281 is a weak activation rather than
an inhibition. (d) Fragment ysbl000294 does not indicate neither inhibition or
activation. (n=1)
6.3.1 Determination of the Michaelis Menten Constant
Enzyme kinetics can be modelled with the popular but simple Michaelis-Menten
model. In this specific experiment, the Michaelis-Menten constant KM of the as-
say is the cell concentration at which the HEWL activity is half maximal (respec-
tively the substrate concentration where the enzyme activity is half maximal).
The KM is obtained with the following equation:
Rate = V =
Vmax[S]
[S] +KM
(6.1)
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(a) N-Acetylglycine ysbl000265 (b) o-Toluic acid ysbl000267
(c) Benzothiazole ysbl000297
Figure 6.9: Interesting dose-response curves of the enzyme activity as-
say. (a)–(b) Dose-response curves of ysbl000265, ysbl000267 and ysbl000297.
Knowing KM the inhibition constant Ki which is independent of the assay con-
ditions, unlike the IC50. The Ki represents the competing ligand concentration
which would bind to 50% of the receptor at equilibrium in the absence of other
competitors. Thus Ki and KD are in most cases identical. Exceptions will occur
when the ligand binds to a form of the receptor prior modified by the substrate
or when the receptor itself modifies the substrate. The Cheng-Prusoff-equation
describes the relationship between Ki and IC50 (Cheng and Prusoff, 1973):
Ki =
IC50
1 + [S]
KM
(6.2)
It was not possible to determine the KM as the enzyme activity does not reach a
saturating maximum. Instead activity decreases after reaching a certain concen-
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(a) N-Acetylglycine (b) o-Toluic acid (c) Benzothiazole
Figure 6.10: Structures of potential activators. (a)–(c) Structures of
ysbl000265, ysbl000267 and ysbl000297.
Figure 6.11: Validation of the potential activators. When HEWL is not
present, no concentration dependant change of rate can be observed.
tration and does not stay at the asymptote. Also a minimum asymptote cannot
be found. This is illustrated in Figure 6.12 which shows a substrate velocity
curve for the substrate Micrococcus luteus. Instead of reaching a maximum and
saturation, the enzyme activity decreases again after 0.23 mg/ml substrate con-
centration. These data cannot be fitted and thus were not used to determine KM.
The experiment was repeated without ligand as well as with 10 mM of the acti-
vators N-acetylglycine, o-toluic acid and benzothiazole. The pH of the solutions
was found to be 7.4 for no ligand present, 7.4 for N-acetylglycine, 6.6 for o-toluic
acid and 7.0 for benzothiazole. The results of this test are illustrated in Figure
6.13. This time the curves neither saturate nor reach a maximum. The shape of
the curves in Figure 6.12 could not be reproduced.
Since these three ligands are expected to be activators, it was attempted to find
the point of maximum activation at the substrate concentration of 0.17 mg/ml,
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Figure 6.12: Cell concentration series for KM determination. Cell concen-
tration was varied to find the KM of the assay where the cell concentration allows
a half maximal enzyme activity. However, instead of saturating at the maximal
activity, the curve goes down again.
Figure 6.13: Cell concentration series for KM determination with lig-
ands. Cell concentration was varied to find the KM of the assay where the cell
concentration allows a half maximal enzyme activity. However the curves do not
reach a maximum rate. The ligands were present at 10 mM concentration.
which lies in the range of the maximum enzyme activity (see above). The com-
pounds were tested up to a concentration of 25 mM. However, benzothiazole
precipitated at 25 mM. The dose-response curves did not reach maximum acti-
vation (Figure 6.14).
Due to the initial failure to obtain the full range IC50 of chitobiose and the non-
consistent results with a lower substrate concentration (Figure 6.12), another
IC50 determination using half the substrate concentration was attempted (Figure
6.15). When a substrate concentration of 177 µg/ml was used, the obtained dose-
response curve can be fitted after excluding one data point. The fit is suboptimal,
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Figure 6.14: Dose-response curves for activators to find maxima. All ac-
tivators were tested up to a concentration of 25 mM to find the maximal activity.
but indicates an IC50 in the expected range (KD in literature is 170 µM).
Figure 6.15: IC50 estimation for chitobiose with the enzyme activity as-
say. Although the fit is not optimal, the calculated IC50 lies within the expected
range. One data point was excluded as an outlier.
6.3.2 Discussion of the Enzyme Activity Assay with
HEWL
The enzyme activity assay is a cost-effective and easily implemented assay. The
50 mM phosphate buffer pH 7.4 was found to buffer the acidic compounds well.
However, the assay faces major reproducibility issues. In this section, 14 frag-
ments were initially tested. Subsequently mainly three different presumably acti-
vating compounds, N-acetylglycine, o-toluic acid and benzothiazole, were tested.
The dose-response curves for the potential activators do not reach their maxima.
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The reasons for this remain uncertain. The difficulties could either derive from
the validity of the assay itself or because of the very weak binding constants of
these compounds. The major problematic aspect is the unknown working con-
centration of substrate. Cells can be prepared as a mass-by-volume suspension.
However, since the cells are heavier than the solvent they will sink to the bottom
of the tubes. Each pipetted aliquot will always have a different number of cells.
Further, it can be assumed that cells sink to the bottom of the plate during the
actual experiment and might not be available as a substrate for HEWL during
the experiment. It must also be considered that not all cell walls have exactly
the same composition which likewise may result in an inaccurate determination
of substrate concentration. Concluding, one can say that an assay with known
substrate concentration would be a big advantage to test potential activators.
6.4 Thermal Shift Analysis
Thermal shift analysis (TSA) is a straightforward assay based on the thermal
denaturation of proteins. The central assumption is that binding of a ligand
will stabilise a protein, yielding improved thermal stability of the protein. The
experiment is performed with a real time PCR machine (qPCR) and environ-
mentally sensitive fluorescent dyes. The fluorescence of the dye is quenched in an
aqueous environment. In the presence of hydrophobic residues which will become
exposed when the heated protein unfolds, fluorescence increases and a protein
melting curve can be recorded. The temperature where the amount of folded and
unfolded protein is equal is named the melting temperature (Tm). The program
MTSA was written to aid fitting and analysis of the data (details of this program
are provided in Chapter 4 of this thesis). The following results were produced
by fitting the 5-parameter logistic equation Sigmoid-5 and taking the inflection
point of the curves as Tm. The experimental setup is described in Section 10.8.
6.4.1 Buffer Screen and Initial Tests
The first step was finding the buffer conditions which best stabilised the protein
for good melting curves. The following buffers were screened at 50 mM concen-
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tration including 150 mM NaCl: HEPES pH 7.5, MES pH 6.5, bicine pH 9.0,
Na/K PO4 pH 7.0, MOPS pH 7.0, CAPS pH 10.0, CHES pH 9.5, PIPES pH 6.5.
Initially 100 µg/ml protein in 200 mM CAPS buffer at pH 10.0 with 150 mM NaCl
was used to test some ligands such as the possible activators N-acetylglycine,
o-toluic acid, benzothiazole and the positive control chitobiose. Ligands were
screened at a maximum concentration of 5 mM for the fragments and 0.5 mM
for chitobiose. However these conditions often produced double-humped curves
(Figure 6.16) which does not allow accurate determination of the Tm.
Figure 6.16: Double humped curves in high pH buffer. The initially chosen
condition 200 mM CAPS pH 10, 150 mM NaCl, 100 µM HEWL (DMSO free)
produced double humped curves in experiments.
According to other reports, HEWL forms dimers at pH 5–9 and higher order
oligomers at pH 10–11 (Sophianopoulos and van Holde 1961, Sophianopoulos
and van Holde 1964). Kumar et al. (2009) states that the self-aggregation at
pH 12.2 can be inhibited by the addition of chitotriose. At pH 4.0 the protein is
almost in its native state. Only heating at 80 for many days can make HEWL
form aggregates at that pH (Arnaudov and de Vries 2005). Thus two lower pH
buffers - sodium acetate pH 4.5 and citric acid pH 3.8 - were tested at 50 and
200 µg/ml HEWL concentration with and without positive control chitobiose and
2.5% final DMSO concentration.
The melting curves at higher protein concentrations (200 µg/ml) are more regu-
larly shaped and produce better fits. The baseline of the curves at low protein
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concentration (50 µg/ml) are rather noisy. Thus, only the curves at higher pro-
tein concentration are considered in the following sections. A good buffer should
feature a high protein melting temperature without ligand present (ergo being a
stabilising buffer), a low standard deviation (meaning low variability and high re-
producibility) and a large temperature shift for the positive control (chitobiose).
The melting temperature for HEWL in sodium acetate buffer was slightly higher
(73.53) than in citric acid (73.13). However, the standard deviation in acetate
buffer was higher (0.21) than in citric acid (0.11). The temperature shift pro-
duced by chitobiose is slightly higher in citric acid buffer (0.19 for the 200 µM
and 0.67 for the 2 mM chitobiose concentration) than in sodium acetate buffer
(0.18 for the 200 µM and 0.65 for the 2 mM chitobiose concentration). For
this reason, citric acid was chosen as the new screening buffer.
6.4.2 Sensitivity Test of Different qPCR Machines
At the time TSA was established in YSBL different qPCR machines were avail-
able (AB 7300, AB 7500, Bio-Rad CFX96 and Agilent Stratagene MX3005). It
turned out that the data is not consistent between them. In particular, the Bio-
Rad machine seemed to produce different results. To obtain a comparison, a
sensitivity check was performed on all available machines to select the best one
for purchase. The established assay conditions of HEWL were used to choose be-
tween the three available devices from Bio-Rad, AB (AB 7500) and Stratagene.
A HEWL concentration of 500 µM in 12 twofold dilution steps was aliquoted
three times and tested in octuplets on each of the three machines. The results
were analysed for the maximum dilution at which a fit of the melting curve was
still possible (sensitivity) and which fit showed the lowest standard deviation (re-
producibility). The Bio-Rad device was found to detect a HEWL melting curve
to a lower concentration limit of 250 µg/ml which made it the device with the
by far lowest sensitivity. The AB and the Stratagene machine were comparable
in sensitivity and reproducibility. Curves could be detected relatively confidently
down to 62 µg/ml and in some cases even down to 31 µg/ml. The Agilent
Stratagene MX3005 machine was purchased for the lab because it offers the most
user-friendly interface and was better value. All the following experiments were
performed on that model.
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6.4.3 Small Fragment Screen with TSA
A small number of fragments were screened against HEWL with the thermal
shift assay including the three activators discovered in Section 6.3 on page 119
and a selection of fragments from “Michele 2 ”. The following two paragraphs
summarise the results of the experiments.
Potential Activators and Chitotriose
For the TSA experiments with HEWL every third well was used as a blank
resulting in 36 blanks per 96-well plate. The standard deviation of the HEWL
plates was relatively high (0.2–0.5). A significant thermal shift was defined as
more than three times the standard deviation (according to Sorrell et al., 2010).
As expected the negative control glucose did not indicate any temperature shift.
Chitotriose showed a significant shift of 1.62 for the high concentration (5 mM),
but not at the 500 µM concentration (0.12). The three potential activators N-
acetylglycine, o-toluic acid and benzothiazole did not demonstrate a significant
thermal shift.
Other Fragments
The buffer 50 mM citric acid pH 3.8 with 150 mM NaCl was used to estimate frag-
ment screening suitability of the assay. Nineteen compounds from “Michele 2”
(Sigma Aldrich) were tested on three plates. The standard deviations of the
blanks were again undesirably high: plate 1 was 0.24, plate 2 0.26 and plate 3
0.51. No significant shift was found. However compound ysbl000461 indicated
a hint of a thermal shift with an average of 0.2 for the low concentration 500 µM
(lower than standard deviation) and an average of 0.4 for the high concentration
5 mM.
Fragment ysbl000497 alters the shape of the plateau of the melting curve. In the
other cases the HEWL melting curves in citric acid buffer produces a very pointed
narrow plateau. However for ysbl000497 the curves of the 5 mM concentration
have a longer, slightly double-humped plateau (Figure 6.17). Interestingly, ac-
cording to NMR this compound has a very low concentration and is not 100%
soluble at 2 mM in D2O.
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(a) Chitotriose (b) ysbl000497
(c) ysbl000497
Figure 6.17: Different shaped melting curve with fragment ysbl000497.
(a) The shape of a melting curve with 5 mM chitotriose is a typical melting curve
for HEWL in citric acid buffer at pH 3.8. (b) The shape of the melting curve
with the fragment ysbl000497 displays a double-humped region at the maximum
asymptote. (c) Structure of ysbl000497.
6.4.4 Discussion of TSA with HEWL
The initial occurrence of double-humped curves in the HEWL TSA experiments
can be explained with the literature: HEWL tends to form aggregates and fibrils
under many pH and heat conditions. HEWL fibrils occur at pH 2.0 and 3.0 when
the protein is heated up to 57 for several days. However, HEWL at pH 4.0
does not aggregate at all even when observed for 42 days. For the pH 4.0 protein,
only incubation at 80 formed small spherical aggregates. These observations
suggest different unfolding pathways for HEWL at pH 3.0 and pH 4.0 (Arnaudov
and de Vries, 2005). Also, the addition of organic solvents although followed
by a long incubation time will lead to fibrils (Krebs et al., 2000). Although the
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heating period of the experiments in this chapter only lasted one to two hours,
the definite influence of the pH and the possible influence of DMSO must be
considered. The unfolding curve of the TSA experiments in the pH 3.8 buffer
confirms the observations made by Arnaudov and de Vries (2005) using static
light scattering that the protein does not aggregate at pH 4.
TSA as a cost-effective high throughput method has a relatively high rate of
false negatives. This fact makes the method more attractive in primary screening
rather than as a cross-validation method. In the TSA screen with HEWL the
binding of the potential activators N-acetylglycine (ysbl000265), o-toluic acid
(ysbl000267) and benzothiazole (ysbl000297) could not be confirmed. Since the
standard deviation of the blanks in the plates was relatively high and the expected
temperature shift would be relatively low, it is likely that the potential activators
were missed out as false negatives. One should also consider the very high melting
temperature of HEWL above 70. It is also possible that some compounds are
not stable at that temperature, and will not result in a thermal shift.
The fragment ysbl000497 seems to influence the unfolding behaviour of HEWL.
This is particularly interesting because the compound is not very soluble accord-
ing to the NMR quality control. However it remains to say that the quality
control took place with another compound batch than that used in the screens.
After the three activators appeared as hits, more solid of them was purchased in
order to have ample material for follow-up experiments.
The plates demonstrated a high standard deviation although using 32 blanks.
The high standard deviations most likely result from pipetting errors.
It would be worth additionally analysing the TSA data obtained with HEWL
with the midpoint method and with the Boltzmann equation. Chapter 8 on
page 151 goes into more detail about how the slightly different Tm determination
methods can produce different results.
It remains to question whether the 14 kDa protein is simply too small for TSA.
The dye SYPRO orange binds to the hydrophobic regions of the unfolding protein.
A small protein like HEWL will not have a big hydrophobic core. It might be
interesting to see if TSA is more suitable for bigger proteins with a higher number
of folded units.
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6.5 Crystallisation
Some initial crystal trays with HEWL were set up in order to confirm the binding
of the potential activators crystallographically. As reported many times they
grew easily and quickly. The best conditions came from the CSS 1 & 2 screen
(tray 2, Dr. Marek Brzozowski’s conditions): 2 M sodium formate, HEPES
pH 7.5, 30 mg/ml HEWL and 0.8 M sodium formate, 10% PEG 8K, 10% PEG 1K,
HEPES pH 7.5, 30 mg/ml HEWL (Section 10.9.1, page 186) and follow-up trays
were set up. First trials to assess appropriate soaking conditions were performed
on tray 1 (Section 10.9.1, page 186) at several highly concentrated fragment
solutions (10–200 mM). However, crystals cracked at the highest concentration.
The lowest tested concentration (10 mM with 2.7% DMSO) did not break the
crystals, although crystals looked damaged.
6.6 Final Remarks about HEWL
HEWL turned out to be a challenging project. While the protein can be pur-
chased at low costs and quickly forms crystals, HEWL does not behave straight-
forwardly in other assays.
A novel Biacore assay was developed which can be used for carbohydrate binding
proteins on the reference cell of a recycled CM5 chip: The protein binds with
its sugar-binding site to the dextran surface of the chip and added ligands will
compete for the binding site of the protein. The set-up allows the protein to be the
reporting signal, which results in a high response. This is a big advantage towards
immobilised protein where binding ligands give far lower responses. Nevertheless
the assay has its drawbacks. Materials may accumulate at the surface and make
it difficult to obtain reproducible results.
Similar experiences were made with the subsequent enzyme activity assay. HEWL
cleaves the cell walls of Micrococcus lysodeicticus and the turbidity of the solution
can be followed at 450 nm absorption. Chitobiose and 14 fragments considered
to influence HEWL activity were tested with the novel Biacore assay. However,
dose-response curves did not give clear results. The major issue with the assay
is the unknown substrate concentration. For strong inhibitors this might not be
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an issue, but it seems to be for weakly binding fragments.
As a third assay thermal shift analysis was applied to HEWL. The conditions were
optimised because under certain conditions, HEWL tends to form aggregates and
fibrils. Controls, the three potential activators and 19 compounds of “Michele 2”
were tested. Only the positive control chitotriose demonstrated a significant
thermal shift. None of the fragment test sets showed any binding neither the
binding. Binding could also not be confirmed for the three potential fragment
activators.
Although issues were encountered when attempting to confirm fragment binding,
initial crystallisation trials were started. As expected, HEWL crystals grew easily
and rapidly. The first soaking tests led to cracking of the crystals - an effect of too
harsh soaking conditions such as high DMSO and ligand concentrations or too
rapid soaking. However at the time the initial crystallisation experiments were
set up with HEWL, the attention moved to the protein BtGH84 (a glycoside
hydrolase from Bacteroides thetaiotaomicron) which turned out to be a much
simpler target (Chapter 7 on page 134). Therefore HEWL was put to the side
for potential later studies.
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Chapter 7
The Target BtGH84
After two challenging protein targets (NMT in Chapter 5 and HEWL in Chapter
6), fragment screening with the glycoside hydrolase BtGH84 turned out to be
very successful. Production of stable protein was straightforward and about 500
compounds were tested with a thermal shift assay. The analysis of the large
amount of data was made possible with the – in Chapter 4 devised – program
MTSA. Interesting hits were assayed with surface plasmon resonance to determine
affinity. A number of attempts were made to determine the structure of hit
fragments complexed to BtGH84 – however no bound fragment was observed.
The project is very promising for follow-up experiments.
7.1 Background of BtGH84
The common post-translational modification of GlcNAc addition (saccharide 2-
acetamido-2-deoxy-D-glucopyranose) in cells of higher eukaryotes was first de-
scribed by Torres and Hart, 1984. The carbohydrate becomes attached to serine
and threonine residues via a beta-glycosidic linkage (O-GlcNAc) and is commonly
found at phosphorylation sites (Kamemura et al., 2002; Cheng et al., 2000) with
a reciprocal relationship between the presence of O-phosphate and O-GlcNAc.
Similar to phosphorylation, O-GlcNAc modification is happening several times
during the lifetime of a protein (Chou et al., 1992). The O-GlcNAc modification
is thought play to a relevant role in Alzheimer’s disease (Griffith and Schmitz,
1995), cancer (Chou and Hart, 2001) and diabetes type II. More than 500 kinases
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are responsible for phosphorylation and more than 140 phosphatases for dephos-
phorylation (Manning et al., 2002). However for the O-GlcNAc modification there
are only two enzymes in mammals: one to add the Glc-NAc (glycosyltransferase
OGTase) (Kreppel et al., 1997) and one to remove it (O-GlcNAcase, glycoside hy-
drolase) (Gao et al., 2001). O-GlcNAcase is very important in cellular signalling
and stress response.
The structure contains a C-terminal acyltransferase and a N-terminal glycoside
hydrolase domain. The N-terminal domains of eukaryotic O-GlcNAcases are
highly similar to some bacterial enzymes. The function of these bacterial enzymes
is not very clear although they have a high sequence similarity. The bacterial and
the eukaryotic O-GlcNAcases have both been grouped into the glycoside hydrolase
family GH84.
A close homologue to the human enzyme is BtGH84 - the glycosid hydrolase
from Bacteroides thetaiotaomicron VPI-5482. It also cleaves O-GlcNAc from
post-translationally modified proteins using a mechanism involving substrate-
assisted catalysis. Nearly the entire catalytic centre is conserved (except one
amino acid) within the active site architecture of BtGH84 compared to the human
O-GlcNAcase (Dennis et al., 2006). BtGH84 consists of four domains whereof
the fourth domain can bind carbohydrates (Dennis et al., 2006). PUGNAc (O-
(2-acetoamido-2-deoxy-D-glucopyra-nosylidene)amino-N-phenylcarbamate) (Mo-
han and Vasalla, 2000) (Figure 7.1) inhibits BtGH84, although the literature
binding constant varies between nanomolar to micromolar range with the most
often mentioned binding constant in low micromolar range (Dennis et al., 2006;
He et al., 2011; PhD thesis of Dr. Yuan He, 2011; Dr. Jens Landstro¨m, unpub-
lished data).
Figure 7.1: PUGNAc. The 353 Da compound PUGNAc binds to BtGH84
although values for the inhibition constant vary starkly in the literature.
Dr. Jens Landstro¨m screened BtGH84 against the first half of “Michele 1” (about
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100 fragments) and found the fragment ysbl000293 to be the best inhibitor with
an IC50 of 600 µM and ysbl000310 to be the best activator with an EC50 of 4 mM
(unpublished data).
(a) ysbl000293 (b) ysbl000310
Figure 7.2: ysbl000293 and ysbl000310. According to Dr. Jens Landstro¨m’s
fragment screen ysbl000293 inhibits BtGH84 with an IC50 of 600 µM whereas it
is activated by ysbl000310 with an EC50 of 4 mM.
In this chapter, the TSA screening results of almost 500 compounds against
BtGH84 are presented, namely fragments from “Michele 1” and “Michele 2” and
neighbours of Dr. Jens Landstro¨m’s hits (library named “Jens”). Interesting hits
were cross validated with Biacore experiments. Some compounds were soaked
into BtGH94 crystals. However none of the structures showed ligand binding.
7.2 Protein Production
Protein stocks of N-terminal His6-tagged protein from Dr. Jens Landstro¨m and
Dr. Yuan He as well as self-produced protein were used in this chapter (Dennis
et al. 2006).
The protein with an N-terminal His6-tag was produced in E. coli BL21(DE3).
Cells were grown overnight at 37 and expression was induced with 1 mM
IPTG at an OD600 of 0.8. Cells were lysed by sonication and the protein was
purified via affinity chromatography using a 5 ml nickel-NTA column. It was
eluted in fractions with 0 to 100% buffer containing 500 mM imidazole. Fractions
were assessed with SDS-PAGE (Figure 7.3) and the protein containing fractions
were pooled together and concentrated. The single step purified BtGH84 to a
suitable purity. (A more detailed description can be found in Chapter 10. Protein
production was published by Dennis et al., 2006.)
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Figure 7.3: Purity of BtGH84. SDS-PAGE analysis of the used fractions of
BtGH84 (82 kDa) after affinity chromatography. (1) and (10): protein marker;
(2)–(9): BtGH84 eluted fractions.
7.3 Thermal Shift Analysis
The main screening method for BtGH84 in this thesis was thermal shift analysis
(for more details about TSA, refer to Section 6.4 on page 126). About 500 frag-
ments from the prior generated fragment libraries “Michele 1” and “Michele 2”
(Chapter 3) and neighbours (compounds similar to hits previously found by
Dr. Jens Landstro¨m, thus called library “Jens”) were screened using this method.
The handling of the resulting large data sets would not have been possible without
the analysis program MTSA (Chapter 4, page 85).
7.3.1 Initial Tests, Buffer and Concentration Effects
BtGH84 itself behaved exemplarily for thermal shift analysis. Using the fluores-
cent dye SYPRO orange melting curves fit nicely and are reasonably reproducible.
According to a student’s project from Bailey Massa who tested several buffers,
Na/K PO4 buffer pH 7.7 was found to be the most suitable to screen BtGH84
with TSA. According to Dennis et al., 2006, the optimum pH for BtGH84 is pH
6.0 (Dennis et al. 2006) and for the human enzyme 6.5 (Cetinbas et al. 2006).
Thus the buffer was changed to sodium phosphate pH 6.0 after initial tests. (More
details about materials and methods in Section 10.8, page 184.)
The thermal shift experiments were performed in 50 mM sodium phosphate
137
buffer at pH 6.0 with 150 mM NaCl and 1x SYPRO orange. The fragment
hit ysbl000293 with an IC50 of 600 µM (Dr. Jens Landstro¨m, unpublished work)
and PUGNAc were used for tests and as positive controls. Two concentration
series were measured for each compound. PUGNAc stabilises BtGH84 signifi-
cantly whereas the thermal shift for the fragment is less obvious but unambigu-
ous: ysbl000293 shifts the Tm about 0.8 at 5 mM concentration, PUGNAc
exhibits a shift of 6 at 2.5 mM concentration. The Tm for PUGNAc increases
almost linearly with each concentration step while the correlation for ysbl000293
is ambiguous (Figure 7.4).
(a) PUGNAc (b) ysbl000293
Figure 7.4: Thermal shift of the positive controls. Both positive controls
PUGNAc and ysbl000293 stabilise BtGH84 significantly in the thermal shift ex-
periments. The zero concentration was adjusted to 1 µM to enable a logarithmic
plot.
The effects of protein concentration and of DMSO in the assay were assessed
to estimate their influence on subsequent TSA screening experiments. Different
protein concentrations at 0% DMSO were tested which revealed that the Tm
increases with protein concentration. Table 7.1 illustrates the different protein
concentrations and their shifts (each measurement was recorded as quadrupli-
cate). Unsurprisingly, higher protein concentrations feature lower standard devi-
ations. The standard deviation becomes comparable for protein concentrations
from 0.5 µM. The higher the concentration, the better the quality of the fits.
Unexpectedly the melting temperature increases with protein concentration which
may suggest cooperative stabilisation effects of the protein. Screening a range of
DMSO concentrations at 1.4 µM BtGH84 reveals a stabilising effect of DMSO
on BtGH84. The melting temperature increases with DMSO concentration up to
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Table 7.1: Working concentration BtGH84 Estimating the best working TSA
concentration for BtGH84. (n=4)
For 0% DMSO
BtGH84 (µM) Tm () σ ()
0.27 50.07 0.37
0.54 52.21 0.16
0.95 53.00 0.06
1.35 54.38 0.14
6% DMSO where the Tm reaches its maximum (Figure 7.5). These findings led
to the final screening conditions of 50 mM sodium phosphate buffer pH 6.0 with
150 mM NaCl, 1.34 µM BtGH84, 5% DMSO and 1x SYPRO orange.
Figure 7.5: Influence of DMSO on BtGH84 stability. BtGH84 becomes
more stable with DMSO in the buffer. Data for 1.4 µM protein.
Interestingly the stabilisation effects of higher DMSO concentrations were not
confirmed by a later experiment using the fluorescent dye Deep Purple (Section
7.3.3 on 141). Here the Tm for wells with 6.5% DMSO was 57.22, but one degree
higher when only 1.5% DMSO was present in the buffer. Yet that experiment
was performed with a different batch of protein.
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7.3.2 TSA Screen of Michele 1 and Michele 2
In total about 300 fragments were screened against BtGH84 with TSA. All men-
tioned structures in this chapter are pictured in Appendix D. The compounds
were screened at low and high concentration (1 and 10 mM) as quadruplicates
in 50 mM sodium phosphate buffer pH 6.0/150 mM NaCl with 1.4 µM BtGH84
protein, 1x SYPRO orange and a final DMSO concentration of 5%. Each plate
was composed of eight blanks with protein in buffer containing 5% DMSO and
of eleven fragments. The data was analysed with MTSA (Chapter 4, page 85)
using the inflection point of the Sigmoid-5 equation (Section 4.3). The results
of the screen are summarised in Table 7.2. Some of the fragment hits stabilised
the protein at low concentration, but destabilised it at high concentration. This
effect was considered to be caused of high concentrated ligands interfering with
the assay rather than deriving from false positives. Some structures are shown
in Figure 7.6.
Table 7.2: Fragment hits for BtGH84 when using the inflection point
(n=4; 8 blank controls per plate)
Soluble in assay Blanks ∆Tm at
Fragment (yes/no) Tm () σ () 1 mM () 10 mM ()
ysbl000298 y 56.69 0.10 0.71 -2.98
ysbl000299 y 56.69 0.10 0.51 -6.63
ysbl000317 n 56.91 0.11 0.68 -0.52
ysbl000416 y 56.66 0.11 0.29 -0.10
ysbl000438 y 56.52 0.22 0.86 1.41
ysbl000486 y 56.34 0.08 0.22 0.14
ysbl000507 y 55.94 0.78 3.11 -11.88
ysbl000509 y 56.35 0.27 2.09 1.68
7.3.3 TSA Screen of Neighbours Jens
A further 150 compounds from the library “Jens” were assayed. This library
contains nearest neighbours to hits of an initial fragment screen (Dr. Jens Land-
stro¨m). The compounds were screened and analysed the same way as the frag-
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(a) ysbl000438 (b) ysbl000507 (c) ysbl000509
Figure 7.6: Fragment hits of the TSA screen.
ments above with the difference of 32 controls and eight compounds per plate.
The hits and their thermal shifts derived with the inflection point method are
summarised in Table 7.3. The table contains further information about the sol-
ubility of the compounds in the screen. All data derived from compounds with
poor solubility should be handled with care because precipitation may interfere
with the assay.
Compounds ysbl000673, ysbl000683, ysbl000708, ysbl000730, ysbl000733,
ysbl000749, ysbl000752 and ysbl000779 were followed up in control experiments
to confirm their binding.
Controls
The neighbours ysbl000673, ysbl000683, ysbl000730, ysbl000733, ysbl000749 and
ysbl000752 were tested in three further controls:
1. without dye
2. without protein
3. with a different dye
1. None of the compounds had intrinsic fluorescence, i.e. when there was no dye
present, no response could be recorded.
2. The tested neighbour ysbl000749 could be ruled out for further tests as it
showed a response while no protein was present. It featured two differently shaped
curves depending on the concentration (1 mM and 10 mM). The compound also
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Table 7.3: Hits from library “Jens” for BtGH84 when using the inflec-
tion point method Solubility was assayed for two steps. The first step is a
pre dilution of the compound on a separate ligand plate, the second step is the
dilution to the final assay conditions. (n=4; 32 blank controls per plate)
Soluble (yes/no) Blanks ∆Tm at
Fragment 1st step 2nd step Tm () σ () 1 mM () 10 mM ()
ysbl000673 y y 56.16 0.24 0.79 1.00
ysbl000683 y y 56.49 0.15 0.36 1.08
ysbl000684 n n 56.49 0.15 0.12 0.89
ysbl000705 n y 56.67 0.20 0.32 0.73
ysbl000720 y y 55.13 1.05 0.41 4.87
ysbl000730 n n 55.87 0.09 1.36 2.69
ysbl000733 y n 55.87 0.09 0.52 1.36
ysbl000734 y n 55.87 0.09 1.58 2.70
ysbl000737 n n 55.87 0.09 0.08 0.63
ysbl000749 n n 54.92 1.68 9.82 11.24
ysbl000752 y y 54.92 1.68 0.98 1.50
ysbl000767 n n 55.26 0.47 0.83 2.49
ysbl000770 n y 56.00 0.13 0.18 0.92
ysbl000775 n n 56.00 0.13 0.21 0.52
changed colour in wells of different concentrations (yellow at low concentration
and red at high concentration on the pre diluted ligand plate) which may indicate
tautomerisation.
3. Deep purple was used as an alternative dye to SYPRO orange. It was found
to work best at 6x concentration which results in a final concentration of 6.5%
DMSO and 1.5% acetonitrile. The SYPRO orange filter and the Nile red filter
were both used to record the melting curves, but the Nile Red filter seemed to
produce better curves.
A thermal shift introduced by all compounds could be confirmed. Although the
absolute number differs, the quality of the shifts was comparable to the results
obtained with SYPRO orange. The only exception was ysbl000733 which caused
a negative shift at high concentration.
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The fragments ysbl000673 (∆Tm(1mM) = 0.11
◦C, ∆Tm(10mM) = 0.82 ◦C), ysbl000
730 (∆Tm(1mM) = 0.18
◦C, ∆Tm(10mM) = 1.69 ◦C) and ysbl000752 (∆Tm(1mM) =
0.23 ◦C, ∆Tm(10mM) = 2.07 ◦C) progressed to the next evaluation step (Biacore)
(Figure 7.7). In accordance with Dr. Jens Landstro¨m these compounds were
considered as the most interesting and the most promising binders.
(a) ysbl000673 (b) ysbl000730 (c) ysbl000752
Figure 7.7: Neighbour compounds progressed to Biacore.
7.3.4 Discussion and Remarks
BtGH84 behaves exemplary with TSA. Almost 500 compounds were tested in
a straightforward assay. Surprisingly BtGH84 is thermally more stable when
DMSO is present in the buffer. Although this finding is dispelled by DMSO
destabilising the protein when using the alternative fluorescent dye Deep Purple.
It may be noted that the experiments were performed with different batches of
protein and it would be interesting to follow up that contradiction with further
experiments. Deep purple was found to work best with the implemented Nile
red filter and at a 6x concentration which results in a final concentration of 6.5%
DMSO and 1.5% acetonitrile. The neighbour compound ysbl000749 looks like it
can tautomerise or react easily and was thus excluded from further assays.
7.4 Biacore with Fragments and Neighbours
In order to cross-validate the hits and to obtain KD of the fragments and neigh-
bours, they were tested with Biacore (some structures of assessed compounds in
Figure 7.8). After catching all protein in the same orientation via its His6-tag,
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BtGH84 was covalently attached to an NTA chip in order to avoid it being washed
off the chip during the experiment. The protein remained stable in the time be-
tween the two experiments when the chip was stored in buffer at 4. Biacore
experiments were performed with duplicate concentration series in quadruplicat-
ing steps. The initial experiment with the maximum concentration of 10 mM
exhibited solubility issues, thus the experiment was repeated with a maximum
concentration of 1 mM. The KDs were determined with the Biacore software using
affinity steady state analysis. (Methods in Section 10.5.2 on page 181.)
(a) Ysbl000299 (b) Ysbl000423 (c) Ysbl000548
Figure 7.8: Compounds assessed with Biacore.
The concentration of the relevant stocks of compounds in the “Jens” library was
unknown since they were saturated solutions only. Thus the calculation was per-
formed assuming the highest concentration is 200 mM like the fragments. That
means the actual derived KDs must be significantly lower since the actual con-
centrations are far below 200 mM. Table 7.4 gives an overview about the KDs.
However the table also illustrates that points needed frequently to be excluded
from the analysis to obtain KD values. In most of the cases the ligand precip-
itated at the high concentration, therefore the experiment was repeated with a
maximum concentration of 1 mM. Table 7.5 suggests that although the fragments
were mostly soluble within the lower maximum concentration series (1 mM), the
response in RU was often too low to fit the data. To analyse the data many points
were excluded as they were outliers. Nevertheless the positive control PUGNAc
(Figure 7.1) proves that the measurement of a binding event with that assay is
possible.
The software has two components to analyse the data. Either steady state affinity
which uses the height of the curves or kinetics analysis which determines the slope
for the kinetic rate constants ka and kd. Fragment binding data were usually
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Table 7.4: Hits for BtGH84 cross validated with Biacore at 10 mM
maximal concentration All binding data was obtained by binding affinity mod-
ule using steady state analysis. Several high concentration data points needed to
be excluded in order to allow the software fit the curves. They were considered
as outliers. (n=2)
Soluble Excluded
Fragment on plate KD (mM) χ2 points (mM)
ysbl000298 n 73.0 0.087 2x 10
ysbl000299 n 39.5 0.026 2x 10
ysbl000317 n 34.4 0.827 -
ysbl000438 y n/a n/a n/a
ysbl000486 y 22.2 0.143 2x 10
ysbl000509 y 2.1 0.566 2x 2.5, 2x 10
ysbl000673 y 0.170 0.086 2x 10
or y 0.489 0.129 2x 2.5, 2x 10
ysbl000730 n 2.9 0.416 2x 2.5, 2x 10
ysbl000752 y n/a n/a n/a
not good enough for a kinetics analysis. However, kinetics analysis could be
performed for PUGNAc and delivered a ka of 0.08 (µMs)
-1, a kd of 0.57 s
-1 and a
KD of 7.3 µM (Figure 7.9 shows the sensorgram of the experiment). When the KD
of PUGNAc is determined with steady state affinity analysis a value of 5.3 µM
is extracted. Table 7.5 gives an overview of the KDs of PUGNAc, fragments and
neighbours tested with Biacore.
7.4.1 Discussion
The determination of the KD of PUGNAc delivered 5–7 µM which is in the same
range as values from He et al. (2011) who found it to be 2.5 µM. The finding
enforces the belief that the binding affinity is indeed in micromolar range and
not in low nanomolar as stated by Dennis et al. (2006). For the remaining
compounds, definition of an affinity constant remained problematic. Compounds
were not soluble up to a concentration of 10 mM, however when using a maximum
concentration of 1 mM data were not reliable enough and KD seem to be above
that concentration. The response produced with the Biacore experiments was
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Table 7.5: Hits for BtGH84 cross validated with Biacore at 1 mM
maximal concentration PUGNAc was analysed with both the steady state
(SS) and the kinetics (kin) module. All other compounds were analysed with
steady state binding analysis. Several high concentration data points needed to
be excluded in order to allow the software fit the curves. They were considered
as outliers. (n=2)
Soluble RU Excluded
Fragment on plate range KD (mM) χ2 points (mM)
PUGNAc (SS) y 14 0.005 1.49 -
PUGNAc (kin) y 14 0.007 0.458 -
ysbl000293 y <1 0.622 0.103 1x series, 1x 1
ysbl000298 y 12 7.4 0.054 -
ysbl000299 y 13 6.1 0.015 0.004
ysbl000317 y 20 8.8 0.996 -
ysbl000438 n 2.5 0.110 0.064 0.25, 1
ysbl000486 y <1 0.660 0.108 -
ysbl000509 y 2.2 6.5 0.019 1
ysbl000673 y 5 3.3 0.0244 1
ysbl000730 y -2 n/a n/a
ysbl000752 y <1 0.844 0.0142 -
often not high enough (third column in Table 7.5). KD greater than half the
highest ligand concentration mean that the data has to be handled with care.
It could mean that the data plots do not have sufficient curvature to generate a
reliable fit. In many cases the KD are even above the maximum concentration.
Furthermore, many data points had to excluded to make the fit possible for the
software to generate (Tables 7.4 and 7.5).
The binding constant for PUGNAc is interesting as it enforces the binding con-
stant to be in the micromolar range and speaks against a nanomolar binding
constant.
In general, binding constants derived with Biacore experiments should be lower
(stronger binding) than with other methods because the protein is attached to
the chip instead of being free in solution. The reduced mobility makes it more
likely for the ligand to find the protein.
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Figure 7.9: PUGNAc sensorgram. The known inhibitor of BtGH84 binds
with an inhibition constant of KD 7.3 µM to the enzyme according to a Biacore
experiment. The experiment was performed with concentration series ranging
from 0.4 µM to 100 µM in 4-fold concentration steps. (n=2)
Affinity constants are often reported with biochemical assays such as enzyme
inhibition assays where a competitive ligand competes for binding to the enzyme.
One major drawback is the time needed to develop such an assay. They can report
IC50 values which can be converted into the Ki values which are usually identical
to KD (more in Section 6.3.1). However, it is difficult to detect weak binding
compounds (high micromolar) with biochemical assays.
Other direct and more sensitive methods to obtain KD values are biophysical, and
include ITC (Isothermal calorimetric) and NMR (Nuclear Magnetic Resonance).
ITC measures quantitatively the thermodynamic parameters of a protein-ligand
interaction. Labelling of the protein is not needed. Drawbacks of ITC are the use
of high quantities of protein and that compounds need to be very soluble which
mostly becomes a problem for testing mM binders. Similarly, titration by NMR
would be limited by compound solubility. NMR becomes difficult for proteins
above 30 kDa when measuring labelled protein and HSQC (BtGH84 weighs more
than 80 kDa). Other NMR methods are more difficult to perform.
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7.5 Crystallisation
BtGH84 crystals grow over night in the known conditions 100 mM imidazole
pH 8.0, 10% PEG 8K, 3% 2M TMAO and 15% ethylene glycol serving as cry-
oprotectant (Figure 7.11). Ligands were tested for soaking with final concen-
trations of about 20 mM and 10% DMSO. Data sets were collected at Diamond
for ysbl000298, ysbl000299, ysbl000317 and ysbl000509 (Figures 7.10 and 7.13 a).
After processing data with Mosflm and Xia2, structures were solved by molecular
replacement with Balbes. Refinement and rebuilding was performed with Ref-
mac5 and Coot (Methods in Section 10.9.2, page 187). The structure of BtGH84
is shown in Figure 7.12.
(a) ysbl000298 (b) ysbl000317 (c) ysbl000509
Figure 7.10: Compounds soaked into BtGH84 crystals.
Crystals grew in space group P21212 with two molecules in the asymmetric unit
and diffracted between 2.0 and 2.7 A˚. None of the structures contained the added
ligand which leads to the conclusion that soaking conditions must be optimised.
The need to optimise soaking was also suggested by other colleagues (Dr. Jens
Landstro¨m). None of the structures were totally refined because they did not
show density for the ligands.
Some of the structures had density of a metal ion in the A-chain between the car-
bonyl oxygen of Glu33 and the carboxyl groups of Glu62 and Asp65 side chains.
Using data with the usual geometry obtained from http://tanna.bch.ed.ac.uk/
qg3.htm, the metal ion is most likely to be a Nickel ion (an example in Figure
7.13).
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Figure 7.11: BtGH84 Crystals.
7.6 Final Remarks about BtGH84
BtGH84 is a very interesting target and easy to handle protein. Almost 500
compounds were screened against the target. Interesting hits were further tested
for their KD and crystal structures attempted to be obtained.
This chapter confirmed the binding constant of PUGNAc to be in the low mi-
cromolar range with a KD around 6 µM, similar to data found by Dr. Yuan He
and Dr. Jens Landstro¨m. Since Dennis et al. (2006) found PUGNAc binding to
have nanomolar affinity, the inconsistency of PUGNAc affinity could be explained
with reasons such as PUGNAc falling apart or PUGNAc being synthesised by
different people.
There are still many open questions. First there are hits from the TSA screen
which got missed with the initial erroneous Tm determination. These could be
further tested with the Biacore. Soaking conditions need to be improved, such as
using a slower soak, i.e. totally exchanging the mother drop with ligand solution
in buffer.
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Figure 7.12: Ribbon diagram of BtGH84. Ribbon diagram of BtGH84 how it
was solved when the ligand ysbl000509 was soaked. (Data was not totally refined
after it was clear that no ligand was present in the crystal structure.) The image
was created using Discovery Studio.
Figure 7.13: Metal ion in BtGH84 structure. Some crystal structures of
BtGH84 contained a bound metal ion. Here the structure of BtGH84 with a test
soak of ligand ysbl000314. Unexplained density was found in the structure (the
2Fo-Fc map is contoured at 1.5 σ and the Fo-Fc map at 3 σ respectively in Coot).
The density indicates most likely a bound Nickel ion.
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Chapter 8
Melting Point Definition
The thermal shift data reported in chapters 6 and 7 were analysed with the
program MTSA described in Chapter 4. This program analyses the change in
fluorescence from a reporter dye as the protein (and ligand) sample is heated to
identify a melting temperature Tm. An increase in Tm suggests that a ligand has
an effect on the ligand stability, and hence is considered as a hit in screening.
During the analysis of the results presented in this thesis and the preparation of a
manuscript describing the program, there was considerable debate about the way
in which Tm is determined. Different conventions for fitting the experimental
data and determining Tm gives small variations in the values obtained which
can be significant for identifying whether a fragment is a hit. This chapter goes
into more detail about the different procedures and whether the TSA method is
suitable for fragment screening.
8.1 Boltzmann, Midpoint and Inflection
Different methods to analyse thermal shift data are available in the literature
(Section 4.2, page 86). At the start of the work described in this thesis, decisions
were made about which method would be most useful for the project. The more
complicated thermodynamic model developed by the inventors of ThermoFluor®
which required knowledge of heat capacity (not obtainable by TSA experiments),
was discarded (Section 4.2.1, page 87). Instead the Boltzmann equation was
initially used to fit the data (more in Section 4.2.2, page 91; Ericsson et al.,
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2006; Niesen et al., 2007; Sorrell et al. 2010) (Equation 8.1). The equation is a
four-parameter logistic model:
γ(T )Boltzmann = min+
max−min
1 + e
T ′−T
a
(8.1)
where the parameter T ′ is equal to the midpoint of the curve and to the point of
inflection and thus defined as the melting temperature Tm:
Tm,Boltzmann = T
′ (8.2)
The initial usage of the Boltzmann fit gave no satisfactory fits (Figure 4.3, page
96). That led to the introduction of an additional parameter c in order to better
refine the fitting of the asymmetry of the curves. (Refer also to Chapter 4, page
85). The five-parameter logistic model is referred to as the Sigmoid-5 equation:
γ(T )Sigmoid−5 = min+
max−min
(1 + e
T ′−T
a )c
(8.3)
For c = 1, i.e. when the curve is fully symmetric, Sigmoid-5 becomes the Boltz-
mann equation. When c 6= 1 then the Tm can be defined as either the midpoint:
Tm,Midpoint = T
′ − a× ln(2 1c − 1) (8.4)
or as the point of inflection:
Tm,Inflection = T
′ − a× ln(1
c
) (8.5)
The equations described above lead to three different ways of possible Tm de-
termination with the software MTSA. These three methods will be referred to
as “Boltzmann”, “Midpoint” and “Inflection” in the following discussion. All
of the equations describe a sigmoidal shaped curve with max and min as the
asymptotes and a being the slope. Depending on which fitting equation is used
(i.e. Boltzmann where c = 1 or Sigmoid-5, with c 6= 1) the midpoint and point
of inflection are the same points or are separated. The parameter are further
illustrated in Figure 8.1.
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Figure 8.1: Parameters of the fitting equations. The parameter min and
max are the same for both fitting equations and corresponds to the minimum
and the maximum of the curve. a is the slope of the curve. For the Boltzmann
equation, the midpoint is equal to the point of inflection, thus Tm,Boltzmann = T
′.
In the Sigmoid-5 equation these two points will be different if c 6= 1. Tm could
be defined as the midpoint Tm,midpoint = T
′ − a × ln(2 1c − 1) or as the point of
inflection Tm,inflection = T
′ − a× ln(1
c
).
Initially, experiments were analysed with the Inflection method. However, during
analysis questions arose as whether this was the most suitable descriptor for the
melting point. By definition, the Tm is the transition midpoint of the curve (i.e.,
equal concentrations of folded and denatured protein), so the fitting equation
should give the Tm equal to the midpoint.
To answer this question, the midpoint was manually determined from the raw
data set: The raw data was transformed into a table of temperature and corre-
sponding fluorescence. In a spreadsheet, the midpoint of the maximum and the
minimum fluorescence was determined. As the temperature increases in 1 /min
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steps, the corresponding temperature can only be estimated. Knowing that the
transition around the Tm is almost linear, fluorescence values were estimated.
Comparing the manually determined midpoints to “Boltzmann”, “Midpoint” and
“Inflection” reveals that “Inflection” over-estimates the Tm value the most. In
almost all cases, the manually found Tm and the mathematically determined Tm
do not conform. An example is shown in Table 8.1 for the compound ysbl000701
(Figure 8.2; library “Jens” screened against BtGH84, Section 7.3.3, page 140).
This analysis provided the motivation to explore the differences between the
methods in more detail.
Figure 8.2: Structure of ysbl000701.
Table 8.1: Manually estimated versus mathematically determined Tm.
Values for compound ysbl000701 are shown which are obtained from the “Jens”
screen against BtGH84.
Blank 1 mM 10 mM Blank 1 mM 10 mM
Est. Midpoint 55.9 56.1 56.6 56.0 56.1 56.6
Boltzmann 55.9 56.1 56.8 56.0 56.2 56.8
Midpoint 56.0 56.2 56.8 56.1 56.3 56.8
Inflection 56.6 56.7 56.9 56.7 56.8 57.0
∆ to Boltzmann -0.2 0.0 0.7 -0.1 0.0 0.7
∆ to Midpoint -0.1 0.1 0.7 0.0 0.1 0.7
∆ to Inflection 0.5 0.6 0.8 0.6 0.7 0.9
The following sections discuss the three methods more into detail and gather
information about reproducibility, comparison and hit identification.
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8.2 Reproducibility
To begin the in-depth analysis, it was first tested if there were differences in re-
producibility for the three Tm determination methods Boltzmann, Midpoint and
Inflection. A sensitivity test with HEWL was performed with a protein concen-
tration repeatedly diluted by half from 500 µg/ml down to 0.24 µg/ml (Section
6.4.2, page 128). Each concentration was measured in octuplicates. In terms of
reproducibility defined as the standard deviation of aliquoted repeats of the same
solution, the Boltzmann, Midpoint and Inflection methods are comparable. The
standard deviations for each octuplicate (compared in Table 8.2) show that all
three methods give similar reproducibility.
Table 8.2: Reproducibility of Tm generated by all three methods The
standard deviations of the three different Tm techniques do not differ signifi-
cantly. At the concentration 62.5 µg/ml one value was excluded as an outlier.
At 31.25 µg/ml two curves could not be fitted with any of the fitting equations.
(Data obtained with HEWL, n=8.)
Lysozyme in µg/ml 500 250 125 62.5 31.25
Boltzmann average Tm () 72.41 72.66 72.98 72.99 73.70
stdev () 0.12 0.09 0.12 0.38 0.62
Midpoint average Tm () 72.54 72.67 72.81 72.68 72.49
stdev () 0.12 0.05 0.18 0.53 1.08
Inflection average Tm () 73.31 73.33 73.51 73.37 74.50
stdev () 0.10 0.14 0.35 0.37 1.43
8.3 Boltzmann Equation versus Sigmoid-5
Equation
In a second step, the comparability of the newer Midpoint and Inflection meth-
ods with the conventional Boltzmann method were assessed. The following fig-
ures derive from a representative 96-well plate with BtGH84 which contained 32
blanks and 8 compounds screened as quadruplicates. Experimental details can be
found in Section 7.3 on page 137. In Figure 8.3, the Tm generated with the new
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Midpoint and Inflection methods are plotted against the conventional Boltzmann
Tm. One can see that the Midpoint method estimates the Tm slightly higher than
Boltzmann, but in a very comparable manner. However the Inflection method
produces more variation and obvious differences towards the Boltzmann method.
The Tm determined with that method is significantly higher.
Figure 8.3: Boltzmann compared to Midpoint and Inflection. The figure
shows a comparing plot of a representative screening plate with BtGH84. On this
example plate, the Midpoint method differs less from the conventional Boltzmann
method than the Inflection method. Nevertheless the Sigmoid-5 equation pro-
duces slightly higher Tm with the Midpoint method, and significantly higher and
more spread Tm with the Inflection method.
8.4 Comparison of the Produced Shifts
After comparing the reproducibility and the value of the melting temperatures,
the individual shifts produced with Boltzmann, Midpoint and Inflection were
compared on an example of a representative screening plate (library “Jens”
screened against BtGH84, Section 7.3.3, page 140). The bar chart on Figure
8.4 reveals that depending on how the Tm was determined, different thermal
shifts are produced. The shift of all 96 wells was calculated with the Boltzmann
(blue), the Midpoint (purple) and the Inflection (pink) method and compared as
bars.
The first striking difference occurs for well number six. Boltzmann and Midpoint
generate a negative shift whereas Inflection produces a positives shift. In such a
case it is required to look in detail at the melting curves. Figure 8.5 displays the
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Figure 8.4: Shifts on a 96-well plate with all three methods. A represen-
tative BtGH84 screening plate with 32 blanks and 8 ligands in quadruplets. The
shifts determined by the three different methods are shown in cyan (Boltzmann),
purple (Midpoint) and pink (Inflection).
actual data curves and it becomes obvious that in this case the data were poor
and thus resulted in low quality hits. This is an example where the curves would
be discarded.
In addition, the same example plate illustrates that even though some compounds
produce high quality data, the different methods result in significantly different
shifts. Table 8.3 lists two wells (well number 36 and well number 48) with dif-
ferent compounds where the compound is classified differently (either as hit or
non-hit following the rule that the shift should be above three times the standard
deviation) depending on the method used for Tm determination. Additional, Fig-
ure 8.6 shows differences in hit classification also occur when data curves and fits
are of good quality. Well number 36 is shown and illustrates the trustworthiness
of the newly five-parameter equation.
In summary, if a curve is misshaped (due to multiple unfolding transitions, ligands
having intrinsic fluorescence etc.) none of the fitting equations will produce
reliable data.
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Figure 8.5: Bad fits resulting in odd shifts. Well number 6 from the above
presented screening plate showed strongly opposed shifts in the hit analysis. How-
ever the inspection of the actual data curve makes clear that the fit is poor and
the data cannot be trusted.
Figure 8.6: Good fit with different Tm depending on method. Well num-
ber 36 from the above presented screening plate is very well fitted with an rsquare
of 0.9999. Despite, this could be considered either as a hit or not depending on
the method used. The rsquare is calculated for data points included in the fit,
i.e. for the points from the left hand minimum to the maximum of the curves
(see Chapter 4).
8.5 Known Binders
All of the examples mentioned above derive from screening random compounds.
Binding and affinity are unknown. This section now examines how some known
binders to BtGH84 behave when analysed by these methods. The compounds
PUGNAc and ysbl000293 bind to BtGH84 with an IC50 in low micromolar range
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Table 8.3: Hit dependency on Tm determination One screening plate of
neighbours with 32 blanks contains more than one example where the Tm deter-
mination is crucial for hit classification.
32 Blanks Well 36
Method Average Stdev Tm Shift Rsquare
Boltzmann 55.95 0.24 57.009 1.057 0.9998
Midpoint 56.07 0.23 57.043 0.977 0.9999
Inflection 56.67 0.20 57.182 0.512 0.9999
32 Blanks Well 48
Method Average Stdev Tm Shift Rsquare
Boltzmann 55.95 0.24 56.712 0.760 0.9999
Midpoint 56.07 0.23 56.690 0.623 1.0000
Inflection 56.67 0.20 56.875 0.206 1.0000
and 600 µM respectively. Figure 8.7 shows the protein stability curves of both
compounds analysed with all three Tm methods recorded at duplicate concentra-
tion series. Blanks were plotted as 1 µM for logarithmic purposes. The curves
for PUGNAc (Figure 8.7 a) show an increase in melting temperature with every
concentration step.
Dose-response curves created with TSA are not typical dose-response curves.
As the protein-ligand complex is heated up and denatures, the concentration of
native protein decreases and (probably) the free concentration of the ligand will
increase. In addition, the solubility of the ligand and its binding affinity for the
native and denatured protein could be affected. This combination of effects will
introduce variability from one ligand to another, and could also affect the detailed
shape of the TSA curves .
The Tm values obtained with all three methods are in good agreement. However,
for the blanks, the Inflection Tm is about 1 higher than the other two methods.
The greater the ligand concentration, the smaller the difference in Tm. At 2.5 mM
the calculated Tm are almost the same across the three methods. A similar trend
can be observed for the fragment ysbl000293 (Figure 8.7 b). However, the results
are far noisier for the weaker binding compound. There is a significant difference
between the line with the circle markers (1) and with the diamond markers (2)
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for the blanks and the lowest concentrations of fragment. Nevertheless, Midpoint
and Boltzmann produce the larger temperature shift for both control compounds.
(a) PUGNAc
(b) ysbl000293
Figure 8.7: Comparison of the Tm methods using positive controls. Pro-
tein stability curves of BtGH84 with positive controls with all three Tm methods.
The point for 0 µM ligand was modified to 1 µM to allow a logarithmic plotting.
(a) PUGNAc (b) Fragment ysbl000293
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8.6 Discussion
Due to the time restraints for completing this thesis, the analysis presented above
is on representative data. It would be very interesting to perform a statistical
analysis on a wider collection of screening data. However, some general conclu-
sions can be made.
The previous examples illustrate that the method of data processing used is
crucial for determining if a fragment is a hit or a non-hit. In addition, there is
no method for straight-forward readout of the transition point of a half unfolded
protein (Tm). The Tm must be estimated using a fitting model. However a
different thermal shift is produced by the different methods used calculate the
Tm. This is probably because the physical model of the experiment is incomplete
and there are additional physical events happening during unfolding which are
not accounted for in the existing models. These could for example be changing
heat capacity or cooperative unfolding. Nevertheless the fit statistics deriving
from the Sigmoid-5 equation are mostly better (never worse) than those of the
Boltzmann model. For this reason the Sigmoid-5 equation is the more robust
model. The effect is self explanatory since an additional parameter is used in
refinement. From the data produced in this thesis it cannot be clearly said which
method of Tm determination is the most appropriate.
In theory, the observed signal in TSA is independent of ligand size and affinity.
However, the thermal shift for a strong binder like PUGNAc will be significant,
whereas it is less for small fragments with a weak affinity. As a result, the stability
curves become more noisy and the compound is likely to be missed as a hit with
the TSA method. Binding affinity detectable with TSA has also been limited by
others to 100 µM–1 M KD (Kranz and Schalk-Hihi, 2011).
All the examples mentioned in this chapter lead to the conclusion that TSA is
a good screening method to test stronger binders. However, the method seems
unsuitable for fragment screening due to the failure of proper Tm determination.
The Boltzmann equation and general inflection point methods are widely ac-
cepted for Tm determination (Sections 4.2.2 and 4.2.3). To remain in accordance
with the definition of the melting temperature (where the protein is half unfolded
and half folded), the Tm corresponds to the midpoint of a curve and not to the in-
flection point. However, the Sigmoid-5 equation represents a more robust way of
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fitting than the Boltzmann equation. In addition, the heat capacity of unfolding
is not independent from the temperature (Gomez et al., 1995) as inadequately
presupposed by the thermodynamic models (Section 4.2.1). The additional pa-
rameter of the Sigmoid-5 equation could account for the changing heat capacity
and justifies that an asymmetric fitting equation is more appropriate for thermal
denaturation curves.
Altogether, this leads to my recommendation that the midpoint of the Sigmoid-5
equation is the most suitable Tm definition for future applications. Neverthe-
less, users of that technique should be more aware that the Tm readout is not
unambiguous.
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Chapter 9
Summary and Future
Perspectives
9.1 Summary
The work presented in this thesis comprises three major parts: Fragment library
design, the coding of the program MTSA to analyse thermal shift data and the
assessment of protein targets for screening.
9.1.1 Fragment Library Design
The aim of the library design presented in this thesis (Chapter 3) was the devel-
opment of Pipeline Pilot protocols which automatically select a fragment set from
an input library. Compound diversity and representation of the input library in
the form of substructures was optimised. The presumptions will guarantee ap-
plicability to the SAR by catalogue approach where fragment hits are searched
for superstructure neighbours in a chemical compound catalogue. Five protocols
were developed which are named as follows:
 Cluster All
 Cluster Fragments
 SIM within Cluster
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 Substructure Count and Substructure Map
 Iterative Removal
All library design protocols can be downloaded from the fragments website http://
www.ysbl.york.ac.uk/fragments/protocols/ and are straight forward to use.
An evaluation strategy was also implemented in Pipeline Pilot which generates
information about similarity to known drugs and inter-library similarity. Each of
the protocols named above was used to generate three different fragment libraries
with input compounds from different suppliers. These fragments libraries were
assessed with the evaluation protocols and profiled for physicochemical represen-
tation of the input libraries and the protocols were compared in order to produce
the best quality fragment library. It was found that the procedure Iterative Re-
moval produces the best quality library.
In two rounds, the in-house fragment libraries “Michele 1” and “Michele 2” were
generated with the Iterative Removal protocol, purchased, controlled for quality
and set up in the database InstantJChem (Appendix C).
Different strategies to design fragment libraries have been approached by scien-
tists: Intense Filtering and visual inspection, 3-dimensional shape-based frag-
ments, focussed libraries and more (Section 1.3).
The procedure presented in this thesis gives a new perspective and is in particular
useful for the SAR by catalogue approach. The fragments in the libraries gen-
erated with the Iterative Removal protocol represent substructures of an input
library. Hits from screening campaigns can be quickly searched for neighbours in
the input library which emphasises the advantage of this user-friendly protocol.
Researchers can use this protocol to design a fragment library where evolution
of the fragments can be rapidly trialled as multiple near neighbours are accessi-
ble for assay. These can be taken from internal collections, designed compound
libraries or the commercially available compounds.
Groups new to fragment screening can use the protocols to quickly generate their
own small fragment library based on laboratory compounds or selecting from their
favourite supplier. This way they can easily perform initial trials with fragments
without needing a chemistry team designing such a library.
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Further, the protocol can be used to design a fragment library that provides a
“window” into a corporate collection to complement high throughput screening
strategies. For example, an organization could maintain a fragment library that
maximally represents the screening collection. A preliminary fragment screen
can be performed on which to judge the ligandability of the target and/or as
a precursor to using the fragment hits to select larger compounds for assay. In-
creasingly, fragment screening is being performed alongside HTS and having such
a representative fragment library could bring benefits.
9.1.2 MTSA
The program MTSA was written to facilitate the analysis of the thermal shift
experiments for which no free software was available by the start of that project
(Chapter 4). MTSA was implemented with Matlab and provides an easy way
to process the raw fluorescence data of the thermal shift experiment. For each
experiment, the program cuts the relevant data and fits the curve with a logistic
(sigmoidal) four- or five-parameter equation and extracts the melting temperature
Tm. If screening plates were set up with a recurring blank (e.g. in the first column
of the plate), the program also calculates the average Tm of the blanks, Tm, and
the thermal shift of all experiments in respect to the average blank ∆Tm. The
program warns the user if the standard deviation of the blanks surpasses a certain
threshold because this could be a sign of errors in the assay. Further, for each
experiment an image is generated.
The choice of the fitting equation is crucial with this technique (Chapter 8). The
four-parameter logistic equation, also known as the Boltzmann equation, has the
property that the Tm is situated at inflection- and midpoint. If using the five-
parameter equations, the Tm can be defined either at the midpoint or at the
inflection point. All three definitions deliver different results for Tm and for the
thermal shift which leaves room for suggestions that the method is very fragile
when applied to weak binding fragments.
In summary, MTSA significantly improves and accelerates the analysis of ther-
mal shift experiments and is especially helpful for high throughput of plates.
It can be downloaded from the fragments website http://www.ysbl.york.ac.uk/
fragments/MTSA.
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Concerning the experimental technique itself, TSA is increasingly used for frag-
ment screening. Giving the reason that fragments only produce small tempera-
ture shifts places particular demands on the methods for analysis of the exper-
imental data. The work on MTSA led to the question whether using TSA for
fragment screening is valuable or not. One challenge here are false negatives.
Not every ligand that binds to a protein will also stabilise it significantly which
is especially true for smaller, weak binding compounds. Tight binding ligands
usually translate into a high thermal shift and TSA might not be suitable for
very small fragments. Also ligands can interfere with the fluorescent dye or have
intrinsic fluorescence. And as common with fragment screening, the thermal shift
assay is limited by compound solubility.
Offering a medium to high throughput, TSA would be a good primary screening
method for fragments. The difficulty of obtaining affinity data also accounts for
the use as a primary technique. (The preference for cross-validation screen should
lay in a method which easily provides affinity data.) In contrast, a technique with
a number of false negatives should rather be considered as an orthogonal assay.
The low material consumption is outweighed by the need to test every fragment
multiple times because the repeatability of the results is limited (in this thesis,
fragments were screened as quadruplicates).
As every screening method, TSA has pros and cons which should be kept in mind
when setting up a screening assay. Notwithstanding, TSA is a good technique for
what it was developed originally - to identify ligands and buffers that stabilise a
protein and an aid to crystallisation.
9.1.3 Fragment Screening
The third part of this work deals with some of the practical aspects of fragment
based ligand discovery in the form of the targets NMT, HEWL and BtGH84.
N-myristoyl transferase (NMT) from the parasites Leishmania donovani (ld),
Leishmania major (lm) and Trypanosoma brucei (tb) were assessed for their
suitability for fragment screening (Chapter 5). The parasites are responsible for
the neglected diseases visceral and cutaneous Leishmania and sleeping sickness.
The project was planned as an exciting collaboration between different institu-
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tions. My part of the project was originally described as performing a fragment
screen with one of the NMT proteins, cross validating hits coming from a high
throughput screen and solving co-crystal structures with promising hits.
ldNMT was successfully subcloned to obtain a protein construct with a dou-
ble His-tag. Expression and purification trials were performed with both single
His-tagged lmNMT and double His-tagged ldNMT. However, production of a
suitable amount of stable protein failed. Nevertheless, initial SPR experiments
were performed to assess the suitability using that method to screen the frag-
ment libraries. Experiments turned out to be challenging. Issues derived from
producing a stable baseline of the protein and observing co-factor binding.
While this project was in process, the widely used test protein HEWL came
up during some experiments. The route of the over-all project was changed to
establish some fragment screening assays with the model protein hen egg white
lysozyme (HEWL). Thus the NMT project was postponed to a later stage.
Although the glycanhydrolase HEWL is often used as a model system, there are
no small molecule inhibitors known to date. Together with being a protein which
can be purchased at low costs which also easily crystallises, HEWL seemed a
suitable target to screen the previously generated fragment library (Chapter 6).
A novel Biacore assay was developed where HEWL binds to the dextran surface of
a CM5 chip and almost 50 fragments from “Michele 1” were screened. Interesting
hits were confirmed with an established enzyme activity assay using whole cells as
substrate. Another 19 fragments from “Michele 2” were screened with thermal
shift analysis. Initial crystallisation trials were also performed. Nevertheless
HEWL turned out to be more challenging than expected and does not behave
straightforwardly in other assays. Results from the different assays could not be
reproduced and optimisation of the experiments was tricky.
At the time of the initial crystallisation experiments with HEWL, the attention
moved to the protein BtGH84 which turned out to be a much simpler target.
Therefore HEWL was put to the side for possible later explorations.
Bacteroides thetaiotaomicron VPI-5482 glycoside hydrolase from GH family 84
(BtGH84) is a close homologue to the human enzyme O-GlcNAcase which is
considered to play a key role in Alzheimer’s disease, cancer and diabetes type II.
Besides being a scientifically strongly relevant target, the protein is also easy to
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handle and reasonably stable. Almost 500 compounds were screened against the
target with thermal shift analysis (Chapter 7). Interesting hits were further tested
for their KD with Biacore experiments and crystal structures with soaked ligands
were solved. Unfortunately, the soaking conditions proved to be unsuitable and
no ligands were present in the structures. Nevertheless the numerous results show
the assays to be good starting points for further studies.
This part of the thesis proved that not every target is suitable for fragment
screening. The bottle neck is the protein which needs to be producible in suitable
amounts and stable in a wide range of conditions. Interesting drug targets can
offer a great challenge for ligand discovery. Fragment screening can be a greatly
useful tool to advance the project as with BtGH84, but might not work for
other targets such as NMT. Proteins which behave well with the challenging X-
ray crystallography can propose problems with other screening techniques - like
HEWL forming aggregates at a wide pH range. No experimental screen in is
suitable for every target.
Testing these different targets gave insight into the different fragment screening
methods and the chance to test the suitability of the prior designed fragment
library. The results of BtGH84 should be used for follow-up experiments to
confirm the initial work.
9.2 Future Perspectives
9.2.1 Analysing the Fragment Library
The generated fragment libraries will now be used by other members of YSBL.
It remains fascinating to see how the generated fragment library would apply
to different targets. I would suggest screening the library against a couple of
proteins of different classes (i.e. one kinase, one phosphatase, one sugar binding
protein, one transferase), evaluate the generated hit rates and classify the types
of hits. Results of such an evaluation would give information about the general
applicability of the library and more details about the usefulness of the individual
compounds as member of a screening library.
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9.2.2 Improving MTSA
The program MTSA provides a huge platform for extensions and improvement.
First of all, one could add functions for the user to choose if the analysis should
be performed with the Tm methods Boltzmann, Midpoint or Inflection, or com-
binations of them. The output could be improved, e.g. with tables and his-
tograms. One has to make sure that the program still remains applicable for use
with different qPCR machines and operating systems. One could also envision
the implementation of an automatic t-test which would be performed to assess
the statistical difference between two curves. Currently, commercial interest was
shown in the program. There may be opportunities for a collaboration so that I
can make further improvements.
9.2.3 Melting Point Discussion
Another exciting aspect would be the gathering and analysis of more information
about the actual melting point definition. First, it would be interesting using the
improved version of MTSA to analyse other targets for their difference in thermal
shift depending on the use of the different Tm methods. If enough data from
different targets were obtained, a complex analysis could be generated. It would
be especially intriguing to find out if the Inflection method always generates
higher melting temperatures than Boltzmann and Midpoint. One could also
keep the Hill factor a constant for one target, and assess the behaviour of the
asymmetric factor c.
It would be useful to develop a new thermodynamic model which includes the
temperature dependency of the heat capacity of unfolding. Such a model is likely
to be in good accordance with the deployed asymmetric Sigmoid-5 equation.
9.2.4 Further Work on HEWL
For HEWL, work on the co-crystal structures could be continued. Although the
screening results were not greatly reproducible, there is a strong suggestion that
the compounds N-acetylglycine, o-toluic acid and benzothiazole alter the protein
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activity. Crystal structures with the compounds would give further conclusions
and ideas how to proceed.
The fragment ysbl000497 altered the shape of the melting curve while producing
a light double-hump at the top of the curve. It would be interesting to perform
more experiments with this compound to assess how it is affecting the unfolding
process. The NMR spectra to control the quality of the compound indicated the
compound was only present at low concentration, so it would be reasonable to
perform future experiments with much lower concentration. Thus disturbances
by precipitate would be ruled out.
In addition, the novel Biacore assay could be improved and tested for suitability
also with other sugar binding targets.
9.2.5 Following Up BtGH84
An evaluation of all TSA data with all three Tm methods suggests very intriguing
results. The new profiling will give different conclusions about possible binders.
The hits could be followed up via crystal structure determination. To do so, the
soaking conditions for BtGH84 crystals need be improved to ensure the ligands
are entering the crystals. These structures would give more starting points for
further investigation.
The influence of DMSO on stability of BtGH84 is an interesting factor which
should be further explored. Whether there is an the influence on stability of the
dyes SYPRO orange and deep purple could also be explored further.
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Chapter 10
Materials and Methods
10.1 Fragment Library
The fragment library was designed with the Iterative Removal procedure in two
steps. The second iteration was built on the first one and passed some additional
selection filters using JChem to remove duplicates and compounds >80% Tani-
moto similarity to members of the first library. (The details are in Chapter 3 and
Appendix C.)
10.1.1 Handling and Storage of the Fragments
The compounds were purchased from Specs, Maybridge, Asinex and Sigma Aldrich
and prepared as 200 mM stock solutions in deuterated DMSO (DMSO-d6). The
solutions were stored on plates at room temperature in the dark.
10.1.2 Quality Control
The quality of the members of fragment library “Michele 2” was checked using 1D
1H spectra with 32 scans on a JEOL 400 MHz NMR spectrometer. Compounds
were tested at 2 mM in D2O with 100 µM TSP as a reference. Spectra were
assessed with the help of Dr. Jens Landstro¨m. The quality of the members of
fragment library “Michele 1” had been demonstrated by Dr. Kerrin Bright.
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10.2 Subcloning ldNMT
10.2.1 Template
The clone of ldNMT with a single N-terminal His6-tag (H6ldNMT) was obtained
from Dr. Jim Brannigan. The gene was in vector pSKB2 also known as pET28-
PPX with a protease cleavage site. The vector was diluted to 6 ng/µl in water.
10.2.2 Cloning Strategy
The coding sequence of ldNMT was PCR amplified using primers (Eurofins MWG
Operon) containing NheI (AGGCTATAAGCTAGCCATCATCATCATCATCAC
AGCAGC) and SacI (ATTGCAGTGGTGGAGCTCGAGCTACAA CATCAC)
restriction sites. pET28a vector and the PCR amplified insert were digested with
NheI (Promega) and SacI (Fermentas) restriction enzymes for ligation to generate
double (N-terminal) His6-tagged ldNMT (2H6ldNMT) clone. Primers were used
at 25 pmol/µl.
10.2.3 PCR
The PCR followed a touchdown protocol (Don et al., 1991) with the annealing
temperatures 63  61  59  57  followed by 20 cycles at 55 and
was carried out in 50 µl volume with dNTPS (deoxynucleotides), MgSO4, Hot
Start KOD DNA polymerase (all Novagen), forward and reverse primers (Eurofins
MWG Operon) and H6ldNMT template.
10.2.4 Agarose Gel Extraction
Amplified DNA and vector digests were separated by agarose gel electrophoresis
with 1% agarose and 0.7% agarose respectively, in 70 ml TAE and 1 µl Sybr safe.
A 2log DNA ladder (NEB) was used to determine the size of DNA fragments.
Products were extracted using a gel extraction kit (Qiagen). The final concen-
trations were quantified by absorbance at 260 nm using a NanoDrop ND-1000
spectrometer (Thermo Scientific).
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10.2.5 DNA Hydolysis with Restriction Endonucleases
To create sticky ends for ligation, the PCR product and the vector were digested
with NheI (Promega) and SacI (Fermentas) restriction enzymes in multi core
buffer (Promega) with BSA (Bovine Serum Albumin, Promega) overnight at
37.
10.2.6 Dephosphorylation
The purified vector was dephosphorylated with CIAP (calf intestinal alkaline
phosphatase) (Promega). Therefore, 3 µl CIAP were added and incubated at
37 for 15 minutes, at 56 for 15 minutes, and repeated these steps once more
(protocol from Promega CIAP manual “Dephosphorylation of 5’ Recessed or
Blunt Ends”).
10.2.7 Ligation
A three fold molar excess of PCR product to digested vector was used in the
ligation reaction (including ligation buffer and T4 DNA ligase, both BioLabs).
One control ligation without PCR product was also set up. The mixtures were
incubated at room temperature for one hour and then overnight at 16.
10.2.8 Transformation
The ligation mixtures were transformed into 50 µl competent Escherichia coli
XL10 Gold cell aliquots containing β-mercaptoethanol. 5 µl of ligation or control
ligation were added to aliquots of competent cells. For transformation the cells
were incubated for 30 minutes on ice, heat-shocked for 1 minute at 42 and
subsequently cooled on ice for 2 minutes (Stratagene transformation protocol).
1 ml prewarmed LB medium was added to each transformation mixture and the
tubes were incubated at 37 for 2.5 hours at 220 rpm. Afterwards, 100 µl of
each cell suspension were plated out on LB plates supplemented with 30 µg/ml
kanamycin and incubated overnight at 37.
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A storage plate supplemented with 30 µg/ml kanamycin was prepared, and
colonies were used to inoculate 5 ml LB supplemented with 30 µg/ml kanamycin,
and these colonies were also used to streak a LB agar plate containing 30 µg/ml
kanamycin. The storage plate was incubated at 37 overnight. The 5 ml cultures
were incubated at 37 overnight at 180 rpm. The storage plate was stored at
4 for later use. The plasmids were extracted using a GeneElute Plasmid Mini
PrepKit (Sigma Aldrich) following the manufacturer’s instructions, from which
the OptiWash step was excluded.
10.2.9 Assessing Cloning Success
All five plasmids were digested in 9 µl volume in multi core buffer (Promega) con-
taining NheI (Promega) and SacI (Fermentas) at 37 for 3 hours. The plasmid
concentration was measured by absorbance at 260 nm using a NanoDrop ND-
1000 spectrometer (Thermo Scientific). DNA samples were separated by agarose
gel electrophoresis using 1 µl loading dye and 1% agarose gel. Two samples were
selected for sequencing by the sequencing service of the TF (Technology Facility,
Department of Biology, York University).
The sequences were analysed with programmes of the following websites:
http://bioinfo.hku.hk/services/menuserv.html
http://www.ebi.ac.uk/Tools/clustalw2/index.html
10.2.10 Recombinant 2H6ldNMT Expression Trial
The single His6-tagged clone from Dr. Jim Brannigan has been expressed suc-
cessfully in Escherichia coli Rosetta(DE3) pLysS. Rosetta strains provide seven
codons rarely used in Escherichia coli on a chloramphenicol plasmid.
1 µl of the plasmid stock was added to 50 µl of competent Rosetta 2 (DE3). Cells
were transformed as described above (Section 10.2.8). Subsequently, the trans-
formed cells were added to 1 ml preheated LB containing 30 µg/ml chlorampheni-
col and 30 µg/ml kanamycin. After shaking for 2 hours at 37, 50 µl and 100 µl
of the cell suspension were plated out on LB plates containing 30 µg/ml chloram-
phenicol and 30 µg/ml kanamycin, and incubated overnight at 37. One of the
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overnight colonies was picked to inoculated 5 ml LB medium containing 30 µg/ml
chloramphenicol and 30 µg/ml kanamycin, and shaken overnight at 37. Three
50 µl aliquots of the overnight culture were added to new Sterilin tubes containing
5 ml LB supplemented with 30 µg/ml chloramphenicol and 30 µg/ml kanamycin.
They were incubated at 37 until they reached an OD600 (optical density mea-
sured at 600 nm) of 0.5 at which point expression was induced by addition of
1 mM IPTG and incubated at three temperatures:
16   overnight
30   5 hrs
37   3 hrs
Cells were pelleted at 13,000 rpm for 3 minutes, resuspended and frozen. On
the following day, the cells were collected into 1.5 ml Eppendorf tubes by cen-
trifugation at 13,000 rpm for 3 minutes on table centrifuge (GenFuge Progen).
The supernatant was discarded. The pellets were resuspended in 0.5 ml buffer as
described below by vortexing and pipetting up and down. The cells were lysed
by sonication (Soniprep 150) for 3 x 5 seconds and cells were stored on ice be-
tween sonication intervals. 5 µl aliquots of each sample were reserved as total
cell lysate. Remaining lysates were pelleted at 13,000 rpm for 3 minutes. A 5 µl
aliquot of the supernatant was taken to represent the soluble fraction. The pellet
was resuspended to take a 5 µl aliquot of the insoluble fraction. The aliquots
were assessed on a 12% SDS-PAGE (gel which was run at 200 V for 50 minutes
using BioRad low molecular range marker.
A range of lysis buffers was tested to assess protein solubility, including a sugar
buffer (40% sucrose, 30 mM NaCl, 50 mM tris-HCl pH 8.0, 0.1% Triton-X 100), a
tris buffer (50 mM tris HCl pH 8.0, 300 mM NaCl) a tris glycerol buffer (50 mM
tris HCl pH 8.0, 300 mM NaCl, 10% glycerol) and a phosphate buffer (100 mM
potassium phosphate pH 8.0, 150 mM NaCl).
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10.3 Large Scale Protein Production
10.3.1 Autoinduction Media
The following autoinduction media as described in Studier (2005) were used in
the large-scale protein production described below:
 50x5052: 25 g glycerol, 73 ml Milli-Q water, 2.5 g glucose, 10 g α-lactose
 25xM: 3.6 g Na2SO4 anhydrous, 13.4 g NA4Cl anhydrous, 17.0 g KH2PO4
anhydrous, 17.7 g Na2HPO4 anhydrous, dissolved sequentially in 200 ml
Milli-Q water
 ZY: 5 g tryptone, 2.5 g yeast, 468.5 ml Milli-Q water
10.3.2 ldNMT
Protein Expression
Escherichia coli Rosetta2 DE3 cells containing a pET28a vector with N-terminal
double His6-tagged ldNMT (2H6ldNMT) were used to inoculate an overnight
culture of 20 ml LB with 30 µg/ml kanamycin and 30 µg/ml chloramphenicol.
1 ml of the overnight culture was added to tubes of 20 ml LB with 30 µg/ml
kanamycin and 30 µg/ml chloramphenicol and grown at 37 for 1 hour. Then
each tube was added to a separate prewarmed autoinduction media (500 ml ZY
media with 1 mM MgSO4, 10 ml 50x5052, 20 ml 25xM, with 30 µg/ml kanamycin
and 30 µg/ml chloramphenicol) and grown for 6 hours at 37. The temperature
was reduced to 20 for overnight growth. The following day, cells were harvested
for 15 minutes at 6,000 rpm and 4 using a Sorvall RC5B centrifuge. Cells
were resuspended with 20 ml phosphate buffer and the soluble fraction isolated
by centrifugation for 15 minutes at 6,000 rpm and 4 using a Sorvall RC5B
centrifuge.
Protein Purification
The cells with double His-tagged ldNMT were resuspended in extraction buffer
(nickel chelating buffer A with 0.5% Triton-X 100, a small amount of DNAse
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(Sigma Aldrich), 10 mM MgCl2, 1 tablet Complete EDTA-free protease inhibitor
cocktail tablet, Roche) and lysed by sonication (Soniprep 150) 6 times for 30
seconds on ice. The crude lysate was loaded on a HisTrap crude 1 ml column
(GE Healthcare) using a peristaltic pump at 4. The column was washed with
nickel chelating buffer A (20 mM sodium phosphate pH 8.0, 300 mM NaCl, 20 mM
imidazole). Elution was performed on an AKTA system at 4 with a gradient
of nickel chelating buffer B (20 mM sodium phosphate pH 8.0, 300 mM NaCl,
1 M imidazole) over 20–30 column volumes.
The eluted protein was slowly diluted 1:10 in anion exchange buffer A (20 mM
tris pH 8.0, 20 mM NaCl, 1 mM DTT). If there were remaining particles, the
sample was filtered with a 0.45 µM filter unit and loaded on a HiTrap Q FF 5 ml
column (GE Healthcare). An ion exchange chromatography was performed using
an AKTA system at 4.
The elution was performed using a step gradient with increasing amounts of anion
exchange buffer B (20 mM tris pH 8.0, 500 mM NaCl, 1 mM DTT). The elution
started at 40% buffer B for 10 column volumes, increased to 100% buffer B over
5 column volumes, followed by a wash step the duration of 5 column volumes at
100% buffer B.
10.3.3 lmNMT
Protein expression followed an autoinduction protocol (Studier, 2005) adapted
by Dr. Jim Brannigan, similar to above.
Protein Expression
Escherichia coli BL21pLysS transformed pET15b and N-terminal His6-tagged
lmNMT (H6lmNMT) were used to inoculate an overnight culture of 20 ml LB
with 100 µg/ml ampicillin and 30 µg/ml chloramphenicol. 1 ml of the overnight
culture was added to tubes of 20 ml LB with 100 µ/ml ampicillin and 30 µg/ml
chloramphenicol and grown at 37 for 1 hour. Each culture was added to sepa-
rate prewarmed autoinduction medium (500 mL ZY medium with 1 mM MgSO4,
10 ml 50x5052, 20 ml 25xM, with 100 µg/ml ampicillin and 30 µg/ml chloram-
phenicol) and grown for 6 hours at 37. The temperature was reduced to 20 for
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overnight growth. The following day, soluble fractions were isolated by centrifu-
gation at 6,000 rpm for 15 minutes and 4 using a Sorvall RC5B centrifuge. Cells
were resuspended in 20 ml phosphate buffer and centrifuged again for 15 minutes
at 6,000 rpm and 4 on the Sorvall RC5B.
Protein Purification
The purification was performed at 4. Cells were resuspended in extraction buffer
(40% sucrose, 300 mM NaCl, 10 mM imidazole, 50 mM tris-HCl, 0.1% Triton-X,
pH 8.0), containing a small amount of DNAse (Sigma Aldrich) and one tablet
Complete EDTA free protease inhibitor cocktail tablet, Roche, per tube, and
were lysed using a French Press (Constant Disruption System). The crude lysate
was loaded onto a NiChelating HisTrap crude 1 ml column (GE Healthcare) at
0.3 ml/min and washed with Nickel chelating buffer A (20 mM sodium phosphate
pH 7.4, 300 mM NaCl, 20 mM imidazole). Elution was performed with a linear
gradient up to 100% buffer B (20 mM sodium phosphate pH 7.4, 300 mM NaCl,
500 mM imidazole) over 15 column volumes. The eluted protein was further
slowly diluted 10fold in anion exchange buffer A (20 mM tris pH 8.0, 20 mM
NaCl) and filtered through a 0.45 µm filter. The protein was loaded onto a
HiTrap 5 ml column (GE Healthcare), and eluted with anion exchange buffer B
(20 mM tris pH 8.0, 500 mM NaCl) using a step gradient composed of: 10 column
volumes at 40% buffer B, 5 column volumes at 100% buffer B, and then washed
at 100% buffer B for another 5 column volumes.
The protein was flash frozen in liquid nitrogen and then stored at -20.
10.3.4 tbNMT
The protein with a N-terminal His6-tag for some initial experiments was kindly
provided by Dr. Jim Brannigan.
10.3.5 BtGH84
The protein was expressed and purified as described by Dennis et al. (2006).
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Protein Expression
Escherichia coli BL21(DE3) with the N-terminal His6-tagged BtGH84 gene on ys-
blLIC pET28 vector were used to inoculate 8 ml LB medium containing 40 µg/ml
kanamycin and which was grown overnight at 37. The next day, the small flasks
were transferred into flasks containing 0.8 l sterile LB media supplemented with
40 µg/ml kanamycin. Cells were grown at 37 until an OD600 of 0.8 and were
then induced with 1 mM IPTG. In the following, the temperature was reduced to
16 and the cells grew overnight. The following day, the cells were harvested at
5,000 rpm for 25 minutes at 4. The pellets were resuspended in 10 ml buffer A
(20 mM HEPES pH 7.5, 200 mM NaCl, 20 mM imidazole) and frozen at -20.
Protein Purification
Cell pellets were defrosted and resuspended in 30 ml buffer A was with one
tablet Complete EDTA free protease inhibitor cocktail tablet (Roche). Cells
were sonicated (Soniprep 150) on ice 15 times for 10 seconds and 20 seconds
rest between sonication steps. The lysate was pelleted by centrifugation for 40
minutes at 15,000 rpm and 4. The supernatant was filtered with a 0.22 µM filter
and loaded onto a 5 ml precharged nickel column (GE Healthcare) The elution
followed a gradient of 0 – 100% buffer B (20 mM HEPES pH 7.5, 200 mM NaCl,
500 mM imidazole) over 40 column volumes.
10.3.6 HEWL
HEWL was purchased from Sigma and dissolved in Milli-Q water to the required
concentration. For some experiments the protein was further purified by buffer
exchange to reduce the ion concentration.
10.4 Mass Spectrometry
The experiments on the electrospray ionisation (ESI) mass spectrometer were
kindly performed by Simon Grist using a QSTAR orthogonal acceleration time
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of flight mass spectrometer (Applied Biosystems). The protein sample was con-
centrated to 2 mg/ml and further buffer exchanged into 2 mM tris pH 8.0. The
concentrated protein was diluted to 4 µM in a solution of 50% acetonitrile and
0.05% formic acid to give the positive charge.
10.5 Surface Plasmon Resonance
When light comes from a medium with a higher refractive index it is partially
refracted and partially reflected. Above a critical angle in incidence, light is
only reflected. However, the electromagnetic field component penetrates a couple
of hundreds of nm into the surface with the lower refractive index creating an
evanescent wave. Under certain conditions such as the light being monochromatic
and p-polarised and the interface between the two media is surfaced with gold,
the intensity of reflected light reaches a minimum. This dip is called surface
plasmon resonance (SPR). The resonance conditions are influenced by material
which is adsorbed onto the metal film. SPR varies almost linearly with the weight
of biologically relevant molecules and can be used to measure their concentration
on the surface.
SPR can detect binding of small molecules via changing of the resonance condi-
tions on a gold surface. The technique was applied to NMT, HEWL and BtGH84.
Concentration series in six wells in 1/4 dilution steps were tested for affinity de-
termination where the lowest concentration was usually a blank and the highest
concentration ten times the expected KD.
10.5.1 Testing NMT
Different test experiments with lmNMT, ldNMT and tbNMT were performed.
Initially, the NMT proteins were tested for binding to an NTA chip (nitrilotri-
acetic acid chip, GE healthcare) via their His-tags. After washing the chip with
HBS-P buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 50 µM EDTA, 0.05% Sur-
factant P20), nickel was attached to the chip and 100–200 nM protein flushed
over it. 100 nM myristoyl coenzyme A (MCoA, Sigma Aldrich) in running buffer
(HBS-P or tris, 200 mM NaCl, 50 mM tris-HCl, pH 7.5) was used as a positive
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control. Covalent binding of the protein to the chip was used when too much
bleeding-off occurred and no binding of the positive control was observed.
The proteins were covalently bound to the chip following the amine coupling
kit by Biacore. 500 µM NiCl2 in HBS-P+ buffer was injected to bind to the
NTA groups. The dextran surface of the chip was activated with 0.2 M/0.05 M
EDC/NHS at 5 µl/min for 8 minutes. His-tagged protein at 10 µg/ml was in-
jected at 5 µl/min to bind covalently to the chip until the response reached 6,000
to 8,000 units. Thereafter, the remaining active groups were deactivated with
ethanolamine at 5 µl /min for five minutes.
Buffers such as HBS-P and tris were tested. The standard regeneration solu-
tion was HBS-P buffer containing 350 mM EDTA. If a stronger regeneration was
needed 5 mM NaOH was used. The nickel solution was prepared by dissolv-
ing 0.5 mM NiCl2 in HBS-P buffer. Protein was handled at a concentration of
10 µg/ml. The running buffer was filtered using a 0.2 µm filter.
10.5.2 Binding Analysis with BtGH84
The chip surface was washed with regeneration solution (10 mM HEPES, 150 mM
NaCl, 0.05% surfactant P20, 350 mM EDTA, pH 7.4) followed by a wash with
HBS-P+ buffer (10 mM HEPES, 150 mM NaCl, 0.05% surfactant P20, 50 µM
EDTA, pH 7.4). 500 µM NiCl2 in HBS-P+ buffer was injected to bind to the NTA
groups. BtGH84 was covalently bound to an NTA chip following the standard
protocol with the Biacore amine coupling kit as mentioned above (10.5.1).
The buffer for the final experiment was changed to HBS-P+ containing 5%
DMSO. The ligands were measured in concentration series in four times con-
centration steps up to 10 mM or up to 1 mM in a second experiment. A solvent
correction was recorded for eight different DMSO concentrations. The protein
remained stable on the chip while it was stored in buffer until it was used for
a second experiment. The activity was tested with 50 µM the known binder
PUGNAc (Tocris bioscience, batch number 3A/103806). KD values were deter-
mined with the Biacore software. In some cases outliers were excluded for the
analysis which is clearly indicated in the results chapters.
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10.5.3 The Alternative Biacore Screen with HEWL
HEWL was buffer exchanged to get rid of additional salts. The running buffer
(RB) was PBS (10 mM phosphate, 2.7 mM KCl, 137 mM NaCl, pH 7.4; made
from 10x stock adding 5% DMSO and 0.05% Surfactant P20). Fragments were
screened at 2 mM in 200 µl running buffer with a final concentration of 5% DMSO
(2 µl fragment plus 198 µl RB in 4.2% DMSO). The final protein concentration
was 70 µM (1 mg/ml). The fragment screen was set-up as an automated pro-
cedure with the Biacore software. Screening of one plate takes 16 hours. It is
possible to screen 48 fragments (two wells per fragment) on one 96-well plate.
The plate was set up to have in the first well fragment alone, and in the second
well a mixture of protein and fragment. The third well contained the second
fragment and so forth. Chitotriose (570 µM, from an 80 mM stock in Milli-Q)
served as a positive control and was injected after each fragment cycle.
In order to prohibit non-specific binding, a solution of 1 mg/ml carboxymethyl
dextran sodium salt in 0.15 M NaCl containing 0.02% NaN2 was tested.
10.5.4 Binding Data with Alternative Biacore Screen
The aim of the screen was to confirm the binding of the first screen and determine
affinity data in the form of a dose-response curve. The positive control was
chitobiose (stock 200 mM in d6-DMSO) and the negative control was one of the
fragments (ysbl000261)which was shown in the first screen not to bind to the
protein. The procedure was implemented using the Biacore software. Every
sixth injection was a wash step with 5 mM NaOH in running buffer with DMSO
(as mentioned above). Every cycle (i.e. six wells) was repeated once. The 96-well
plate was designed using one row per fragment.
Each fragment was tested at six different concentrations from 0 to 10 mM in
running buffer with 5% DMSO on its own and then in the same concentration
together with HEWL. After every concentration series, the chip was washed with
5 mM NaOH. The screening took ten hours.
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10.5.5 Plotting and Analysis
The Biacore T100 system has the ability to output tables with three points per
injection: baseline, binding and stability. There are further absolute and rela-
tive responses measured in response units (RU). For the analysis, only relative
responses were used.
For all the experiments where cycles contained more than two injections (the
initial tests and the affinity screen), protein buildup on the chip needed to be
corrected. Therefore the values were further corrected using the relationship:
RUcorrected = RUbinding −RUstability. For the fragment screen RU = RUbinding was
used.
For logarithmic plotting purposes, the blank concentration 0 mM was assigned
with a value of 0.01 mM. The plots were created with Matlab.
10.6 IC50 Determination
Plots were created with a script in Matlab. Where possible the data were fitted
with a four-parameter logistic function to extract the IC50:
y = min+
max−min
(1 + x
IC50
)a
(10.1)
min and max are the asymptotes which are forced by the fitting script to be
within ±2% of the experimentally determined values. a is the Hill coefficient
which describes the slope of the curve at its midpoint. The IC50 is the corre-
sponding x-coordinate of the inflection point. The function assumes symmetry
around IC50.
10.7 Enzyme Activity Assay for HEWL
HEWL lyses cell walls of bacteria. Micrococcus luteus (Sigma Aldrich) is espe-
cially susceptible to lysozyme and is used as a substrate. When the protein lyses
the cells, the solution becomes more transparent. The IC50 of a ligand can be
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determined by following changes in the turbidity of the solution. The change of
turbidity was measured on a plate reader (Hidex Plate Chameleon) in 96-well
format at a wavelength of 450 nm. Glucose, chitobiose and chitotriose served as
controls and 14 fragments in the “Michele 2” library were tested. The final reac-
tion volume was 300 µl. The working concentration of lysozyme was in the range
of 2.3 µM (33 µg/ml)–4.6 µM (66 µg/ml) and 0.33–0.5 mg/ml of M. luteus. The
stock of cells was prepared freshly before every experiment. The experiment was
performed in phosphate buffer (50 mM phosphate pH 4.7,150 mM NaCl). Con-
centration series were tested in six wells in 1/4 dilution steps of the ligand, where
the lowest concentration was zero and the highest concentration ten times the
expected KD. The reaction started by dispensing lysozyme into the reaction mix-
ture. The plate was shaken for six seconds at 3 mm amplitude. Ideally, the initial
concentration gave an absorbance of 0.8 and the rate should be between 0.015
and 0.040 ∆A450/minute to give non-noisy results. For most of the experiments,
the absorbance was recorded for 200–300 counts (approximately 1 count/minute).
The slope from the first 30 seconds was excluded in the analysis to guarantee a
linear decrease in the absorbance to determine the slope. The slope of the linear
part was determined in Excel. The negative slope was multiplied by -100,000 and
plotted against the concentration to obtain the dose-response curves.
10.8 Thermal Shift Assay
With the thermal shift method (TSA), the unfolding curve of a protein can be
recorded following the signal of a fluorescent dye. When the protein unfolds and
hydrophobic groups are exposed, the fluorescence of the dye which was before
quenched in the aqueous environment increases. 96-well plates were heated in
1 steps from 25 to 95. The analysis was performed using the software MTSA,
written in Chapter 4 on page 85. The programme was devised to enable fitting
of an unlimited number of curves automatically and to output error statistics as
well as the thermal melting point.
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10.8.1 HEWL
For the sensitivity test, a master mixture for a final concentration of 50 mM citric
acid pH 3.8, 150 mM NaCl and 1x SYPRO orange (Sigma Aldrich) was prepared.
The mixture was aliquoted onto a master plate. 500 µg/ml HEWL were added
to the first column to a final volume of 30 µl per well. The first column was
diluted by half for each of the following columns to obtain octuplicates for 12
concentrations ranging from 500 µg/ml to 0.24 µg/ml. Three aliquots were taken
from the master plate to test identical plates on three different qPCR machines.
HEWL was further tested against the hits discovered in the SPR screen mentioned
in Section 10.5.3. 200 µg/ml HEWL was screened in 50 mM citric acid buffer pH
3.8, 150 mM NaCl, 1x SYPRO orange in 40 µl solution per well. The final DMSO
concentration in the wells was 2.5%. All screening experiments with HEWL were
performed as quadruplicates if not otherwise mentioned. The fragments were
tested at 0 mM, 500 µM and 5 mM with 32 blank samples (protein in buffer
without ligand) per plate.
10.8.2 BtGH84
BtGH84 was screened for ligand binding against the fragment libraries “Michele 1”
and “Michele 2” as well as against some nearest neighbour compounds of the li-
brary “Jens”. The compounds were screened as quadruplicates at 1 mM and
10 mM in 96-well plates. Each plate contained 8–32 blanks. The screen was car-
ried out with 50 mM sodiumphosphate buffer pH 6.0, 150 mM NaCl, 1x SYPRO
orange and 1–2 µM protein. The screens were performed on the Agilent Strata-
gene qPCR machine. SYPRO orange was used at 1x concentration, Deep Purple
(GE Healthcare) at 6x. The final volume per well was 40 µl with containing 5%
DMSO. ∆Tm is the difference of the Tm of the sample to that of the averaged
blanks.
10.9 Crystallisation
Protein crystallisation is one of the major techniques to determine the structure
of proteins. With the reinforced signal of repeating protein units, a three dimen-
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sional diffraction pattern can be recorded with which help the three dimensional
structure can be calculated. To evolve fragments, it is extremely important to
know where and how the compound is binding. If the protein is suitable for crys-
tallisation, the binding site is exposed to solvent channels in the crystal lattice,
and if a native structure is already known, the method molecular replacement
may generate a solution to the phase problem, after which point positive differ-
ence density may be evident for the bound fragment.
10.9.1 HEWL
Known crystallisation conditions for HEWL were reproduced. Sitting drop trays
with different conditions were set up: One 96-well plate (tray 1) was prepared
with 100 mM sodium acetate trihydrate, pH 4.5–6.5 with drops of 150 nl mother
liquor and 150 nl protein solution, and 300 nl of each respectively. Conditions
were adopted from the “Lysozyme Kit” by Hampton Research. One 96-well plate
each with the CSS I& II screen (Clear Strategy Screen, Molecular Dimensions,
CSS II was developed at York; Brzozowksi and Walton, 2001; tray 2) and one
with the PGA screen (Poly-γ-Glutamic Acid polymer; Molecular Dimensions; Hu
et al., 2008; tray 3) with the buffers tris pH 8.0 and HEPES pH 7.5 with 55 µl per
well were prepared. Drops of 250 nl mother liquor mixed with 250 nl protein were
added. As follow-up plates, one 48-well (tray 4) and one 96-well plate (tray 5)
with 2 M sodium formate, 100 mM HEPES pH 7.5 and 0.8 M sodium formate,
10% PEG 8K, 10% PEG 1K were set up. The 48-well plate had a reservoir
volume of 500 µl and drop volume of 1 µl mother liquor and 1 µl protein. The
96-well plate had a reservoir volume of 50 µl and drops of 250 nl mother liquor
mixed with 250 nl protein. For each condition, drops were set with 10 mg/ml
and with 30 mg/ml HEWL concentration. The nano litre drops were set with
the Mosquito robot.
Fragments were soaked into wells of tray 1. The fragment solution in 500 mM
DMSO was prediluted in distilled H2O or mother liquor in ratios 1:1, 1:2, 1:3 and
1:4, and 0.2–0.5 µl of the diluted fragments were added to the protein crystals. In
some cases, the crystal drop was enlarged by 1 µl of mother liquor to dilute the
ligand solution further. Assuming that the original drop size was 300 or 600 nl,
these soaking conditions resulted in final concentrations of 10–200 mM ligand
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and 3–30% DMSO.
10.9.2 BtGH84
48-well plates with 100 µl mother liquor (100 mM imidazole pH 8.0, 10% PEG 8K,
3% 2 M TMAO with protein > 10 mg/ml and with 10, 12.5 and 15% ethyleneg-
lycol as cryoprotectant) as sitting drop were prepared (personnel communication,
Dr. Yuan He, 2011). The protein to mother liquor ratio was 1 µml : 1 µl and
0.75 µl : 1 µl. The protein concentration used was more than 10 mg/ml and
crystals grew overnight. Ligands were soaked into the crystals with an estimated
final concentration of 20 mM and 10% DMSO.
10.10 Structure Solution
BtGH84 crystals soaked with the fragments ysbl000298, ysbl000299, ysbl000314,
ysbl000317, ysbl000370, ysbl000509, ysbl000545 and ysbl000548 were tested in-
house and then sent to Diamond for data collection. BtGH84 data sets were pro-
cessed with Mosflm (Leslie and Powell, 2007) and Xia2 (Winter, 2009). BtGH84
datasets were solved by molecular replacement with Balbes (Long et al., 2008).
The solved structures were refined with Refmac5 (Vagin et al., 2004) and rebuilt
in Coot (Emsley and Cowtan, 2004).
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Appendix A
SMARTS Strings
The SMARTS strings listed below were implemented by Dr. Kerrin Bright in
course of the collaboration of the fragment library design.
Table A.1: SMARTS strings. List of SMARTS strings used to define compounds
from the Input Libraries with unwanted functionality, a brief description of the
chemical feature and the number of compounds from each supplier that contained
each feature.
SMARTS string Functionality Asinex Maybridge Specs
[OX2H]c1ccccc1[OX2H] Catechol 417 31 209
[CX4](−[OX2])(−[OX2])(−[OX2]) Ortho ester 0 2 33
[$([NX3](= O) = o),
$([NX3+](= O)[O−])][!#8] Nitro 34477 6529 23314
O −O Ether 0 0 3
[NX2] = [OX1] Nitroso 155 73 63
[CX3] = ([NX2]−OH) Oxime 1066 688 551
[CX3]− [CX3](= O)− [CX3] Aliphatic ketone 5660 1125 2681
[CX4](−[OX2])(−[OX2]) Acetal 19437 1468 7065
c1nsnc1 Thiadiazole 876 320 180
C = C[H2] Methylene 82066 4168 37903
[#6][C!H0] = O Aldehyde 1523 7 1210
c1(NH2)cccs1 Aminothiophene 8013 677 13033
C1CN1 Aziridine 42 10 89
NC(= S)N Thiourea 18077 4433 11669
c1ncns1 Thiadiazole 271 118 91
[NX3, NX4+][CX3](= [OX1])
Continued on next page
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Table A.1 – continued from previous page
SMARTS string Functionality Asinex Maybridge Specs
[SX2, SX1−] Thiolactone 1576 96 2610
[CX4](−[SX2])(−[SX2]) Dithioacetal 58 308 503
[CX3; !R](= [SX1])[NH2] Thioamide 465 384 323
c1(NH2)ccsc1 Aminothiophene 2133 916 2051
S −H Thiol 2328 595 1590
[NX3+] Tertiary amine 39219 8190 24954
N = C = O N=C=O 1 0 1
S(= O)(= O)[OX2] Sulphoxide 570 543 1153
c2ccc1nonc1c2 Benzoxadiazole 248 264 116
N = C = S N=C=S 11 0 9
c1scnn1 Thiadiazole 10349 535 5249
[CX4](−[NX3])(−[OX2]) Aminal 6032 648 5037
[$([CX3]([#6])[#6]), $([CX3H][#6])] =
[$([NX2][#6]), $([NX2H])] Imine 19678 2133 13930
S − S Thioether 565 49 410
[CX3] = [CX3][Cl,Br, F, I] Alpiphatic C=C-Halogen 2032 389 1533
C(= O)[F,Cl,Br, I] Acyl halide 37 0 21
O = C1CSCO1 Oxathiolane 2 0 6
[C; !R](= O)− [S; !R] acyclic C(=O)-S 105 320 138
C1CO1 Epoxide 234 0 175
N − [NH2] Hydrazide 1074 690 652
[CH2, H3; !r][CH2!r][CH2!r][CH2, H3; !r] Aliphatic chain 11413 847 11047
[NX4+] Quarternary amine 86993 4647 19080
[#6]C(= O)OC(= O)[#6] Anhydride 0 0 32
O = C − C = [A; !O; !N ; !S; !a] R=C-C=O 139968 10466 69559
[∗; !#1; !#6; !#7; !#8; !#9; !#16; !#17] Not C,N,F,Cl,S 27118 3042 40808
[N ; !R] = [C; !R] = [N ; !R] Acyclic N=C=N 1 4 1
[NX3, NX4+][CX3](= [OX1])[OX2, OX1−] N-C-O acetal 4065 2229 2472
C − [CX3](= O)[CX4, CX3, CX2][Cl,Br, F, I] Halo-acetophenone 184 109 376
[C; !R](= S)− [O; !R] Acyclic C(=S)-O 41 62 51
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Appendix B
Physicochemical Properties of
All Fragment Sets
The tables in this appendix give a detailed overview about the physicochemical
properties of the Fragment Libraries of the suppliers Asinex, Maybridge and
Specs. Also all physicochemical properties of all 18 created Fragment Sets (six
different procedures times three different suppliers) are listed.
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Table B.1: Physicochemical Profile of the Fragment Sets - Part 1. Prop-
erties of the fragment set, generated by the different protocols for the three Frag-
ment Libraries. MW: Molecular weight, AC: Number of heavy atoms (non hy-
drogen), FC: Formal charge, ALogP, HA: Number of hydrogen bond acceptors.
Library MW AC FC ALogP HA
Asinex 216.5±33.35 15.3±2.30 -0.23±0.47 1.11±1.03 3.1 ±0.99
Cluster All 209.6±30.02 14.8±2.24 -0.07±0.29 1.38±0.93 2.6±1.00
Cluster Fragments 201.8±30.87 14.3±2.36 -0.09±0.38 1.24±0.92 2.7±1.10
SIM within Cluster 218.6±30.61 15.4±2.28 -0.09±0.37 1.21±0.99 3.0±1.06
Substructure Count 228.0±25.08 16.8±1.50 -0.05±0.38 1.79±0.63 2.7±0.99
Substructure Map 241.8±23.60 17.6±1.27 -0.03±0.25 1.91±0.73 2.6±0.90
Iterative Removal 196.7±30.87 13.8±2.24 -0.09±0.28 1.46±0.94 2.3±0.93
Maybridge 203.4±30.71 14.3±2.17 -0.18±0.42 1.36±0.89 2.9±1.03
Cluster All 194.1±28.72 13.5±2.16 -0.08±0.39 1.50±0.85 2.6±1.13
Cluster Fragments 191.5±28.58 13.2±2.17 -0.10±0.40 1.42±0.94 2.6±1.07
SIM within Cluster 204.5±33.14 14.2±2.28 -0.10±0.44 1.60±0.81 2.8±1.07
Substructure Count 212.2±29.58 15.7±1.95 -0.08±0.44 1.80±0.71 2.5±1.03
Substructure Map 232.3±31.34 16.8±1.88 -0.04±0.26 1.78±0.67 2.5±0.96
Iterative Removal 189.2±26.90 13.1±1.97 -0.09±0.32 1.52±0.72 2.6±0.91
Specs 205.4±37.69 14.5±2.63 -0.11±0.42 1.35±0.94 2.8±1.03
Cluster All 180.1±37.56 12.7±2.87 0.01±0.40 1.32±0.91 2.5±1.18
Cluster Fragments 179.5±36.87 12.7±2.80 0.01±0.38 1.33±0.86 2.5±1.12
SIM within Cluster 201.9±38.42 14.3±2.79 -0.04±0.43 1.48±0.92 2.8±1.18
Substructure Count 220.7±28.24 16.3±1.74 0.00±0.40 1.95±0.62 2.7±1.07
Substructure Map 237.7±26.34 17.3±1.46 -0.01±0.22 2.10±0.65 2.6±0.93
Iterative Removal 174.9±31.58 12.2±2.23 -0.11±0.32 1.38±0.96 2.1±0.85
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Table B.2: Physicochemical Profile of the Fragment Sets of Specs -
Part 2. HD: Number of hydrogen bond donors, RB: Number of rotatable bonds,
PSA: Polar surface area, LogS: Solubility, ArB: Number of aromatic bonds.
Library HD RB PSA LogS ArB
Asinex 0.8±0.76 2.42±1.30 57.9±14.35 -2.30±0.76 7.09±3.57
Cluster All 0.7±0.71 2.41±1.29 53.2±16.73 -2.37±0.81 6.98±3.22
Cluster Fragments 0.7±0.72 2.14±1.18 53.3±16.31 -2.26±0.88 6.98±3.58
SIM within Cluster 0.7±0.68 2.49±1.31 57.3±15.76 -2.35±0.85 7.46±4.06
Substructure Count 0.9±0.75 2.43±1.11 51.7±16.13 -3.03±0.25 12.54±1.99
Substructure Map 0.6±0.85 1.68±0.86 48.3±15.94 -2.61±0.57 8.47±4.08
Iterative Removal 0.6±0.70 2.08±1.35 47.3±16.61 -2.39±0.73 6.71±3.15
Maybridge 0.7±0.75 1.94±1.27 56.6±14.78 -2.34±0.69 7.10±3.50
Cluster All 0.7±0.74 1.74±1.16 52.8±16.16 -2.37±0.76 7.17±3.60
Cluster Fragments 0.6±0.74 1.76±1.24 54.2±16.75 -2.32±0.68 6.90±3.89
SIM within Cluster 0.7±0.79 1.82±1.27 55.8±14.77 -2.40±0.78 7.41±3.98
Substructure Count 0.8±0.77 1.87±1.00 50.3±16.51 -2.84±0.35 12.30±2.02
Substructure Map 0.7±0.79 1.58±0.76 49.6±16.86 -2.75±0.52 8.94±4.28
Iterative Removal 0.5±0.68 1.76±1.17 50.0±14.61 -2.31±0.60 7.27±2.54
Specs 0.8±0.71 2.18±1.45 54.1±15.35 -2.33±0.74 6.90±3.31
Cluster All 0.7±0.69 1.44±1.30 49.8±17.84 -2.12±0.86 6.77±4.13
Cluster Fragments 0.7±0.71 1.59±1.35 48.9±17.60 -2.11±0.84 6.54±3.92
SIM within Cluster 0.7±0.67 1.90±1.43 52.3±16.13 -2.30±0.88 7.51±3.98
Substructure Count 0.8±0.78 2.21±1.11 49.3±16.67 -3.01±0.26 12.73±2.03
Substructure Map 0.7±0.81 1.77±0.93 47.2±17.05 -2.79±0.44 8.76±3.92
Iterative Removal 0.4±0.62 1.54±1.26 42.7±16.13 -2.17±0.77 6.02±2.98
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Table B.3: Physicochemical Profile of the Fragment Sets of Specs -
Part 3. R: Number of rings, ArR: Number of aromatic rings, RA: Number
of ring assemblies.
Library R ArR RA
Asinex 1.9±0.63 1.3±0.69 1.5±0.52
Cluster All 1.8±0.69 1.2±0.60 1.5±0.54
Cluster Fragments 1.8±0.76 1.2±0.69 1.5±0.55
SIM within Cluster 2.0±0.70 1.4±0.76 1.6±0.58
Substructure Count 2.4±0.53 2.2±0.43 2.1±0.35
Substructure Map 3.0±0.52 1.5±0.74 2.2±0.43
Iterative Removal 1.6±0.64 1.2±0.60 1.4±0.54
Maybridge 1.8±0.73 1.3±0.67 1.4±0.55
Cluster All 1.7±0.74 1.3±0.67 1.4±0.55
Cluster Fragments 1.6±0.76 1.2±0.73 1.3±0.57
SIM within Cluster 1.9±0.73 1.3±0.75 1.4±0.56
Substructure Count 2.4±0.50 2.2±0.42 2.0±0.44
Substructure Map 2.8±0.78 1.6±0.77 2.1±0.48
Iterative Removal 1.6±0.61 1.3±0.48 1.4±0.49
Specs 1.8±0.71 1.2±0.63 1.4±0.52
Cluster All 1.7±0.78 1.2±0.77 1.3±0.51
Cluster Fragments 1.6±0.74 1.2±0.72 1.3±0.51
SIM within Cluster 1.9±0.73 1.4±0.75 1.4±0.55
Substructure Count 2.4±0.52 2.2±0.43 2.0±0.33
Substructure Map 2.9±0.68 1.5±0.71 2.1±0.44
Iterative Removal 1.5±0.70 1.0±0.54 1.2±0.45
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Appendix C
Detailed Fragment Library
Generation
C.1 Library Generation – First Iteration
The first iteration to set up a new fragment library was performed with a version
of the Iterative Removal protocol that does not contain the Diverse Molecules
component, but runs on the Pipeline Pilot Student Edition (Figure C.1).
After the separation in Fragments and Non-Fragments (Figure 3.1, page 63), both
Libraries are compared and the number of nearest neighbours is calculated for
each fragment (Figure C.1 2). The fragment with the highest number of nearest
neighbours is selected and written to a separate file. The reference compounds
to that fragment are determined. Subsequently the selected fragment is removed
from the Fragments list and the nearest neighbours are removed from the Non-
Fragment Library (Figure C.1 3). The loop executes as many times as members
required for the Fragment Set. In the final step, all selected fragments are merged
to a Final Fragment Set (Figure C.1 4).
500 fragments from Specs were selected. The compounds were visually inspected
with the help of Dr. Gideon Grogan and Dr. Kerrin Bright to discard reactive
compounds which unintentionally passed the unwanted groups filter (Appendix
A). 201 fragments with the highest score of nearest neighbours were purchased,
and dissolved at a concentration of 200 mM in DMSO-d6.
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95% of the compounds were soluble which confirms the adequate estimation of
the solubility threshold. The library was named “Michele 1”.
Figure C.1: Iterative Removal – Student Version.
C.2 Library Generation – Second Iteration
After the generation of Michele 1, a library extending Fragment Set (“Michele 2”)
was selected. Four different suppliers were chosen: Asinex, Maybridge, Sigma
Aldrich and Specs, which offered more than one million compounds. The protocol
version of the Iterative Removal on page 70 was used.
200 fragments were selected. The aim was breaking this number down to 100
compounds physically available at 200 mM stock solutions. Two programmes of
the JChem programme suite (ChemAxon) were used for the following steps: Li-
braryMCS and InstantJChem. LibraryMCS (Maximum Common Substructure)
clusters structures based on common substructures and outputs cluster trees.
InstantJChem is a database for chemical compounds.
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All duplicate compounds (about 50) already contained in Michele 1 were re-
moved. For the remaining compounds, cluster trees were generated with Li-
braryMCS. Two compounds were deleted because they had a close neighbour in
the generated trees. Within InstantJChem, the overlap component was used to
run a superstructure search which lead to the removal of further 27 compounds
(the superstructures). A Tanimoto similarity search was performed with ≥ 80%
SIM. Four compounds were removed. The remaining library contained 108 com-
pounds. Two further fragments were deleted because one was a superstructure of
compounds in Michele 1 and the other one had no protons, which is unsuitable
for NMR experiments. 97 compounds from the remaining list were available from
the above named suppliers. Three compounds were too volatile or not soluble at
200 mM in DMSO, which reduced Michele 2 to 94 compounds.
C.3 Purchasing Compounds and
Quality Control
NMR spectra for Michele 2 were recorded. The analysis of the spectra was per-
formed with the help of Dr. Jens Landstro¨m. Eight compounds showed an in-
correct spectrum (ysbl000468, ysbl000474, ysbl000492, ysbl000506, ysbl000507,
ysbl000525, ysbl000527, ysbl000539). Further eight spectra showed that the com-
pounds were not fully soluble (ysbl000467, ysbl000490, ysbl000496, ysbl000497,
ysbl000501, ysbl000506, ysbl000529, ysbl000540).
C.4 Creating Database
A database for all available compounds in YSBL was created in InstantJChem
(ChemAxon). The new “YSBL Library” contains the fragment sets Michele 1
and Michele 2, “Yasu” ( Dr. Yasuhiko Kanda), “Kerrin” (Dr. Kerrin Bright) and
“Jens” (Dr. Jens Landstro¨m). All 805 compounds were sorted and numbered
with a consecutive ysbl number to facilitate the fragment screening for future
colleagues in YSBL.
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Appendix D
YSBL Compounds
All in this thesis mentioned YSBL compounds are shown with their structure
below:
(a) ysbl000259 (b) ysbl000260 (c) ysbl000261
(d) ysbl000262 (e) ysbl000263 (f) ysbl000264
Figure D.1: Ysbl Compounds - Part 1.
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(a) ysbl000265 (b) ysbl000266 (c) ysbl000267
(d) ysbl000268 (e) ysbl000269 (f) ysbl000270
(g) ysbl000271 (h) ysbl000272 (i) ysbl000273
(j) ysbl000274 (k) ysbl000275 (l) ysbl000276
Figure D.2: Ysbl Compounds - Part 2.
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(a) ysbl000277 (b) ysbl000278 (c) ysbl000279
(d) ysbl000280 (e) ysbl000281 (f) ysbl000282
(g) ysbl000284 (h) ysbl000285 (i) ysbl000286
(j) ysbl000287 (k) ysbl000288 (l) ysbl000289
Figure D.3: Ysbl Compounds - Part 3.
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(a) ysbl000290 (b) ysbl000291 (c) ysbl000292
(d) ysbl000293 (e) ysbl000294 (f) ysbl000295
(g) ysbl000296 (h) ysbl000297 (i) ysbl000298
(j) ysbl000299 (k) ysbl000300 (l) ysbl000301
Figure D.4: Ysbl Compounds - Part 4.
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(a) ysbl000302 (b) ysbl000303 (c) ysbl000304
(d) ysbl000305 (e) ysbl000307 (f) ysbl000308
(g) ysbl000314 (h) ysbl000317 (i) ysbl000370
(j) ysbl000377 (k) ysbl000416 (l) ysbl000423
Figure D.5: Ysbl Compounds - Part 5.
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(a) ysbl000438 (b) ysbl000461 (c) ysbl000464
(d) ysbl000469 (e) ysbl000470 (f) ysbl000471
(g) ysbl000473 (h) ysbl000477 (i) ysbl000481
(j) ysbl000483 (k) ysbl000484 (l) ysbl000485
Figure D.6: Ysbl Compounds - Part 6.
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(a) ysbl000486 (b) ysbl000489 (c) ysbl000490
(d) ysbl000491 (e) ysbl000494 (f) ysbl000495
(g) ysbl000496 (h) ysbl000501 (i) ysbl000502
(j) ysbl000507 (k) ysbl000509 (l) ysbl000545
Figure D.7: Ysbl Compounds - Part 7.
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(a) ysbl000548 (b) ysbl000673 (c) ysbl000683
(d) ysbl000684 (e) ysbl000705 (f) ysbl000708
(g) ysbl000720 (h) ysbl000730 (i) ysbl000733
(j) ysbl000734 (k) ysbl000737 (l) ysbl000749
Figure D.8: Ysbl Compounds - Part 8.
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(a) ysbl000752 (b) ysbl000767 (c) ysbl000770
(d) ysbl000775 (e) ysbl000779
Figure D.9: Ysbl Compounds - Part 9.
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Definitions
Boltzmann Equation: Four-parameter logistic model
Boltzmann Method: Midpoint and inflection point of Boltzmann equation
IC50 Half maximal inhibitory concentration
Jens Compound library containing nearest neighbours
Inflection Inflection point of Sigmoid-5 equation
ka Association rate constant, also k1
kcat Product forming rate constant
kd Dissociation rate constant, also k-1
KD Dissociation constant,
k−1
k1
or kd
ka
Ki Inhibition constant; competing ligand concentration binding to half of the
receptors in absence of a ligand in equilibrium
KM Michaelis-Menten constant; substrate concentration where the enzyme ac-
tivity is half maximal
Kerrin Fragment library
Michele 1 Fragment library
Michele 2 Fragment library
Midpoint Midpoint of Sigmoid-5 equation
Sigmoid-5 Five-parameter logistic model
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Tm Melting temperature in a thermal unfolding curve; equal concentration of
folded and denatured protein
Yasu Fragment library
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Glossary
Asp Aspartic acid
CAPS N-cyclohexyl-3-aminopropanesulfonic acid
CHES N-Cyclohexyl-2-aminoethanesulfonic acid
D2O Deuterium oxide
DMSO Dimethyl sulfoxide
DMSO-d6 Deuterated DMSO
DTT Dithiothreitol
EDC 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
EDTA Ethylenediaminetetraacetic acid
ESI Electrospray ionisation
GlcNAc N-Acetylglucosamine
Glu Glutamic acid
HBS HEPES buffered saline
HBS-P HBS buffer with surfactant P20
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
IPTG Isopropyl β-D-1-thiogalactopyranoside
LB Lysogeny broth (medium)
208
MCoA Myristoyl coenzyme A
MES 2-(N-morpholino)ethanesulfonic acid
MOPS 3-(N-morpholino)propanesulfonic acid
MW Molecular weight
NHS N-hydroxysuccinimide
NMR Nuclear magnetic resonance
NTA Nitrilotriacetic acid
OD Optical density
PCR Polymerase chain reaction
PEG Polyethylene glycol
PIPES Piperazine-N,N-bis(2-ethanesulfonic acid
PUGNAc O-(2-acetoamido-2-deoxy-D-glucopyra-nosylidene)amino-N-phenylcarb-
amate
QPCR Quantitative Real Time Polymerase Chain Reaction
RU Response units
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SIM Similarity
SPR Surface plasmon resonance
TAE Tris-acetate-EDTA
TSA Thermal shift analysis
TSP Trimethylsilyl propanoic acid
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